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RIASSUNTO 
 
INTRODUZIONE 
L’infezione da HIV è caratterizzata da marcati difetti nella funzionalità delle cellule T CD4
+
 con uno 
sbilanciamento verso le cellule Th2 durante la progressione ad AIDS. La terapia antiretrovirale HAART mira 
a sopprimere la replicazione virale e ad indurre il recupero quantitativo dei linfociti T CD4
+
. Il 15-30% dei 
pazienti trattati risulta essere immunologicamente non responsivo alla terapia. Diversi sono i fattori coinvolti 
in questo mancato recupero e il nostro interesse si è concentrato sulle cause alla base di un’eccessiva 
distruzione dei linfociti T helper. Recente è stato evidenziato come anche l’idrossiclorochina (HCQ), farmaco 
antimalarico, presenti effetti antivirali e immunomodulanti. Lo scopo di questo studio è stato quello di 
identificare i meccanismi immuni coinvolti nel mancato recupero dei linfociti T CD4
+
 osservato in pazienti 
immunological non responder alla terapia e verificare se HCQ può ridurre lo stato di immunoattivazione 
caratterizzante l’infezione da HIV e quindi portare all’aumento delle cellule T CD4
+
. 
MATERIALI E METODI 
Per la prima parte dello studio sono stati arruolati 67 pazienti divisi in due gruppi in base alla conta di linfociti 
T CD4+ (superiore o inferiore alle 500 cellule/µl) mentre per la seconda parte, le analisi sono state condotte 
su 20 pazienti non responsivi alla HAART caratterizzati da una conta CD4+ inferiore alle 200cellule/µl 
nell’ultimo anno di terapia. I pazienti sono stati trattati con HCQ per sei mesi con dose somministrata pari a 
400mg/die. Le analisi sono state condotte al momento dell’arruolamento, al termine del trattamento e due 
mesi dopo la sospensione. 
I parametri di immunosoppressione, immunoattivazione e apoptosi sono stati valutati in citometria a flusso. 
Per identificare la presenza di traslocazione microbica è stato dosato l’LPS plasmatico mentre il pathway di 
signaling dei TLR è stato analizzato in Real-Time PCR. Le analisi sono state condotte in condizione basale e 
stimolata in modo HIV-, CMV-, LPS-, ssRNA-specifico in base ai diversi parametri presi in considerazione. 
RISULTATI E DISCUSSIONE 
Confrontando i pazienti con conta CD4
+ 
inferiore alle 500cellule/µl con i pazienti con conta CD4
+
 maggiore di 
500cellule/µl emerge che i pazienti con conta dei linfociti T CD4
+
 inferiore alle 500cellule/µl mostrano: 1) 
maggiore percentuale di linfociti T regolatori, 2) incremento dell’apoptosi, 3) maggior percentuale di linfociti T 
CD4
+
 producenti citochine immunosoppressorie quali IL10 e TGFβ, 4) maggiore percentuale di T CD4
+
 
esprimenti il KI67 sia in condizione basale che stimolata; 5) maggior percentuale di Treg HIV-specifici 
esprimenti TLR2 e TLR4; 6) maggiore concentrazione di LPS plasmatico. Questi dati indicano che il 
mancato recupero dei linfociti T CD4
+
 è associato alla presenza di un basso nadir, alla traslocazione 
microbica, all’immunoattivazione, alla maggior presenza e attività de linfociti T regolatori, ed aumentata 
suscettibilità all’apoptosi. Nella seconda parte dello studio, è stato visto come nei pazienti non responsivi alla 
terapia antiretrovirale, caratterizzati da una conta linfocitaria inferiore alle 200 cellule/µl e trattati con 
idrossiclorochina si osservi la riduzione dell’immunoattivazione sia dei linfociti T CD4
+
 che T CD8
+
, nonché 
dei monociti. Alla riduzione dell’immunoattivazione si accompagna anche la riduzione del LPS plasmatico 
durante tutto lo studio, decremento che permane anche nei due mesi di sospensione. I risultati mostrano che 
l’idrossiclorochina è in grado di controllare l’immunoattivazione e promuovere la riduzione della citochina 
infiammatoria IL6, come dimostrato dalle indagini citofluorimetriche e dai dosaggi immunoenzimatici condotti. 
Si è inoltre osservato il controllo dell’infezione da parte dalle cellule dendritiche plasmacitoidi (pDC). La 
presenza di uno stato immunosoppressorio è stata accertata tramite la valutazione della percentuale di 
linfociti Treg naïve e attivati e di Treg esprimenti il TLR2 e TLR4: entrambe le popolazioni di Treg incrementa 
in percentuale dopo sei mesi di terapia, l’immunoattivazione e l’immunosoppressione sono quindi processi 
strettamente correlati e interagenti l’una con l’altra. In letteratura è stato sottolineato il ruolo 
dell’idrossiclorochina sul pathway di signaling dei TLR e questi ultimi, a loro volta, sullo stato di 
immunoattivazione. Dati citofluorimetrici mostrano la riduzione dell’espressione dei TLR da parte dei 
monociti anche in presenza di agonisti dei TLR4 (LPS) e TLR7/8 (ssRNA). Lo studio del pathway di signaling 
dei TLR è stato analizzato in presenza e assenza di agonisti dei TLR: già con sei mesi di terapia si osserva 
una down regolazione dei geni coinvolti nel signaling intracellulare.  
CONCLUSIONI 
Si può affermare che il mancato recupero dei linfociti T CD4
+
 caratterizzante i pazienti imunologicamente 
non responsivi alla HAART è associato ad un basso nadir dei CD4 pre-terapia, all’immunoattivazione, 
dovuta anche ad un aumento nella traslocazione microbica, e all’immunosoppressione operata dai linfociti 
Treg sia tramite induzione dell’apoptosi nelle cellule target sia con la promozione di un ambiente citochinico 
immunosoppressorio. L’incremento della popolazione di Treg potrebbe giocare in prima linea un ruolo 
fondamentale nel ridurre l’immunoattivazione e l’incremento di Treg esprimenti TLR supporta ancora di più 
come una forte attività immunosoppressoria sia in grado di controllare lo stato di immunoattivazione. 
L’idrossiclorochina, per i risultati preliminari ottenuti, mostra un effetto positivo sul recupero dei linfociti T 
CD4
+
 nei pazienti immunologicamente non responsivi alla HAART e sul controllo dell’immunoattivazione: si 
può pensare ad una possibile applicazione di questo farmaco nella terapia dell’infezione da HIV come 
immunomodulante. 
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ABSTRACT 
 
INTRODUCTION 
HIV infection is characterized by a profound impairment of CD4
+
 T cell functionality with an immunological 
unbalance toward Th2 response during progression to AIDS. Antiretroviral therapy HAART suppresses viral 
replication and leads to the recovery of CD4
+
 T lymphocytes. 15-30% of HIV-infected HAART-treated 
patients are immunological non responder (INR) to therapy. Several factors are involved in this lack in CD4
+
 
T cell recovery, our attention was focused on the excessive depletion of CD4
+
 T cells. Recently, 
hydroxychloroquine (HCQ), an anti-malarian drug, demonstrates to have antiviral and immune modulating 
effects. Aim of this study was to identify immune mechanisms involved in the lack of CD4
+
 T cell recovery 
observed in INR patients and to verify if HCQ might reduce immune activation typical of HIV infection thus 
leading to a recovery in CD4
+
 T cells. 
MATERIAL AND METHODS 
In the first part of this study, 67 HAART-treated HIV-infected patients were enrolled and stratified into two 
groups of the basis of CD4
+
 T cell counts (<500cells/µl and >500cells/µl) while in the second part of this 
study, analyses were conducted on 20 HAART-treated HIV-infected patients with an absolute CD4 count 
less than 200 cells/µl during the last 12 months of therapy. Patients were treated with 400mg/die of HCQ and 
analyses were conducted at baseline, 6 months of therapy and 2 months after HCQ suspension. Immune 
suppression, immune activation and apoptosis were evaluated in flow cytometry. To identify microbial 
translocation, plasma LPS was measured with immunoenzymatic assay and TLR signaling pathway was 
analyzed in Real-Time PCR. 
Analyses were conducted in both unstimulated and stimulated (HIV-, CMV-, LPS-, ssRNA-specific) 
conditions. 
RESULTS AND DISCUSSION 
Patients characterized by CD4
+
 cell counts less than 500cells/µl compared with individuals characterized by 
CD4
+
 cell counts more than 500cells/µl showed: 1) increase percentage of Treg cells subpopulations and 2) 
apoptosis, 3) higher percentage of immune suppressive cytokine-expressing CD4
+
 T cells, 4) a higher 
percentage of KI67
+
 CD4
+ 
T cells in both unstimulated and stimulated conditions. 5) an increased percentage 
of TLR expression on Treg cells and 6) a higher concentrations in plasma LPS. Data herein indicate that 
defective CD4
+
 cell counts recovery observed in patients characterized by CD4
+
 cell counts less than 
500cells/µl is associated with lower CD4
+
 nadir, gut microbial translocation and immune activation, 
augmented percentage and activity of Treg cells, and higher susceptibility to apoptosis. 
In the second part of the study, data showed a reduction in immune activation of CD4
+
 T cells, CD8
+
 T cells 
and monocytes. which was coupled with a reduction in plasma LPS concentration and of IL6 pro-
inflammatory cytokines production. Moreover it has been shown the pivotal role played by plasmacytoid 
dendritic cells in the control of infection. Immune activation and immune suppression are strictly correlated, 
presence of immune suppressor state was well studied thanks to the analyses of both naïve and activated 
Treg lymphocytes, and TLR-expressing Treg cells: these populations were increased in percentage after 6 
months of therapy. Several studies put in evidence HCQ effectiveness on TLR signaling pathway which 
influences immune activation. Flow cytometric analyses elucidate the reduction in TLR expressions by 
monocytes even in the presence of TLR4 and TLR7/8 agonists (LPS and ssRNA respectively).  
TLR signaling pathway was studied following PBMC stimulation with specific TLR agonists by Real-Time 
PCR: 6 months of HCQ treatment resulted in a reduction of TLR responsiveness and the effect was 
maintained also 2 months after HCQ suspension. 
CONCLUSIONS 
The lack in the recovery of CD4
+
 T lymphocytes characterizing immunological non responder patients to 
HAART is associated with a low CD4
+
 nadir, with immune activation due to an increase in microbial 
translocation and with immune suppression conducted by Treg cells through the induction of apoptosis 
mechanism and immune suppressor environment. The augment in Treg population might play a pivotal role 
in reducing immune activation and the increase of TLR-expressing Treg cells supports the effectiveness of a 
strong immune suppressive activity in controlling immune activation. 
Preliminary data suggest that HCQ plays a positive effect on CD4
+
 T cell recovery in immunological non 
responder patients to HAART and a control of immune activation, sustaining an application of this drug as 
immune modulating agent, in the treatment of HIV infection. 
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1. HUMAN IMMUNODEFICIENCY VIRUS (HIV) AND INFECTION 
Human immunodeficiency virus (HIV) belongs to the Retroviridae family, Lentiviridae gender. 
HIV is the etiological agent provoking the human immunodeficiency syndrome, characterized by variable 
clinical manifestations, and in particular by a state of severe immunodeficiency determined by the reduction 
in the number of CD4
+
 T cells that accompanies the onset of opportunistic infections and cancers. 
Two different types of HIV have been identified: HIV-1 is more pathogenic and mainly spread in America and 
Europe, HIV-2 is less pathogenic and common in West Africa. 
1.1. HIV virus structure and genome 
HIV has a spherical form with an external lipoproteic envelope and an internal nucleocapside called core. 
The envelope is formed by a double phospolipid layer of host-cell origin in which the viral glycoproteins 
gp120 and gp41 are embedded. Gp120 and gp41 originate from the proteolitic cleavage of the gp160 
precursor encoded by the env gene, they are exposed on the envelope in a trimeric form and control viral 
tropism by mediating the fusion of the virus membrane with the target cell. The core is made by p24 proteins 
and it encloses HIV genome, and virus-specific enzymes like reverse transcriptase, integrase and protease. 
The integrity of virion particle is ensured by the viral protein p17, which forms the matrix and surrounds the 
internal core (fig.1).  
Figure 1. Structure of Human Immunodeficiency Virus type-1. 
 
HIV genome (fig.2) is composed by two identical copies of single-strand RNA, 9.2kb long, associated with 
two nucleocapside proteins (p7 and p9). HIV genome shows the typical genomic organization of virus 
belonging to Retroviridae family. It encodes for structural genes (gag, pol and env), regulator genes (tat, rev, 
nef, vpr, vpu and vif) and regulator sequences. 
Gag encodes for nucleocapsid and matrix proteins, pol for reverse transcriptase, integrase and protease 
while env for gp160 glycoprotein, this is a precursor from which gp120 and gp41 proteins derive. [1] 
A peculiar characteristic of HIV consists in its capability to create overlapping transcripts, to operate 
alternative splicing and to produce polyproteins which are subsequently splitted into different functional 
proteins. 
 
Figure 2. Genome organization of Human Immunodeficiency Virus type-1. 
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1.2. Replicative cycle of HIV-1 
HIV begins its life cycle when the viral glycoproteins gp120/gp41 (ENV complex) bind to a CD4 receptor and 
one of two co-receptors on the surface of a target cell (fig.3). Physiologically HIV-1 co-receptors belong to 
chemokine receptor family the most important of which are CCR5 and CXCR4. CCR5 is typically expressed 
on macrophages therefore viral strains that exploit it are named M-tropic strains, conversely CXCR4 is 
mainly expressed on T cells and virus strains that use it are known as T-tropic strain. 
 
Figure 3. Schematic representation of HIV entry mechanism in a target cell. 
 
The Env complex mediates a multistep fusion process. Gp120 binds to CD4 receptor and subsequently to 
the chemokine coreceptor, allowing gp41 to change its conformation and to expose a hydrophobic region 
called fusion peptide; this peptide inserts into the cell membrane and allows the fusion between the target 
cell membrane and the viral membrane. 
After the fusion, the nucleoprotein core is disrupted, reverse transcriptase transcribes genomic RNA in 
double strand DNA which enters into the nucleus together with the integrase enzyme. Integrase promotes 
the integration of viral DNA in the cellular genome. The integrated viral DNA is called provirus and it can be 
latently inactive for long periods of time without being transcripted.  
Transcription of the provirus genes is regulated by the LTR sequences. LTR are regulator sequences at the 
ends of HIV genome which form during retrotranscription of RNA in proviral DNA; they are important 
because they contain polyadenylation signal sequences, the TATA box promoter sequence and binding sites 
for two host cell transcription factors, NF-κB and AP1 which regulate the provirus transcription following the 
interaction with viral and host factors. Initiation of HIV gene transcription in T-cells can be initiated only after 
T-cell activation induced by antigen presentation or cytokine action. 
 
Figure 4. Mechanism of action of HIV-1 virus. 
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HIV genes expression can be divided in an early and late phase. Regulator genes (tat, rev, nef) are 
transcribed in the early phase of HIV life cycle, in a full-length transcript which is spliced and translocated 
from nucleus to cytoplasm to be translated in proteins.  
Rev promotes nuclear export of incompletely spliced and unspliced viral mRNAs. Tat is required for 
elongation of viral transcripts by direct binding to mRNA and by increasing the processivity of host RNA-
polimerase. Moreover Tat can be secreted by infected cells, as a matter of fact, its concentration is 
consistent in sera of HIV-infected and extracellular Tat can act as a viral toxin triggering T cell apoptosis and 
the secretion of many cytokines by monocytes contributing to immune dysfunction and progression of HIV 
disease. 
Nef plays a pivotal role in accelerating endocytosis and degradation of CD4 and MHCI host cell molecules 
other than enhancing the release of virus from infected cells. The role played by Vif, Vpr and Vpu :in viral 
replication is not completely clarified. Vif enhances infectivity of viral particles, Vpr promotes nuclear import 
of viral DNA and Vpu plays a similar role to that played by nef and also promotes maturation and trafficking 
of gp160 protein. 
The switch from early gene to late gene is regulated by Rev, which allows the translocation of unspliced late 
genes to the cytoplasm. 
As previously mentioned, late genes (pol, gag and env), are synthesized as precursor protein and are 
subsequently cleaved. Pol gene encodes for reverse transcriptase, protease, ribonuclease and integrase 
protein. Gag encodes for a precursor protein that it‟s subsequently cleaved in p24, p17 and p15 by pol 
protease, these are core proteins, necessary for assembly of viral particles. Env gene encodes for gp160, 
precursor of gp120 and gp41. 
Assembly of viral particles begins by packaging full-length RNA transcripts of the proviral genome with 
proteins encoded by gag genes and pol enzymes. Viral particles are released from the target cell through a 
process of budding and in this passage they acquire the phospolipid layer and expose gp120 and gp41 
proteins on viral particles surface (fig.4). [2] 
1.3. Pathogenesis of HIV disease 
HIV infection can be transmitted through three main different route: contact with HIV infected blood, 
unprotected sexual contact and vertical transmission between mother to child. Thus, groups at risk of HIV 
infection include: homosexual, heterosexual partner of HIV infected subjects, intravenous drug users, babies 
born from HIV infected mother; healthcare workers accidentally exposed to the virus. [3] 
The chance of HIV-1 transmission is directly associated with the biologic properties of the virus, its 
concentration in the exposed body fluid and the intrinsic susceptibility of the host. 
 
The evolution of HIV infection can be subdivided in three stages (fig.5): 
1) Primary infection or acute phase 
2) Clinically asymptomatic period 
3) AIDS 
The course of HIV infection can be followed quantifying the viral load and the blood CD4
+
 T cell count. The 
different stages of HIV-1 infection are commonly classified using the CDC system. The system combines 
clinical data and the number of CD4
+
 T lymphocytes for HIV-1 infection classification [4]. 
 
HIV infection begins with the acute phase, which lasts few weeks (2-3 weeks) and whose manifestation is 
commonly similar to a short flu-like illness. Typical symptoms include: fever, headaches, sore throat with 
pharyngitis, generalized lymphadenopathy and rashes. 
This stage is characterized by an intense viral replication at mucosal sites thus it‟s possible to find up to 107 
viral copies per ml in the plasma. Usually after this viral spread, viral load stabilizes around 102-105 RNA 
copies per ml. This reduction of viral replication is due to the activation of a CTL-mediated immune response 
which allows a partial control of HIV-infection.and it‟s followed by the production of HIV specific antibodies, 
which signs the seroconversion of the patients.  
HIV preferentially infects activated T cells, DCs and macrophages while naïve T cells are not susceptible of 
HIV infection because they express the active form of a cytosine deaminase called APOBEC3G which is 
able to inhibit HIV replication by introducing mutations within single-stranded DNA during reverse 
transcription.  
Recent studies suggest that a higher expression of this enzyme within cell is associated with lower viral 
replication during acute infection [5] while others suggested that its antiviral activity depends on the 
interference exerted in primer tRNA annealing, progression, removal and DNA elongation [6].  
During the acute phase [7] DCs in the lamina propria capture the virus and migrate to lymphnodes where 
they transfer HIV to CD4
+
 T cells HIV begins to replicate. Thus in a few day it‟s possible to detect it in the 
lymphoid tissue. This replication leads to viremia, during which high numbers of HIV particles are present in 
the patient‟s blood, accompanied by an acute HIV syndrome that includes a variety of non specific signs and 
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symptoms typical of many viral diseases. The viremia allows the virus to disseminate throughout the body 
and to infect helper T cells, macrophages and dendritic cells in the peripheral lymphoid tissues. As the HIV 
infection spreads, the adaptive immune system mounts both humoral and cell-mediated immune responses 
directed at viral antigens. These immune responses partially control the infection and viral production, and 
such control is reflected by a drop in viremia to low but detectable levels by 12 weeks after the primary 
exposure.  
Figure 5. Course of HIV infection. 
 
The acute infection, is followed by a clinically asymptomatic period characterized by persistent HIV 
replication in the lymph nodes and spleen without clinical manifestations. During this period, the immune 
system is still capable of handling most opportunistic infections but it‟s possible to observe the reduction in 
the number of CD4
+
 T may be due to continuous virus infection, T cell death and other viral co-infection. As 
the immune system fails, symptoms develop; initially they are mild but as the immune system deteriorates 
the symptoms worsen. Overall this transition period between acute infection and progression to AIDS can 
last 7-10 years, in presence of an antiretroviral therapy it could be longer. When HIV disease progresses to 
AIDS, there‟s the complete destruction of peripheral lymphoid tissue and reduction of CD4
+
 T lymphocytes 
level (below 200cells/mm3); the increase of plasmatic viremia is due to the inability of immune system to 
control any kind of infection. AIDS patients suffer from combinations of opportunistic infections, neoplasms, 
cachexia, kidney failure and CNS degeneration. Because CD4
+
 T helper cells are essential for both cell-
mediated and humoral immune responses to various microbes, the loss of these lymphocytes is the main 
reason that patients with AIDS become susceptible to many different types of infections. 
1.4. Immune response to HIV 
Following HIV infection the immune system responds to the virus through the production of HIV-specific 
antibodies and CD8
+
 T lymphocytes. Neutralizing antibodies appear 2-3 weeks after primary infection, they 
explicate their antiviral activity binding to viral particles and mediating their incorporation and destruction by 
phagocytes. However because of the high rate of HIV mutation, their antiviral action is easily overcame by 
immune escaping HIV-1 variants. [4, 8] 
CD8
+
 T lymphocytes control virus replication by killing infected cells and producing cytokines and 
chemokines which affect viral replication. CTLs induce cell-death in infected cell through the release of 
perforins and granzymes after binding a target cells expressing viral antigens in association with MHC I 
molecules on cell surface. Target cells can be also induced to apoptosis through the interaction between 
FasL and Fas receptor expressed on CTL surface on infected cells respectively. Moreover CTLs are able to 
produce and release antiviral factors like IFNα, MIP1α, MIP1β and RANTES. [4, 9] 
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2. CD4+ T CELLS DEPLETION IN HIV INFECTION 
Many factors can be involved in CD4
+
 T lymphocytes loss and immune dysfunction and according to their 
origin they can be classified in virologic (direct cytopathic) or immunopathologic (indirect cytopathic) [10]. 
 
Direct cytopatic mechanisms 
Direct cytopathic effects may depend on viral replication. HIV replication can influence cell homeostasis in 
several ways: 
 When HIV replicates, it exploits cellular ribosomes and enzymes to synthesize its own proteins so 
host cells are unable to produce their own proteins and to survive.  
 Cell death may be secondary to early genes (nef, vpr and tat) mechanism of action.  
 Intracellular accumulation of viral genome may be cytotoxic. 
 Budding of new virions from infected cells may induce osmotic lysis. 
 
Indirect cytopathic mechanism 
These mechanisms are independent from viral replication and are secondary to immune response and 
alteration in presentation of viral peptides: 
 Defects in antigen presentation could depend on altered expression levels of receptors involved in 
antigen recognition/presentation (TCR or MHCII molecules) 
 Reduction of TCR surface expression inhibits proper T cell activation  
 Down-regulation of MHCII molecules causes a reduction in antigen presentation and therefore CD4
+
 
T lymphocytes priming. 
 ADCC, antibody dependent cell death, secondary to antibodies specific for soluble gp120 bound to 
CD4 molecules expressed by non infected lymphocytes that induce cell lyses in these cells. 
 CTL responses against infected cells that expose viral antigens on their surfaces. 
 Inhibition of T helper activation due to cross reaction between gp120/gp41 and HLA molecules. 
2.1. Apoptosis in HIV infection 
Apoptosis is a mechanism of programmed cell death which plays a key role in the development of immune 
system and in controlling the immune responses [11]. 
Since 90‟s, apoptosis has been described as a mechanism responsible for T cell depletion in HIV-infected 
patients. There are two main apoptotic pathways: the extrinsic one activated by death signals and the 
intrinsic one induced by cellular stress signals (fig.6). 
Apoptosis results in the activation of aspartate-specific cysteine proteases known as caspase family. 
Figure 6. Extrinsinc and intrinsic apoptotic pathways. 
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The extrinsic apoptotic pathway is initiated by the interaction between death ligands and death receptors 
expressed on cell surface. The death receptors mainly involved in this process are members of the tumor 
necrosis factor receptor superfamily and include Fas, TNFR1 and TRAIL. At intracellular level these 
receptors show death domains and when activated by binding with their specific ligands, they recruit adaptor 
proteins that lead to the activation of caspase 8 and the priming of apoptosis execution phase. 
The intrinsic apoptosis is independent by death receptors and it is induced by cellular stress signals acting 
on mitochondria membrane permeability. Mitochondria permeability is controlled by proteins belonging to the 
Bcl2 family, their alteration leads to the release of cytocrome c, a pro-apoptotic protein, from intermembrane 
space of mitochondria. In the cytoplasm, cytocrome c works as a cofactor of Apaf-1. Cytocrome c associates 
with Apaf-1 and procaspase 9 (inactive form) is converted into caspase 9, the active form. Both the intrinsic 
and extrinsic pathway culminate in the activation of the effector caspase 3. Cellular alterations induced by 
the apoptotic process include chromatin condensation, DNA fragmentation and bubble-like blebs on cellular 
membrane. Cells in apoptosis are splitted in little fragments known as apoptotic bodies. [2] 
HIV infection provokes apoptosis in both infected cells and uninfected cells through several mechanism: 1) 
direct infection of T lymphocytes, 2) direct role of HIV proteins, 3) AICD and 4) deregulation of cytokine 
production. 
2.1.1. Direct infection of T lymphocytes 
HIV can induce lymphocytes death during the infection stage through direct cytophatic mechanisms as 
previously described in paragraph 2. 
2.1.2. Direct role of HIV proteins 
Most of the proteins encoded by HIV genome show pro-apoptotic and anti-apoptotic properties.  
A key role is played by gp120, which can mediate apoptosis in both infected and uninfected cells. Gp120 is 
expressed in two isoforms, soluble and membrane bound, both are able to induce the expression of death 
receptors on target cells following CD4 or CXCR4/CCR5 binding. 
Gp120-CD4 interaction can lead to the activation of apoptosis through the upregulation of Fas/FasL 
(extrinsic pathway) or the alteration of Bcl-2 expression  (intrinsic pathway). Gp120-CXCR4 interaction 
activates the intrinsic apoptosis pathway while CCR5 binding mediates the upregulation of Fas/FasL 
expression. 
CD4
+
 T cells and CD8
+
 T cells from HIV infected patients show an upregulation in the expression of Fas and 
of FasL on APC and of TRAIL on CD4
+
 T lymphocytes. It has also been reported that in resting CD4
+
 T 
lymphocytes following the signaling through the homing receptor CD62L, Fas/FasL expression is 
upregulated. [12] 
The complex gp120/gp41 can induced syncytia formation. Syncytia derives from cell membranes fusion to 
form large cells with many nuclei. In HIV infection it happens when infected cells expose gp120/gp41 
complex on their membrane and they interact with CD4 receptor expressed by an uninfected cell. Syncytia 
have short lifespan and are more often seen in advance stage of infection. Different studies suggest that 
nuclear apoptosis of syncytia is caspase-dependent, the key events include the activation of p53 that 
induces the transcription of pro-apoptotic proteins (Bax, PUMA), the translocation of Bax to mitochondria 
where it induces the release of cytocrome c and the activation of the intrinsic apoptosis. [13] 
Nef plays a chief role in inducing viral replication. Studies conducted on infected T cells have confirmed the 
role of nef in upregulating Fas/FasL and PD1 expression, and in downregulating anti-apoptotic factors as bcl-
2 and bcl-xl. [14, 15] 
Tat is secreted by infected cells and taken up by uninfected cells in which it interacts with microtubules 
preventing their depolymerization leading to the alteration of microtubules dynamics. Furthermore tat is 
responsible for inducing BimL release. BimL is a pro-apoptotic factor, belonging to Bcl-2 family, involved in 
apoptotic signal transduction as a consequence of microtubule perturbation. Interestingly, HIV-infected cells 
are resistant to tat-mediated apoptosis and probably this represents a viral strategy to allow HIV survival. 
[16] 
As previously said, HIV uses its protease to obtain several proteins from precursor ones. Nie et al. [17] have 
shown that viral protease cleaves procaspase 8 to generate a fragment of 41kDa (Casp8p41) which is able 
to induce apoptosis in infected memory CD4
+
 T cells. Moreover Sainski et al have demonstrated that 
Casp8p41 doesn‟t contain a catalytic site of caspase 8 and it induces death of infected cells through bax/bad 
mitochondrial depolarization and caspase 9 activation. Bax/bad are pro-apoptotic factors at mitochondrial 
level, Casp8p41 is unable to bind them directly but probably it induces other factors (BH3-only proteins) that 
bind to anti-apoptotic proteins (bcl-xl or bcl-2) allowing bax/bad activation. Once bax/bad are activated they 
oligomerize and create pores in mitochondrial membrane, cytocrome c is released and intrinsic apoptosis 
pathway begins. [18, 19] 
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2.1.3. AICD 
Activated induced cell death (AICD) is a mechanism of programmed death induced in persistent activated 
lymphocytes in the absence of the appropriate co-stimulation signal. Several studies have demonstrated that 
during chronic activation of immune system by HIV virus, expression of death receptors and death ligands is 
upregulated, in particular the Fas/FasL pathway is alterated leading to an increased susceptibility of 
lymphocytes to apoptosis. Fas is a membrane protein expressed on the surface of several cellular types and 
FasL is a homotrimer expressed on T lymphocytes cellular membrane after activation induced by antigen 
presentation and IL-2 action. Activated lymphocytes coexpress Fas and FasL, inducing apoptotic process in 
both autocrine and paracrine ways. Several studies underline that as a consequence of the Fas/FasL 
pathway impairment, PBMC of HIV-infected patients are more susceptible to apoptosis than PBMC of 
healthy subjects. [20] 
2.1.4. Disregulation of cytokine production 
Lymphocyte survival is guaranteed by survival signals, as the ones furnished by IL2 . IL2 is a factor involved 
in growing, surviving and differentiation of T cells, it works in autocrine and paracrine ways and it plays an 
important role in regulation of T-dependent pathway. IL2 is fundamental for cell survival because it induces 
the expression of the anti-apoptotic protein Bcl-2. In the absence of IL2, Bcl-2 expression is downregulated 
while the pro-apoptotic Bax protein is upregulated. Bax induces an increase in mithocondrial membrane 
permeability, cytocrome c is released and the intrinsic apoptotic pathway is activated. Bcl-2 is an anti-
apoptotic factor because it blocks the mitochondrial membrane permeability, the release of cytocrome c and 
of Apaf-1 inhibiting caspase 9 activation. 
The balance between bcl-2 and bax omodimers is key to establish an apoptosis or survival status. 
The positive effect of IL2 on cell survival is well documented. In particular it has been demonstrated that low 
levels of blc2 associated with IL2 absence and CD28 downregulation leading to apoptosis in CD4
+
 T 
lymphocytes. Therefore it has been hypostasized the use of a combined therapy based on antiviral drugs 
and cytokines with immunomodulating properties able to prevent apoptosis. [21, 22] 
 
In conclusion apoptosis is both physiologic and “pathologic” mechanism, it determines the correct 
development of immune system and self-tolerance but following viral infection, like HIV one, it‟s used by the 
virus to control, overcome and destroy immune response and cells. In particular HIV virus acts through 
different mechanisms that culminate in lymphocyte depletion usually observed during the infection. 
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3. HIV AND IMMUNE ACTIVATION 
Persistent immune activation plays a central role in driving immune pathogenesis and progression to AIDS. 
Immune activation is characterized by increased frequencies of T-cells and B-cells with an activated 
phenotype, accelerated lymphocyte turnover with abnormalities in cell cycle regulation and high serum levels 
of pro-inflammatory cytokines and chemokines. Typical markers of immune activation are CD38 and Ki67. 
CD38 expression on CD8
+
 T lymphocytes increases all along the progression of the disease that‟s why it‟s 
considered the most reliable marker of immune activation, disease progression to AIDS and death. Ki67 is 
expressed in the nucleus of cycling cells. 
Considering that HIV replicates better in activated cells than in resting ones, immune activation favors HIV 
replication cycle as well as the spread and maintenance of infection because of the continuous recruitment 
of activated lymphocytes to lymphoid tissue. 
CD38 has been correlated with CD4
+
 T cells decline. Several works established a correlation between 
immune activation and CD4
+
 T cells decline and clinical progression independently from viral replication. It 
has been suppose that CD38 might be a useful set-point of immune activation to take in consideration at the 
time of introduction of antiretroviral therapy: pre-therapy T cell activation set-point may be predictive of 
subsequent T cell recovery concomitantly of a therapy. 
A study by Deeks and collegues [23] asserts that immune activation set-point is a steady state level of T-cell 
activation which characterizes untreated HIV-infected patients even in early HIV infection. Furthermore it has 
been suggested that immune activation set-point is negatively correlated with viral load set-point and that the 
level of viremia and of T-cell activation provide important prognostic information for the introduction of 
antiretroviral treatment in a HIV subject naïve to therapy. [24, 25, 26] 
Hazenberg and colleagues demonstrated that persistent immune activation is associated with progression to 
AIDS. They established that the size of the CD4
+
 T cell pool and the level of immune activation before HIV-1 
infection were key factors for subsequent disease progression. Furthermore, patients characterized by a 
small naïve T cell pool have a more rapid progression of the disease because T cell depletion induced by 
persistent immune activation provokes continuous recruitment of naïve T cells. [27] 
The degree of immune activation is a better predictor of disease progression than plasma viral load. 
An important consequence of HIV immune activation is its impact on immune tissue, persistent immune 
activation leads to the dysregulation of the architecture of tissues like bone marrow, thymus and lymph node, 
that are important for T cell regeneration and function.  
To date it‟s well known that the main mechanisms promoting immune activation are: microbial translocation 
and HIV RNA that binding TLR in plasmacytoid dendritic cells (pDC) directly stimulates IFNα production. 
3.1. Mucosal immune dysfunction and microbial translocation 
The mucosa-associated lymphoid tissue (MALT) plays a central role in protecting the organism from the 
invasion of different pathogens like HIV. MALT is mainly localized in the gastrointestinal tract (gut-associated 
lymphoid tissue – GALT) where it plays a pivotal role in maintaining the immunologic tolerance toward the 
commensal and non commensal flora.  
GALT is organized in inductive and effector sites, the inductive sites comprehend mesenteric lymph node, 
Peyer‟s patch and isolated lymphoid follicles while the effector ones are represented by epithelium and 
epithelial lamina propria. Within the inductive sites the antigens of mucosal lumen are collected and immune 
responses are induced, while within the effector sites effector cells are activated, differentiated and they 
exert their immune effector functions, either cellular response mediated by T-cells or humoral responses 
mediated by B-cells and plasma cells. Anatomically, the lymphocytic populations can be divided into the one 
inside the epithelium, counting intraepithelial lymphocytes mainly CD8
+
 T cells, and the one inside the 
underlying lamina propria, containing CD4
+
 T helper cells, CD8
+
 T cells, natural killer cells and B-cells. 
It‟s essential to maintain the integrity of the mucosal barrier and this can be realized by several factors like 
phagocytic activity, immunoglobulin A secretion and the presence of a thick mucosal layer [28]. A damage in 
the mucosal barrier allows pathogens to penetrate in the sub-mucosal layer and to lead to the activation of 
the immune system.  
Considering that HIV spreads mainly through mucosal surfaces, several studies have focused their attention 
on the immunologic consequences of HIV infection in the mucosal tissue. 
Definitely mucosal immune dysfunction contributes to HIV-associated chronic immune activation through the 
massive CD4
+
 T depletion in the early stage of infection (fig.7). The first cells to be depleted in the GALT are 
CCR5
+
 CD4
+
 T and mucosal T lymphocytes consist predominantly of memory cells, expressing CCR5 and 
markers of activation that transform them in the ideal target of HIV virus.  
In the chronic stage of infection, the massive depletion of CD4
+
 T lymphocytes causes the alteration of 
immune control that favors the breakdown of physical and biological mucosal barrier. 
Experiments conducted in SIV (Simian Immunodeficiency Virus)-infected rhesus macaques showed that the 
early stages of infection are characterized by a massive depletion of mucosal CD4
+
 T cells, and monkeys 
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that are able to partially reconstitute this cellular population progress to AIDS at a slower rate than those that 
don‟t display T cell recovery. As a consequence of the impaired balance in immune response CD8
+
 T cell are 
activated, pro-inflammatory cytokines are released leading to chronic immune activation and mucosal 
damage. [28, 29]  
 
Figure 7. HIV-associated damage to GI tract. Schematic representation of a healthy GI tract (a) and of a 
chronically HIV-infected GI tract (b), blunted villi (1), crypt hyperplasia (2), epithelial barrier compromission 
(3), decrease antimicrobial agents (4), massive CD4
+
 T cell depletion (5-6), microbial translocation (7) and 
increased permeability (8) are indicated. 
 
Based on these observations it has been formulated a pathogenetic model in which selective depletion of 
mucosal memory CD4
+
 T cells, during acute HIV infection, is primary in determining the progression of the 
disease. According to this model the depletion of CD4
+
 T cells in the MALT induces an impairment in 
mucosal immunity that leads to a series of pathogenic sequelae distinctive of the chronic phase of the 
disease [30] 
Microbial translocation is the first event following the disruption of mucosal barrier. Several factors participate 
to promote microbial translocation such as enterocytes apoptosis and loss of gastrointestinal CD4
+
 T cells.  
Studies conducted in SIV-infected rhesus macaques demonstrated that enterocytes apoptosis might be the 
cause of increased intestinal permeability that allows microbial translocation. HIV virus could have a main 
role in enterocytes apoptosis. Moreover HIV infection is associated with the presence of a pro-inflammatory 
environment. [31] 
Breakdown of intestinal barrier allows the microbial translocation process, pathogens are able to colonize 
sub-epithelial layer and microbial products activate the immune system via their binding to TLR. 
 
As previously said, persistent CD4
+
 T cell loss characterizes the early phase of infection while immune 
activation is typical of the chronic stage of the disease. Brenchley and Douek proposed a device to connect 
these two processes. 
The increased translocation of microbial products like lipopolysaccharide (LPS) or flagellin from the intestinal 
lumen to the systemic circulation, may cause the persistent activation of immune system through TLR 
triggering. LPS is a component of Gram negative bacteria cell walls that can be quantitatively assed in 
plasma. 
Brenchley and Douek conducted several studies on immune activation and mucosal immunity, in both SIV-
infected animal models and HIV-infected patients. They proposed that LPS might be the factor responsible 
for the persistent loss of MALT CD4
+
 T cells and immune activation. They found that HIV-infected patients, in 
chronic stage of the disease, were characterized by high quantities of plasma LPS, persistent activation of 
monocytes and by a pro-inflammatory environment. All of these factors suggest that increased microbial 
translocation directly contributes to systemic immune activation in the chronic phase of HIV infection and so 
they may determine the rate of progression to AIDS. It has been found a positive correlation between LPS 
levels and frequency of activated memory CD8
+
 T cells and pro-inflammatory cytokines. Maybe plasmatic 
LPS is detectable only during the chronic phase because during the acute phase microbial products are 
localized mainly within tissue macrophages (fig. 8). Moreover they compared LPS level in HIV-infected 
patients before and after initiating antiretroviral therapy, the results obtained showed a reduction in plasmatic 
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LPS level during HAART therapy suggesting that HIV plays a direct role in maintaining microbial 
translocation and in the disruption of mucosal barrier. [26, 31, 32, 33, 34] 
 
Figure 8. Immune activation hypothesis. 
 
HIV can induce immune activation through both direct and indirect mechanisms. HIV gene products can 
induce directly the activation of lymphocytes and macrophages, the production of pro-inflammatory cytokines 
and chemokines. Gp120, binding CD4, induces cellular activation even in the absence of direct infection 
leading to increased calcium concentrations in enterocytes and an impairment in intracellular ionic balances.  
Nef shows pleiotropic effects, it‟s able to promote the synthesis of paracrine factors by infected macrophages 
resulting in the activation of bystander T cells and it targets cell membranes of enterocytes eliciting organelle 
formation, cytoskeletal rearrangement and increases intestinal epithelial tight junctions permeability. It has 
been demonstrated that nef could be secreted from infected cells in association with small membrane-bound 
vescicles and encompassed by enterocytes, moreover in vitro model showed that nef might prolong cell 
survival allowing accumulation of viral particles before inducing cell destruction of intestinal cells and virus 
release. Nef upsets the IFNγ-induced impairment of intestinal epithelial cells because it interferes with IFNγ 
driven pathways. [35] 
Furthermore, Tat provokes intestinal dysfunction because it influences the uptake of glucose by enterocytes 
and causes microtubule depolymerization. 
HIV may also act through indirect mechanism by inducing the synthesis of inflammatory cytokines (TNFα, 
IL1, IL6). High level of TNFα is thought to cause apoptosis of enterocytes while high levels of IL1 and IL6 
have been found in the lamina propria of the colon of HIV-infected individuals. [36] 
 
To date it has been described how HIV is responsible for the gastrointestinal CD4
+
 T cell depletion and how 
it compromises the integrity of mucosal barrier. Considering that HAART is capable of restoring CD4
+
 T cell 
count and suppress viral load, several studies are investigating whether antiretroviral therapy might control 
mucosal CD4
+
 T cells depletion and microbial translocation. HAART effects on immune activation will be 
discussed in paragraph 5.1.1. 
3.2. TLR in the immune system 
TLRs play an important role in innate immune recognition, they are the first line of innate defense against 
microorganisms. TLRs belong to the family of pattern recognition receptors (PRR) due to their ability to 
recognize pathogen conserved structures, known as pathogen-associated molecular patterns (PAMPs). 
PRRs are expressed mainly by macrophages, dendritic cells, endothelial cells mucosal epithelial cells and 
lymphocytes, they can be localized at intracellular level or on the surface of these cellular populations. Other 
receptors are involved in innate recognition but TLRs have been studied most extensively, to date 13 
receptors (TLR1-TLR13) have been described. They are distinct on the base of their cellular localization and 
their specific ability in PAMPs recognition. 
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TLR-1, -2, -4, -5, -6 are expressed on cell surface and they are mainly involved in detecting microbial 
products while TLR-3, -7, -8, -9 are localized on late endosome-lysosome vesicles and do recognize nucleic 
acid of both viral and bacterial origin. So far, TLR-10, -11, -12, -13 are orphan receptors and less is known 
about them. 
All the TLRs show the same structural organization, they are type I integral membrane glycoproteins 
characterized, at the extracellular side by leucine-rich regions responsible for the recognition of pathogens 
and at the transmembrane and cytoplasmic level by Toll/interleukin-1 receptor (TIR) domain. Signal 
transduction is activated only after TLRs dimerization because this allows the binding of adaptor proteins like 
MyD88 or TIR-domain containing adapter inducing IFNβ (TRIF). Recruitment of MyD88 leads to the 
activation of MyD88 dependent pathway while the binding of TIR domain with TRIF induces the activation of 
the MyD88 independent pathway 
All of the TLRs, except for TLR3 and in some cases also TLR4, bind MyD88 adaptor protein. 
3.2.1. MyD88 dependent and independent pathways 
After recognition of a pathogen-specific molecular pattern, TLRs are capable of differentially activating 
distinct downstream signaling events via different cofactors and adaptor proteins mediating diverse immune 
responses (fig.9). 
 
Figure 9. TLR signaling pathway. MyD88-dependent and independent pathways are illustrated. 
 
MyD88-dependent pathway culminates in the activation of NF-κB and JNK transcription factors. This 
pathway is activated via the conserved, cytoplasmic TIR domain, which provides a scaffold for recruitment of 
the adaptor molecule MyD88 and serine/threonine kinases of the IL-1R-associated kinase (IRAK) family. 
Four IRAK have been identified: IRAK-1, IRAK-2, IRAK-4 and IRAK-M. IRAK-1 and IRAK-4 possess intrinsic 
serine/threonine protein kinase activities, IRAK-2 and IRAK-M lack this activity, suggesting that they 
negatively regulate TLR-mediated signaling. IRAK1 and IRAK4 are sequentially phosporilated and 
dissociated from MyD88, which results in activation of tumor necrosis factor receptor-associated factor 6 
(TRAF6). The TRAF6 adaptor protein activates transforming growth factor-β-activated protein kinase 1 
(TAK1) which in turn triggers the IKK complex that leads to the transcription factor NF-κB activation. TAK1 
simultaneously phosporilates two members of the MAP kinase kinase family (such as JNK) which in turn 
activate AP-1. 
NF-κB and AP-1 promote the transcription of genes codifying macrophage inflammatory mediators, inducing 
B cell proliferation and endotoxin shock. Experiments conducted in mice elucidated that this pathway is 
essential for TLR-mediated inflammatory responses. 
MyD88-independent pathway activation is based on IFN-regulatory factor 3 (IRF-3) activity a transcription 
factor that promotes IFNβ synthesis. Recently, it has been discovered that IRF-3 is associated with IκB 
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kinases (IKKs). IKKs are composed of IKKα and IKKβ, both of which phosphorylate IκBα thereby inducing 
NF-κB activation. In addition, there are two noncanonical IKKs, TANK-binding kinase 1 (TBK1) and 
IKKε/IKKi, which have distinct kinase activities compared with the canonical IKKα and IKKβ and both of them 
are able to promote the phosporilation of IRF-3. 
This signaling pathway could also be activated via the TIR-domain-containing adaptor protein (TIRAP; also 
designated Mal for „MyD88-adapter-like‟) and results in activation of the dsRNA-binding protein kinase PKR. 
This protein has been proposed to be a central downstream component of both the TIRAP- and MyD88-
dependent signaling pathways and could mediate potential crosstalk between them. The MyD88-
independent pathway appears to utilize both IRF3 and NF-κB, and results in the expression of IFN-inducible 
genes including IP-10. 
It has been demonstrated that NF-κB can be induced in a later phase thanks to the activation of IRF-3. 
Moreover TLR4 activation might lead to the induction of both MyD88-dependent and -independent pathway, 
according to the adaptor protein that is recruited to the TIR domain of the receptor. Adaptor protein TIRAP 
promotes the activation of the MyD88-dependent pathway while TRIF is the inducer of the independent one 
[37, 38, 39]. 
Following HIV infection TLR2, TLR4, TLR7 and TLR8 are triggered. TLR2 binds to peptidoglycan and 
bacterial lipoprotein, TLR4 recognizes LPS, TLR7 and TLR8 bind to ssRNA.  
Moreover experimental evidences show that TLRs expression is not restricted to APC but they characterize 
other cellular population like T regulatory cells (Tregs). Their role on Treg cells population will be discussed 
later in paragraph 4.2. 
3.2.2. TLR2 
TLR2 recognizes components from a variety of microorganism, as lipoproteins from Gram-negative bacteria, 
peptidoglycan and lipoteichoic acid from Gram-positive bacteria. TLR2 cooperates with TLR1 and TLR6, and 
its dimerization with other TLRs occurs constitutively or in response to ligand stimulation. TLR2 triggering 
culminates in the activation of NF-κB transcription factor through MyD88 dependent pathway. 
3.2.3. TLR4 
TLR4 is the first mammalian TLR identified, its ligand is LPS from Gram-negative bacteria. Recognition of 
LPS requires adaptor proteins, LPS firstly binds to soluble LPS-binding protein (LBP) and then to CD14, 
preferentially expressed on monocyte surface. Once LPS binds CD14, LBP dissociates and LPS can be 
recognized by TLR4. Moreover MD-2 protein is useful to increase the binding affinity of the LPS-
CD14complex with TLR4. TLR4 signaling pathway can progress through a MyD88 dependent or 
independent pathway. 
3.2.4. TLR5 
TLR5 binds flagellin which is the primary component of flagellar, a highly complex structure that extends out 
from the outer membrane of Gram- bacteria. Flagellin elicits a strong immune response. 
3.2.5. TLR7 and TLR8 
TLR7 and TLR8 are localized in the intracellular endolysosomal compartment, they are specialized in 
recognizing nucleic acids. TLR7 and TLR8 are activated by single stranded RNA. TLR7 is preferentially 
expressed on plasmacytoid dendritic cells (pDC), B cells and monocytes while TLR8 is expressed by 
monocytes and DCs. TLR7 and 8 activation proceeds through the MyD88 dependent signaling pathway. 
Experimental evidences show that TLR7 and TLR8 stimulation with specific agonists results in the induction  
of a different cytokine milieau:TLR7 activation results in a strong production of type I interferon while TLR8 
activation provokes the release of TNFα, IL12, IL1 and IL6. [40, 41] 
3.2.6. TLR9 
TLR9 is localized in the intracellular endolysosomal compartment, it‟s activated by unmethylated CpG motifs 
within single strand DNA. TLR9 is expressed on pDC, B cells and monocytes/macrophages. CpG DNA is 
recognized in the endosome following nonspecific uptake into the cells and the activation of TLR9 leads to 
the induction of MyD88 dependent signaling pathway. Stimulation of TLR9 triggers B-cell proliferation and 
secretion of antibodies, secretion of Type 1 cytokines and chemokines. [41] 
3.3. Role of pDC in HIV infection 
Recognition of microbial components by TLRs triggers the activation of both innate and adaptive immunity. 
The signals for adaptive immunity are mainly provided by dendritic cells. 
pDC represent 0.2-0.5% of circulating PBMC and following activation they are able to produce large amount 
of IFNα and pro-inflammatory cytokines like TNFα and IL6. DCs can be subdivided in two subpopulations, 
mDC and pDC. pDCs are involved in immune response to viral infections. The term “plasmacytoid” refers to 
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their plasma cell-like morphology, resulting from an abundant cytoplasm with well-developed endoplasmic 
reticulum. 
pDCs lack markers of PBMC lineages (CD3 for T cells, CD19 for B cells, CD14 for monocytes, CD56 and 
CD16 for NKs) but they are positive for CD123 (IL3-Rα chain) and HLA-DRII. 
Immature dendritic cells are localized in peripheral tissue, they have high capacity of endocytosis which 
allow them to easily uptake the antigens. Microbial recognition induces DC maturation, mature DC migrate to 
the draining LN where they can present the antigen associated to MHC to naïve T lymphocytes. Naïve T 
lymphocytes require two signal for their activation: the first one is the antigen-specific signal coming from the 
binding of TCR with peptide presented by MHC while the second signal is provided by costimulatory 
molecules CD80 and CD86 that are up-regulated on DC surfaces subsequently TLR activation. Once CD4
+
 T 
cells are activated they differentiate into effector Th1 or Th2 cells.  
Activated tissue pDC migrate in the LN where they can interact with other cell types thus favoring HIV 
transmission. Homing to LN is guaranteed by the fact that HIV up-regulates the expression of CCR7. 
pDCs represent the linkage between innate and adaptive immunity, they influence T cell polarization, 
humoral immunity and immune tolerance. pDCs are able to induce different T cell responses according to 
the signals that they transmit, virus-stimulated pDCs induce naïve T cell to produce IFNγ and IL10 while in 
presence of IL3 they stimulate Th2 differentiation. HIV-specific pDCs can induce the differentiation of Treg 
cells from naïve CD4
+
 T cells thanks to the upregulation of IDO expression [42], a gene whose transcription 
is dependent on TLR7 signaling pathway. Induction of Treg development, it‟s useful to control immune 
activation. 
Activated pDCs exert antiviral activity through the production of type I interferon (IFNα and IFNβ) but they are 
also able to secrete pro-inflammatory cytokines. The production of type I interferon is mediated by the 
transcription factor IRF7, which is constitutively expressed at high level by pDC, after the activation of 
TLR7/8 pathway, IRF7 is translocated into the nucleus where it regulates the expression of IFNα and pro-
inflammatory cytokines genes. Activated pDCs show a typical phenotype, they up-regulate the expression of 
costimulatory molecules such as CD80 and CD86, MHC I, MHC II and CD40. IFNα works in an autocrine 
and paracrine way because it acts on target cell with an antiviral mechanism and it is also a survival factor 
for the same pDCs that produce it [43, 44]. 
Furthermore IFNα might induce apoptosis in CD4
+
 T cells thanks to different mechanisms, it‟s well known 
that it up-regulates the expression of p53, a nuclear protein that regulates apoptotic pathway in cycling cells, 
and of TRAIL/Fas mediated pathways. 
Prolonged pDCs activation and type I interferon production have been associated with the upregulation of 
activation markers on CD8
+
 T cells, the suppression of functional T-cell responses by Treg cells and the 
progressive depletion of CD4
+
 T cells through apoptotic mechanisms such as TRAIL or Fas/FasL. 
Experimental evidences suggest that the induction of apoptotic pathways due to IFNα action might explain 
the persistent cell depletion observed during HIV infection. Moreover type I interferons exert a double action: 
they play a positive effect in destroying infected CD4
+
 T cells that have become infected by infectious HIV-1 
while but when pDCs and CD4
+
 T cells bind non infectious HIV-1, uninfected pDCs will produce IFNα and 
CD4
+
 T cells will express TRAIL and DR5, resulting in the immunopathogenic apoptosis of uninfected T 
helper cells. Because the frequency of circulating noninfectious HIV-1 particles exceeds that of infectious 
HIV-1 by a factor of 10
2
-10
4
, the binding of noninfectious HIV-1 to CD4 on both pDC and CD4
+
 T cells would 
be expected to occur much more frequently than the binding of infectious virus to these important antiviral 
cells. Therefore, the apoptosis of HIV exposed but uninfected CD4
+
 T cells would outpace the apoptosis of 
productively infected CD4
+
 T cells. This predominant death of uninfected CD4
+
 T cells would provide a 
distinct advantage for the virus, by destroying T helper cells that are specific for opportunistic pathogens, as 
well as those that recognize HIV-1 antigens. It has been demonstrated that this effect on CD4
+
 T cells might 
be unique to HIV-1 because this virus uses the CD4 molecule as its primary receptor and also that only the 
binding of viral gp120 to cellular CD4 is required to induce IFN-α. [45, 46, 47] 
 
The persistence of HIV virion provides a chronic stimulus for DCs, pDCs express CD4 receptor, CXCR4 and 
CCR5 co-receptors so they are ideal target of HIV virus and they can be infected by both R5 and X4 strains 
of HIV-1. Viral gp120 interacts with CD4 receptor and HIV is accumulated in early endosomal compartments 
where it starts its replication. 
pDCs express TLR7, TLR8 and TLR9 at intracellular level, thus they can be activated by the interaction of  
viral RNA by TLR7. [38, 48] 
In HIV infection, pDCs are responsible for different effects. First of all they produce high quantities of IFNα. 
Even if the role played by IFNα in HIV infection remains controversial, it‟s thought that in the acute phase, 
high level of IFNα provides a protective antiviral effect and sustain the adaptive immune response while 
during chronic phase, high levels have been correlated with both T cell activation and disease progression.  
The production of high level of IFNα in response to high level of HIV virions, might be considered beneficial 
as it upregulates TRAIL expression in uninfected T cells and thus apoptosis. In addition as TRAIL expression 
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is upregulated even on the pDC surface they can kill both HIV-infected and uninfected T CD4
+
 cells as 
previously explained. [49] 
 
Figure 10. The role of pDCs during HIV infection. Red arrows indicate detrimental effects while green arrows 
indicate beneficial effects 
 
HIV-infected patients are characterized by low level of circulating pDC and reduced ability to produce IFNα, it 
has been suggested that this depletion might be due to the homing to lymphoid tissue in order to control and 
fight the infection. However in LN of HIV infected patients it hasn‟t been detected a raise of pDCs; maybe 
because of a contemporary increased pDCs death rates. However despite a decrease in circulating pDCs, 
there‟s an over-expression of IFNα; in fact in a study conducted by Lehmann [50], it has been shown that 
HIV-infected patients present 100-fold higher levels of IFNα than uninfected control but probably with 
reduced antiviral properties. As previously said, CD4-gp120 interaction induces the production of IFNα, it 
should be noted that soluble gp120, in monomeric or trimeric isoform, displays an inhibitory effect on IFNα 
production by pDCs. Moreover chronic stimulation of pDCs with IFNα may lead to hyporesponsiveness of 
these cells upon exposure to HIV particles of TLR9 ligand. [51] 
Moreover, it has been demonstrated that CD4
+
 T cell and pDC count are positively correlated, suggesting 
that HIV-induced mechanisms may lead depletion of both cellular populations, and between pDC count, viral 
load and disease progression.  
Clinical studies have shown that women display a faster progression to AIDS than men, it‟s thought that 
strong pDCs activation and sustained production of type I interferon might be the causes. [43, 46]  
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4. HIV AND IMMUNE SUPPRESSION: ROLE OF TREG CELLS 
Treg cells control immune responses to self- and non self antigens and they play an important role in 
maintaining the right balance between immunity and tolerance. They are essential for maintaining peripheral 
tolerance to self antigens, preventing autoimmune diseases and limiting chronic inflammatory diseases. 
Treg cells operate by modulating the intensity and the quality of immune reactions and they are identified by 
specific superficial markers. 
Treg cells belong to CD4
+
 T lymphocyte subset, so they are CD4 positive and they express CD25 and 
FoxP3. CD25 is the marker for alpha chain of IL2 receptor while FoxP3 is a nuclear transcription factor 
fundamental for Treg cells differentiation. CD25 is expressed also by effector T cells but at lower level, that‟s 
why Treg cells are defined as CD25
high
 cells. FoxP3 and IL2 receptor are fundamental for the development, 
function and survival of Treg cells and mutations or polymorphisms in the genes encoding this molecules 
predispose to autoimmune disease: for example mutations in FoxP3 gene provoke the IPEX syndrome. [52] 
There are two main subsets of Treg cells: naturally occurring Treg cells (nTregs) and induced/adaptive Treg 
cells (iTregs). 
 
nTregs represent 2-5% of the CD4
+
 T lymphocytes, they originate in the thymus and they are present from 
birth, they play a pivotal role in the maintenance of immunological self-tolerance and in the modulation of 
immune responses. nTregs recognize self antigens because of their development and selection in the 
thymus but also self antigens of injured tissue released in acute disease [53]  
nTregs show an activated/memory status and also high level of CTLA-4, GITR, CCR4 and CD62L (L-
selectin). The main ligands of CCR4 are CCL17 and CCL22 which are secreted by mature APC and the 
circuit CCR4/CCL17-CCL22 is involved in homing of nTregs to secondary lymphoid organs and inflamed 
areas. CD34 and MadCam1 are ligands of CD62L expressed by endothelial cells, their mutual binding is 
fundamental for extravasation of nTregs through high endothelial venules to peripheral inflamed tissue and 
also to homing them to lymph nodes. By contrast, in a study directed by Benoist [54] it‟s affirmed that CCR4 
isn‟t expressed by thymic Treg cells but only by extralymphoid Treg cells, thus further investigations are 
required. 
Several studies are trying to define their generation but until now it seems that they require both TCR ligation 
and strong co-stimulation through CD28 to develop from immature precursor. [55, 56, 57]  
 
iTregs develop in periphery from CD4
+
 T cells following antigenic stimulation during inflammatory processes 
and unlike nTregs they don‟t require CD28-mediated co-stimulation to develop or function. 
iTregs can be subdivided into two different subsets according to the specific cytokine production: Tr1 Th3. 
Tr1 and Th3 share the mechanism of development: both of them require a repeated TCR stimulation and the 
presence of a specific cytokine environment, IL10 and TGFβ for Tr1 and Th3 respectively. 
Once differentiated, Tr1 are able to produce IL10 and TGFβ. Th3 produce high levels of TGFβ and less 
quantities of IL4 and IL10, considering their localization at mucosal sites, they are necessary to control 
immune response at mucosal level, their absence could determine the onset of autoimmune or inflammatory 
disease in the gut. [55, 58] 
 
The key difference between nTregs and iTregs is the specificity of TCR in antigen recognition and signals 
involved in generation and maintenance of these cells. TCR of nTregs recognize self antigens in the thymus 
with high avidity while iTregs work mainly in periphery and they show a TCR pool similar to the one that 
characterizes conventional T cells.  
To date it was reported that the generation and survival of Treg cells are regulated by TGFβ and IL2 and by 
costimulatory molecules belonging to the B7:CD28 family. Recently two groups have tried to clarify the 
differentiation pathway of Treg cells. They suggest a two-step process in which CD4
+
CD25
high
FoxP3
-
 T cells, 
repeatedly stimulated through their TCR, are exposed to IL2 leading to the complete differentiation in FoxP3
+
 
cells. They suggested a key role for IL2 in the complete differentiation of Tregs and the minor role for TGFβ 
which should work in the neonatal period for the development of thymic Treg cells. 
By contrast in another work it was suggested that IL2 and TGFβ are important for iTregs development but 
not for nTregs differentiation as mice deficient for these two cytokines were still able to produce nTregs. So 
important signals to obtain Foxp3
+
 iTregs could be both IL2 and TGFβ. 
Co-stimulatory molecules such as CD28, CTLA-4 and ICOS play an essential role in the differentiation steps 
of both nTregs and iTregs. Mice models show that a strong CD28 co-stimulation is fundamental for nTregs 
differentiation while CTLA-4 favors iTregs generation. ICOS has been recently included in co-stimulatory 
signals useful for Tregs differentiation. [59, 60] 
The development of Treg cells depends on several factors and the fine regulation of their actions is 
fundamental. Apart from the role played by cytokines, specific transcription factor are also important and 
show different effects. Transcription factor NF-κB, and the pathway that it activates, is important for the 
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differentiation of Tregs. Studies conducted in mice put in evidence that the absence of molecules involved in 
NF-κB activation leads to the lack of Treg cells and they suggest that the strength of the NF-κB pathway sets 
a threshold for thymocyte differentiation in Treg or conventional CD4
+
 T cells. The signal of proper intensity is 
required for FoxP3 expression induction and nTregs development. [61] 
By contrast Akt pathway has been recently defined like an important suppressor of thymic differentiation of 
Tregs because it down-regulates the expression of TGFβ. [54] 
Ox40 is an other member of TNF-TNFR superfamily that displays effect on Treg cells development, studies 
conducted in mice show its negative action on Treg cells generation and function. Ox40 signaling pathway 
blocks iTregs generation and it abolishes the capability of nTregs to block T cell proliferation and cytokine 
secretion. [60] 
The development of Treg cells depends on Foxp3 expression which is finely regulated by different factors. 
IL12, IFNγ and pro-inflammatory cytokines like IL1 and IL6 are able to influence Foxp3 expression, 
transforming Treg cells in other type of effector cells. The ability of these cytokines to transform Treg cells in 
other effector cells is related to specific activated STAT and nuclear transcription factors. 
Above of all, in mice it has been demonstrated that IL6 combined with TGFβ reduces the suppressor activity 
of nTregs and they are transformed in pro-inflammatory Th17 cells. By contrast iTregs are resistant to IL6-
induced Th17 transformation. IL6 is one of the principal mediator during inflammation, its ability in 
transforming Treg cells in pro-inflammatory cells could have an important effect for the outcome of diseases. 
IL6 different effect on nTregs and on iTregs might play a precise role in adaptive immune response. 
Following microbial invasions, nTregs conversion in Th17 activates immune responses capable to eliminate 
pathogens while in a second time the activity of iTregs is useful to terminate antigen-specific immune 
response and to avoid an exaggerated reaction of the immune system. IL1 exerts a similar activity to IL6, 
while IL12 and IFNγ promote Th1 cell differentiation. IFNγ, in particular, induces STAT1 activation and Tbet 
expression, nuclear transcription factor characteristic of Th1 cells. These are preliminary works that give an 
idea of the plasticity of immune cells anyway further studies are needed to gain more detailed information. 
[60, 62]  
4.1. Mechanism of action of Treg cells 
Treg cells use different mechanisms to control immune response (fig.11). 
4.1.1. Direct cell-to-cell contact 
The first mechanism involves cell elimination by cell-to-cell direct contact at the site of inflammation, iTregs 
use Fas/Fas-L pathway to induce apoptosis in target cells while activated nTregs express granzyme A and 
so they kill the effector cells through perforin/granzyme action after the adhesion of CD18. The best known 
and studied mechanism of cytolysis is the one mediated by granzyme anyway the involvement of TRAIL/DR5 
pathway in promoting Treg-mediated apoptosis seems to be as much important. Treg cells express high 
level of TRAIL while activated T cells express increasing level of DR5 and in experimental models it has 
been demonstrated that using a blocking antibody for DR5, apoptosis and consequently the suppressor 
activity of Tregs are significantly reduced both in vitro and in vivo. Moreover, nTregs can suppress effector T 
cells through the intercellular transport of cAMP via gap junctions. Treg cells are characterized by high level 
of cAMP because the enzyme (cAMP-cleaving enzyme phosphodiesterase 3B) responsible of its 
degradation is strongly reduced. In T lymphocytes, endogenous cAMP displays different effect like inhibition 
of cell activation, cytokine production and it interferes with the activation of molecules (i.e. Ras and Rap1) 
involved in cell proliferation. When Tregs interact with target cells through gap junctions, cAMP can enter into 
lymphocytes where cAMP levels increase resulting in immune suppression. Reduction of adenyl cyclase in 
Tregs, resulting in low level of cAMP, abrogates Tregs suppression. [63] 
4.1.2. Inhibition of cytokine production by target cells 
The second mechanism is based on the inhibition of proliferation and cytokine production by target cells. IL2 
is a cytokine, mainly produced by activated CD4
+
 T cells, that plays a pivotal role in survival and proliferation 
of lymphocytes. It acts as an autocrine and paracrine growth factor and an alteration in its availability alters 
cell homeostasis. Upon TCR stimulation, activated antigen-specific-effector T cells start to synthesize and 
secrete IL2 and to up-regulate CD25 expression, receptor of IL2. Clonal expansion of antigen-specific T and 
B lymphocytes, induced by IL2, is an important step in immune response because it allows immune system 
to quickly eliminate non self antigens. In addition IL2 is able to control the immune responses through the 
action of Treg cells. Treg cells constitutively express IL2R-α on their surface so they are always able to 
receive IL2 signals and they represent a way to block the action of antigen-specific cells when the infection is 
completely eradicated. 
So Treg cells undergo the action of IL2 and they survival seems to depend on it but they can also block or 
reduce the quantities of IL2. Tregs could be the main acceptor of IL2 thanks to the high expression of CD25, 
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they subtract this important growth factor to T cells inducing them into a state of anergy. When the absence 
of IL2 stimulus lasts for a long time T cells can be induced to apoptosis.  
4.1.3. Modulation of cytokine environment 
The third mechanism of Treg action involves the modulation of the cytokine environment through direct 
secretion of IL10 and TGFβ. TGFβ performs different actions: it reduces cytokine secretion by activated 
CD4
+
 T cells blocking IL2 production and it induces IL10 production in effector cells, a cytokine that 
influences negatively effector T cell function. TGFβ exists in two forms, a membrane bound and a secretory 
one. Membrane bound TGFβ suppresses cell activity through cell-to-cell contact while the secretory bind its 
receptor on T cells and it induces apoptosis through an extrinsic apoptosis pathway. 
IL10 down-regulates IL12 production by APC and inhibits the development of Th1 responses, it shows a 
synergic effect with TGFβ and it upregulates TGFβ receptor expression [52, 64, 65] 
At last Treg cells can induce metabolic disruption in target cell. Depletion of IL2 can also be included in this 
type of action considering that its absence causes starvation in active effector T cell and consequently their 
apoptosis. 
A pivotal role is played by adenosine nucleosides which bind to adenosine receptor 2A. Adenosine 
nucleosides is a component of nucleic acids coming from the action of specific ectonucleotidases CD39 and 
CD73 expressed on Tregs cell surface. CD39 degrades nucleoside tri- and diphosphates like ATP into 
adenosine monophosphate (AMPs) and the subsequent action of CD73 catabolizes the conversion of AMP 
into adenosine. Adenosine-adenosine receptor 2A binding blocks effector T cell functions and it abolishes 
the expression of pro-inflammatory cytokines like IL1 and IL6, the proliferation of Th1 cells and the 
production of TNF or IFNγ. Considering that the presence of ATP within the extracellular environment 
indicates tissue damage and represent a pro-inflammatory marker, the generation of adenosine and its 
interaction with adenosine receptor 2A expressed by effector T cells favors the activity of Tregs in order to 
suppress immune responses. [63, 64] 
4.1.4. Suppression by targeting dendritic cells 
Treg cells might also modulate the maturation and function of DCs, which are required for the activation of 
effector T cells. Treg interacts with DC and suppress their activity with a mechanism involving the co-
stimulatory molecule cytotoxic T-lymphocyte antigen 4 (CTLA4), which is constitutively expressed by Treg 
cells. Studies have suggested that lymphocyte-activation gene 3 (LAG3) may block DC maturation. LAG3 
binds MHC II molecules and it has a negative regulatory T-cell intrinsic function and is required for maximal 
Treg-cell suppression. Binding of LAG3 to MHC II expressed by immature DCs induces an immunoreceptor 
tyrosine-based activation motif (ITAM)-mediated inhibitory signaling pathway that suppress DC maturation 
and their immunostimulatory capacity. Treg cells are able to modulate DC function, they could condition DCs 
to express indoleamine 2,3-dioxygenase (IDO) resulting in the suppression of effector T cells through a 
mechanism dependent on interactions between CTLA4 and CD80/CD86. [64]  
Cell-to-cell contact is the mechanism of action mainly used by nTregs while iTregs use indifferently all the 
mode of actions. 
 
Figure 11. Basic mechanism of action used by Treg cells. 
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4.2. TLR expression on Treg cells 
TLRs are expressed by different cellular type and recently they have been discovered also on Treg cells. 
Treg cells express higher level of TLR4, TLR5, TLR7 and TLR8 in comparison with effector CD4
+
 T cells. 
TLRs ligands can exert a positive or negative effect on Treg cells activity. Activation of TLR5 provokes an 
increase in Treg immune suppression while activation of TLR2 and TLR4 leads to cells proliferation and 
augments Treg activity. The influence on Treg number and activity was confirmed in studies conducted with 
animal models, mice knockdown for TLR2 or TLR4 were characterized by fewer Treg cells than control mice 
and the administration of TLR2 or TLR4 ligands (respectively bacterial lipoprotein and LPS) in wild type mice 
increases Treg cell number. Moreover the treatment with LPS increases the immunosuppressive ability of 
Treg by 10-fold. By contrast TLR8 and TLR9 activity antagonizes Treg immune suppression, TLR8 acts 
directly on Treg while TLR9 attenuates suppressor activity of Tregs and at the same time it induces 
expansion of effector T cells rendering them more resistant to the regulation exerted by Tregs. It‟s supposed 
that negative effects on Treg-mediated immune suppression could be realized through an alteration in Foxp3 
expression but how it happens still remains unclear. The modulation of Treg activity can be carry out with an 
indirect mechanism involving DCs. TLR-induced activation of DCs leads to the secretion of soluble factor like 
IL6 or IL1 which, as previously described, display negative effects on Treg activity. [65, 66, 67, 68] 
4.3. PD1 pathway, Treg cells and their involvement in HIV infection 
PD1 (Program Death receptor 1) is an inducible receptor expressed on CD4
+
 T cells, CD8
+
 T cells, NKT, B 
cells and activated monocytes. It‟s a monomer with a cytoplasmic domain containing two tyrosine-based 
motif. PD1 transduces an inhibitory signal when crosslinked with TCR or BCR. 
It represents a discriminatory marker for the identification of naïve and activated Treg cells, according to its 
cellular localization. Naïve Treg cells retain PD1 in intracellular compartments and when they are stimulated 
via TCR, PD1 is exposed on their surfaces. Cellular ligands of PD1 are PDL1 (B7H1) and PDL2 (B7DC). 
PD1 is expressed on CD4
+
 T cells, CD8
+
 T cells, NKT cells, B cells and monocytes upon activation. PDLs 
differ in their expression, PDL1 is expressed much more broadly than PDL2. PDL1 is constitutively 
expressed and moderately induced upon inflammation on B cells, DCs and macrophages while PDL2 is 
found on activated DCs and macrophages. PD1-PDL pathway regulates the immune response in both 
lymphoid and non-lymphoid organs. [69, 70] 
Treg cells are also characterized by the presence of both PD1 and PDL1, anyway less is known about their 
influence on Treg cells function. To date several efforts have been made to clarify the effects of PD1-PDL1 
pathway in the regulation of T-cell responses, it‟s well established that Tregs, through PD1, inhibit T cell 
proliferation and cytokine production.  
4.3.1. PD1-PDL1 pathway in HIV infection 
PD1 pathway is involved in several cellular processes, it plays a pivotal role in both central and peripheral 
tolerance where it avoids the onset of autoimmune diseases and it ensures the maintenance to self-
tolerance. 
Furthermore it‟s implicated in infectious diseases, in fact several groups studied the existence of differences 
in PD1 pathway involvement in various infectious disease. It has been demonstrated that the establishment 
of an infection caused by non persisting virus displays different effects on PD1 expression than that seen in 
association with chronic infection. 
PD1 expression on T cells infected by non persisting virus is lower compared to the one on T cells infected 
by virus like HIV, HBV and HCV that might cause chronic infection. The higher expression of PD1 on virus-
specific T cells can influence antiviral immune response limiting their function and proliferation. The 
persistent immune suppression leads the cells in a state of exhaustion, characterized by inability to 
proliferate, to produce cytokines and consequently to direct immune responses. Persistent immune 
exhaustion may lead T cell apoptosis through the mechanism of AICD. It has been demonstrated that 
blocking the PD1-PDL1 pathway with specific antibodies reverts the exhausted status of T cells and restores 
effector function. PD1 also might serve as a useful marker to indicate the degree of T-cell exhaustion and 
disease severity (fig.12). The level and percentage of PD1 expression on HIV-specific lymphocytes 
correlates with the viral load and declining of CD4
+
 cell count. Moreover it‟s evident that HAART therapy 
reduces PD1 expression on HIV-specific lymphocytes so it can be assumed that high viral load stimulates 
PD1 expression and functional exhaustion. Similarly PD1 might be a marker for disease progression in HCV 
infection, as it‟s upregulated on HCV-specific CD8
+
 T cells and it declines in patients with resolving infection 
but it remains high in patients who develop chronic infection. [71, 72, 73] 
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Figure 12. PD1/PDL1 pathway and its role in immune exhaustion. 
 
Clerici‟s group analyzed PDL1 expression during HIV infection and they proposed PDL1 as a marker of 
disease progression because of its increasing expression during the course of infection. The data obtained 
demonstrated that PDL1 was up-regulated on PBMC of HIV-infected patients and that this increase was 
associated with a reduced CD4 cell count and an augment of HIV plasma viremia. Furthermore HIV infection 
leads to an impairment of immune responses with an increased secretion of type 2 cytokines like IL10. IL10 
displays immune suppressive actions towards Th1 activation and it enhances HIV entry into target cells 
through the up-regulation of CD4 and CCR5. Concomitantly HAART therapy was highly effective in 
enhancing CD4
+
 T cell count and in reducing IL10 production, this was positively correlated with the 
reduction in PDL1 expression observed. That findings supports the idea of the direct involvement of PD1-
PDL1 pathway in the degree of HIV infection. [74] 
4.3.2. Treg cells in HIV infection 
Several factors have been implicated in the impaired immune response that characterizes HIV infection. 
Treg cells-mediated immune suppression plays an essential role in the incapability of immune system to 
overcome the infection. Long efforts have been made to define how and when this process can influence the 
disease. 
The initial phase of infection is characterized by a strong immune activation in primary sites of infection, the 
mucosal tissues, that causes CD4
+
 T cell depletion and disease progression. Because of this chronic 
immune activation, the expansion of Treg cells can be interpreted as a protective mechanism trying to 
control and attenuate the HIV-induced chronic immune activation. 
Treg cells express both CXCR4 and CCR5 co-receptors and so they are suitable target for HIV-1 infection. In 
particular, in vitro, it has been discovered [75] a greater susceptibility to HIV infection by X4 viral strain than 
by R5 strain, this allows to suppose that in the early phase of infection, typically characterized by R5 viral 
strain infecting mucosal macrophage and CCR5-expressing DCs, Treg cells could be protected from HIV-1.  
HIV-1 might display several effects on Treg functionality and localization. HIV-1 replicates successfully in 
activated Treg cells while in resting Treg cells it results in abortive infection, moreover it has been 
demonstrated that HIV-1 infected Treg cells have an increased expression of homing receptors, CD62L and 
α4β7, to peripheral lymph nodes and mucosal tissue. These two receptors are expressed also by 
conventional CD4
+
 T cells and cross-linking of α4β7 induces apoptosis in these cells, by contrast in vitro 
Tregs resulted to be resistant to apoptosis. Treg cells resistance to apoptosis induced by α4β7 cross-linking 
worsen the immune dysfunctions characterizing HIV infection. [76] 
 
Survival of Treg cells is also guaranteed by the induction of bcl-2 expression and because of the up-
regulation of Foxp3 expression.  
Treg can directly interact with HIV through Foxp3 action and CD4-gp120 interaction. 
Foxp3 is able to influence the expression of several HIV gene. FoxP3 is a transcription factor containing 
prolin-rich amino terminal domain reported to function as a nuclear factor of activated T cells (NF-AT) and 
NF-kB binding domain, a central region important for protein-protein interactions and a carboxyl-terminal 
forkhead domain required for nuclear localization and DNA-binding activity. FoxP3 with its aminoterminal 
domain might establish protein-protein interactions with NF-AT and NF-kB factors and acting like a 
transcriptional repressor. Regarding HIV gene expression, it is dependent on NF-kb activity and it‟s regulated 
by two NF-kB sites located within LTR sequences. Considering that LTR sequences play the role of 
enhancer of HIV genes transcription, when FoxP3 interacts with them binding to the NF-kB sites through its 
amino terminal domain it suppresses the viral transcriptional activity. 
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As Foxp3 interferes with the activation of NF-kB pathway, Treg cells might be resistant to HIV replication, 
moreover the negative effect played by Foxp3 on NF-kB could protect Treg cells from HIV-mediated cell 
death. The same effect played by FoxP3 has been observed with HTLV-1 infection, in this case its inhibitory 
action is directed on the CREB pathway. [77] By contrast a study by Holmes et al. assumes that FoxP3 
enhances HIV-1 gene expression by modulating chromatin structure and NF-κB activity. [78] 
It can be supposed that Foxp3 interacts with distinct HIV LTR sequences and, according to type of 
interaction and cellular type, it‟s possible to obtain repressor rather than inducing effect. Anyway further 
investigations are required. [79] 
It has been verified that, thanks to the interaction between CD4 and gp120, HIV is directly responsible of 
increased FoxP3 expression, survival and immune suppressor activity of Treg cells. Gp120 and Tat play a 
pivotal role because, as previously described, gp120 increases the expression of FoxP3 and inhibits Treg 
apoptosis while in DCs Tat increases CTLA-4 expression and the suppressive strength of Treg cells. 
This explains why during HIV infection Treg cells depletion or impairment are not observed despite the 
persistent impairment of immune responses able to eradicate the infection. [76, 79, 80] 
Experimental evidences, coming from a study directed by Tsunemi, suggested that HIV infection leads to the 
induction of Treg that inhibits antiviral immune responses in early stage disease, while in progressive 
disease, Treg function is decreased which results in immune activation and CD4
+
 T cell lymphocytopenia. 
In particular, it has been underlined the interplay between HIV infection and Treg activity. Patients 
characterized by a progressive HIV infection, identified by high level of plasma HIV RNA (>50 copies/ml), 
showed an increase in Treg cells frequency and this was inversely correlated with CD4
+
 T cell count but may 
be these Treg cells has lower immune suppressive capacity seen the progression of the disease and 
according to data obtained. [81] 
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5. HIGHLY ACTIVE ANTIRETROVIRAL THERAPY – HAART 
Several efforts have been made to eradicate HIV virus and up to now many goals have been reached  
Each step of HIV replication represents a potential target for antiretroviral drugs and so they are classified 
according to the viral life-cycle phase they inhibit. Drugs are divided into two main categories: drugs that 
inhibit the virus replicative cycle and drugs that interfere with the adhesion process (fig. 13). 
Drugs able to influence the replicative cycle of HIV include 
 Inhibitors of the Reverse Transcriptase, nucleotide (NRTI) and non nucleotide (NNRTI) 
 Integrase strand transfer inhibitors (II) of integration of proviral DNA into cellular DNA 
 Inhibitors of assembly, maturation or fusion of viral particles: protease inhibitors (PI). fusion inhibitors 
(FI), entry inhibitors (EI), maturation inhibitors (MI) and chemokine R5 inhibitors (CCR5 inhibitors).  
 
Figure 13. Replication cycle of HIV with indicated targets of antiretroviral drugs. 
 
NRTIs are the first class of antiretroviral drugs developed and they act on HIV reverse transcriptase as 
competitive inhibitors by blocking the addition of nucleosides to the DNA chain during reverse transcription of 
the HIV genome. Actually commercial drugs include: Abacavir (ABC), Didanosine (DDI), Emtricitabina (FTC), 
Lamivudina (3TC), Stavudina (d4T), Tenofovir (TDF) and Zidovudine (ZDV). 
NNRTIs interfere with the activity of RT through a non competitive mechanism, they block hydrophobic 
pocket of p66 subunit of RT inducing a conformational change that alters the catalytic site of the enzyme. 
The main drugs belonging to this category are Delavirdina (DLV), Efavirenz (EFV), Etravirine (TMC125) and 
Nevirapine (NVP). 
INSTIs, integrase strand transfer inhibitors act on viral integrase, a protein involved in the integration of viral 
genome in the DNA of the host cell, Raltegravir (RAL) is one of these. 
PIs bind to the catalytic site of HIV protease blocking its ability in originate viral proteins from the cleavage of 
precursor protein. HIV protease regulates the generation of mature core and capside proteins and 
consequently the assembly of infectious virions, the absence of protease activity leads to the production and 
release of immature, non infectious virions. Atazanavir (AZT), Darunavir (DRV), Fosamprenavir (FPV), 
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Indinavir (IDV), Lopinavir (LPV), Nelfinavir (NFV), Ritonavir (RTV), Saquinavir (SQV) and Tipranavir (TPV) 
are drugs belonging to this category. 
IFs work in competition with gp41 blocking fusion and entry process of the virus into host cells, Enfuvirtide 
(ENF) belongs to this group. 
CCR5 inhibitors block the entry of HIV into CD4 T cells by binding to CCR5 protein. Maraviroc (MVC) is one 
of this. 
NRTIs NNRTIs and PIs are the three main antiretroviral classes currently used to treat HIV-1 infection in both 
treatment-naïve and treatment-experienced patients. Administration of a NNRTI or NRTI alone is able to 
reduce plasmatic level of viral RNA but not to block disease progression; while a therapy based on a single 
PI isn‟t recommended given the high risk of early onset of mutant strains of the virus.  
Nowadays the therapeutic approach is based on a combined therapy. The combined therapy is based on the 
administration of drugs with synergistic effects and it‟s called Highly Active AntiRetroviral Therapy (HAART). 
Current international guidelines suggest to combined 2 NRTI and 1 NNRTI or 2 NRTI and 1 PI because are 
combinations well tolerated and with less drug interaction, furthermore the PI might be boosted with Ritonavir 
to increase the power of treatment. Ritonavir is poorly tolerated because of its high toxicity and so it has to 
be administer in sub-therapeutic dose. 
HAART is an effective way of treatment to control viral replication and to increase CD4
+
 T cell count.  
Several parameters are monitored to decide when to start HAART therapy administration but the main ones 
are CD4
+
 T cell count (<350 cells/ml) and viral load. Several clinical trials have been conducted to elucidate 
which are the positive and negative parameters implicated in a successful therapy: a decrease in CD4
+
 T cell 
is an important factor that should always be considered in initiating an antiretroviral therapy, anyway it must 
be underlined that there isn‟t a threshold at which starting it. 
Therapy is recommended regardless of CD4
+
 T cell count in the following settings: increased risk of disease 
progression associated with a rapid decline in CD4
+
 T cell count or a plasma HIV-1 RNA level greater than 
100.000 copies/ml, older than 60 years, pregnancy, chronic HBV and HCV coinfections, opportunistic 
infections and heightened risk of HIV transmission (ie, HIV-serodiscordant couples). [82, 83, 84] 
Nevertheless initiating the therapy with a higher number of 350 cells/ml CD4
+
 T cells might have beneficial 
effects like maintaining a high T cell count, reducing the risk of HIV-associated complications, coinfections 
and transmission. 
Moreover studies conducted in SIV-infected macaques showed that initiation of early therapy might mitigate 
the early and profound loss of T cells within gastrointestinal lymphoid tissue and enhance tissue repair 
critical to restoring the mucosal immune system. This aspect is of key importance in controlling and reducing 
the immune activation that characterizes HIV infection. 
To date in literature have been published only 4 randomized controlled trials. All of them underlined the fact 
that early therapy reduces viral load, immune activation and increases CD4
+
 T cell count. Benefits in early 
starting HAART have been proved but data regarding virological control after treatment interruption are still 
conflicting. 
Among benefits there are potential disadvantages of early treatment such as HAART-related toxicity and 
drug resistance important factors in determining the failure of therapy.  
To avoid drug resistance, current guidelines suggest to test genotyping drug resistance at the time of HIV 
diagnosis and before initiation of HAART, this might be useful in choosing the right drug combinations to 
have positive effects in controlling HIV replication and in inducing T cell recovery. Drug-drug interactions are 
a specific problem for PIs and NNRTIs, because both classes are metabolized through the cytocrome P450 
hepatic metabolic enzyme system and they exhibit inductive or inhibitory activities on specific subsets of this 
system in complex. Ritonavir is a strong inhibitor of the cytocrome P450 system. [85] 
Responsiveness to antiretroviral treatment should be evaluated after 4 weeks and 3 months after initiation of 
therapy through the control of HIV-RNA levels. Generally HAART display its efficacy in 4-6 months with 
suppression of viral replication less than 50 copies/ml and an increase of 100-150 cells/mm
3
/year of cell 
count. 
5.1. Immune reconstitution with HAART 
The kinetic of immune reconstitution with HAART is a two phase process (fig.14). 
In the first 2-3- months a reduction in viral load (1-2 log10 of viral copies) can be observed and usually this is 
coupled with an increase in CD4
+
 T lymphocytes count, with an average rate of 20 to 30 cells/µl monthly. 
This phase is accompanied by a reduction of circulating pro-inflammatory cytokines such as TNFα, IL6 and 
MCP-1. This trend is observed each time HAART therapy is initiated independently from the phase of the 
infection. It has been demonstrated that the increase of CD4
+
 T cells is negatively correlated with the viral 
load before the treatment as well as the extent of CD4
+
 T depletion pre-HAART. 
The second phase of immune reconstitution occurs over several years and the extent of recovery depends 
upon the magnitude and sustainability of viral control but not on the extent of CD4 depletion before 
treatment. CD4
+
 T cell count over 200 cell/mm
3
, which guarantees a protection against opportunistic 
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infections, is reached in 2-4 years of therapy and it depends on the rate of the immune system impairment at 
the beginning of antiretroviral therapy, the control of viral replication and age.  
 
Figure 14. Schematic representation of the mechanism of CD4
+
 T cell reconstitution after HAART initiation. 
 
Several studies have demonstrated that most of the initial reconstitution seems to be the consequence of a 
redistribution of memory CD4
+
 T cells from the lymphoid tissue toward the blood compartment, this was 
confirmed by immunophenotipic analysis showing an increase in the expression of CD45RO and in a down-
regulation of adhesion molecules like VCAM-1, ICAM-1 and of CCR7, CD62L lymphoid-homing receptor by 
CD4
+
 T lymphocytes. These adhesion molecules play a role in maintaining CD4
+
 T cells into secondary 
lymphoid organs, as their down-regulation leads to the release of CD4
+
 T lymphocytes into the periphery.  
Memory CD4
+
 T cells are retained in the lymphoid tissue to set immune responses against viral replication, 
so their redistribution might be correlated with a viral load reduction secondary to HAART therapy. 
The repopulation of CD4
+
 T pools is a double step process. In the first step the increase is related to memory 
cells while the second step is up to the CD45RA
+
 naïve pool, leading to the achievement of a normal ratio 
between naïve and memory T lymphocytes. 
Experimental evidences explained that the increase of naïve CD4
+
 T cells is due to a direct thymic activity 
and not to conversion of CD45RO
+
 CD4
+
 T cells. The thymic output of naïve CD4
+
 T cells can be monitored 
through TREC level analyses. TREC stands for TCR Rearrangment Excision Circle, they are episomal DNA 
sequences resulting from TCR gene rearrangement in the thymus, so naïve T cells with high content of 
TREC refer to recent thymic output. Moreover TREC level is inversely correlated to viral load and it is higher 
in younger than older HAART-treated patients because in the last one thymic production is impaired. 
IL7/IL7R pathway is involved in thymic output too. HAART decreases IL7 level and it has been observed that 
higher level of IL7 pre-HAART is positively correlated with higher ex novo production of thymic CD4
+
 T cells 
and of TREC level. [86, 87] 
Important evidences come out from a study conducted by Tan, he enrolled HIV-infected patients starting 
antiretroviral therapy at the time of the recruitment and analyzed immunologic and virologic responses after 3 
to 9 months from HAART initiation. Tan observed that the type of immunologic and virologic responses in 
this short period might be predictive of long-term clinical outcomes relative to disease progression. Patients 
without suppression of viral load and CD4
+
 T cell recovery were predisposed to a faster negative progression 
of the disease. He supposed that the first months of antiretroviral treatment are the more important to 
determine the clinical outcome and that this is independent from the therapeutic regimen adopted. [88] 
5.2. Failure of HAART: Immunological Non Responder patients 
The 15-30% of HIV-infected HAART-treated patients have discordant responses to long-term treatment 
consisting of a lack in CD4
+
 T cells count increase despite a full suppression of HIV replication, they are 
called immunological non responder (INR). 
Several factors have been associated with immunological failure during HAART: age, CD4
+
 T cell nadir, 
adherence to antiretroviral therapy, concurrent viral hepatitis, failure in de novo CD4
+
 T cell production and 
excessive CD4
+
 T cell destruction. 
Older age is negatively correlated with de novo CD4
+
 T cell production because older patients have a restrict 
pool of naïve T cells which is insufficient to compensate for CD4 T
+
 cell depletion induced by HIV. 
CD4
+
 T cell nadir is the number of CD4
+
 T lymphocytes which are present in a HIV-infected patient before 
initiating antiretroviral therapy. It has been proved that low CD4
+
 T cell nadir is inversely correlated with 
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lymphocyte recovery. Recent evidences demonstrate that CD4
+
 T cell count greater than 500 cells/µl and 
long-term combination of antiretroviral therapy might be positive factors for a better outcome of the disease: 
presence of 500 cells/µl after 6 years of HAART has been associated with the same rates of mortality as 
among the general uninfected population. Thus, CD4
+
 T cell nadir influences not only the possibility to 
normalize cell count in response to therapy but also affects the time needed to reach this goal and the time 
between HAART initiation and achievement of CD4
+
 T cell count more than 500 cells/µl was found to be 
significantly longer in individuals with lower baseline lymphocyte count.  
Moreover the presence of concurrent viral infections and mainly viral hepatitis, might contribute to the 
immunological failure during HAART as the presence of coinfection contributes to a persistent immune 
activation. At last loss of adherence to antiretroviral therapy provokes viral rebounds that worsen the 
situation [89, 90]. 
5.2.1. Failure in de novo CD4+ T cell production 
Failure in de novo CD4
+
 T cell production may be due to persistent bone marrow impairment, smaller 
thymuses and lower thymopoietin levels, normal plasmatic IL7 levels and defective IL-7R expression. [91] 
Marziali conducted a pivotal study which clarified some of the mechanisms involved in the failure of de novo 
cell production. He suggested that IL7/IL7R pathway plays a fundamental role in this process. IL7 is a key 
cytokine in the regulation of T-cell homeostasis because of its effects on thymopoiesis and a survival factor 
for naïve and memory lymphocytes. Moreover IL7 acts as a co-stimulatory molecules after T-cell activation. 
IL7Rα is IL7 receptor and an impairment in IL7/IL7Rα pathway has been directly correlated with CD4
+
 T cell 
depletion. In this study he observed that INR patients showed a reduction in IL7Rα expression both on naïve 
and memory CD4
+
 T cells and a positive correlation between the percentage of CD4
+
 T cells and the 
expression of IL7Rα receptor as well as an inverse correlation between IL7 level and CD4
+
 cell count. Thus 
defects in the expression of IL7 receptor is directly involved in the failure of CD4
+
 T cell recovery observed in 
INR patients. [92] 
In another work Marchetti et al. demonstrated, that INR are characterized by high level of plasma IL7 
because of a reduced consumption of this cytokine due to a decrease in the expression of its receptor rather 
than an increased production. [93] 
Recently Rajasuriar et al. studied the correlation between the 4 haplotypes of IL7Rα gene and immune 
recovery. Haplotype 2 was significantly associated with more rapid immune recovery. IL7Rα exists also in 
soluble form and in that case it may limit the availability for IL7 to mediated its effects on T cells. HIV-infected 
patients homozygous for haplotype 2 have significant lower sIL7Rα levels than those presented by non-
haplotype 2 carriers so there‟s a great availability of IL7 to bind to the membrane-bound receptor. Moreover 
it has been proved that high IL7 level downregulates IL7Rα expression on lymphocytes so low pre-HAART 
IL7 level is directly correlated with improved thymic function. [94] 
In 2008 Isgrò et al. clarified that the impairment of naïve T cell depends on an alteration in bone marrow 
cellular components mainly due to apoptotic mechanisms and changes in cytokine production. HIV-infected 
bone marrow cells secrete large amounts of proinflammatory cytokines, such as TNFα, which inhibit 
hematopoiesis by the induction of apoptosis through the FasL-Fas pathway on the bone marrow progenitor 
cells. This cytokine unbalance is mainly dependent on TNFα and IL2. TNFα has a suppressive effect on 
bone marrow progenitors, it influences cell viability, modulates the expression of cytokine receptors on the 
cell surface and induces the expression of Fas receptor on progenitors cells. By contrast, IL2 is a strong 
growth and survival factor. HAART treatment induces an amelioration of stem cell activity, a restoration of 
stromal cell pattern and functions. Regarding cytokine environment, antiretroviral treatment reduces TNFα 
and increases IL2 levels but these changes do not occur in immunological non responder patients. 
Conversely, INR patients are characterized by TNFα augmented level, IL2 reduced level and alteration of 
IL7/IL7Rα pathway. Furthermore, CD4
+
 T cell depletion observed in INR patients cannot be reverted by 
augmented thymic output because the reduced clonogenic potential of bone marrow lymphoid progenitors 
cannot replenish the loss of thymocyte progenitors. [93, 94, 95, 96] 
5.2.2. Excessive CD4+ T cell destruction 
Excessive CD4
+
 T cell destruction may be provoked by ongoing viral replication, CD4
+
 T cell hyperactivation, 
persistent antigenic stimulation (LPS) and immune regulatory mechanisms. 
Several factors are implicated in the immunological impairment characterizing HIV infection. 
 
INR have been shown to have higher levels of proviral DNA in total, memory and naïve CD4
+
 T cells, 
reinforcing the role of increased HIV antigen-driven CD4
+
 T cells in INRs. The persistence of residual 
undetectable low-level viral replication contributes to the maintenance of HIV-1 reservoir in these patients 
and triggers immune activation. It has been observed that proviral DNA is associated with CD4
+
 T cell 
activation, with the increase of CD4
+
 T effector cells and consequently it influences the immune 
reconstitution. Furthermore, the frequency of CD4
+
 T cells containing HIV-1 proviral DNA is inversely 
correlated with CD4:CD8 ratio suggesting that persistent HIV-1 replication is a crucial factor in determining 
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the CD4
+
 T lymphocyte depletion. Moreover in absence of disease progression and CD4
+
 T cell recovery, 
CD8
+
 T cells predominate in order to maintain total T cell homeostasis even if it interferes with regeneration 
of CD4
+
 T cells. Ostrowski confirmed this findings investigating the associations between low level viremia, 
proviral DNA, CD4
+
 T cell gain and T cell subsets in INR patients. He found that reduction in CD4
+
 T cell gain 
might be due to a constant ongoing viral replication that persists even in the presence of antiretroviral drug 
treatment. Ongoing viral replication influences also the homeostatic balance of immune cells in fact INR 
patients were characterized by an increase in percentage of memory and activated CD4
+
 and CD8
+
 T cells 
despite a reduction in the percentage of naïve T cells, indicating that proviral DNA level interferes with 
immune reconstitution. Furthermore another study [97] confirmed that higher CD4
+
 T cell activation and 
proviral DNA lead to a naïve T lymphocytes decrease and an increase in cell death due to hyperexpression 
of Fas death, thus these might be critical parameters for the lack of immune recovery characterizing non 
responder patients. [91, 98, 99] 
 
HIV induced immune activation might be one of the mechanism responsible for damaging the immune 
system. CD4
+
 T cell hyperactivation has been demonstrated to persist even after HAART-induced virological 
suppression and to play a significant role on CD4
+
 T cell count recovery during antiretroviral treatment. CD4
+
 
T cell depletion may occur both for persistent activation and for virus-directed cytophatic effect, as a 
consequence the immune system tries to replenish cells depletion stimulating the activation and proliferation 
of naïve and central memory lymphocytes. Experimental evidences, coming from a study conducted by Hunt, 
confirmed that INR patients were characterized by a higher level of activated CD4
+
 and CD8
+
 T cells than FR 
patients but that this increase was not accompanied by CD4
+
 T cell recovery, which is normally induced by a 
successful antiretroviral therapy. This lack in CD4
+
 T cell gain might be due to major susceptibility of HIV-
infected cells to apoptosis, besides the increase in activated CD8
+
 T cells was associated with lower CD4
+
 T 
cell gains confirming once more how CD8
+
 T cell activation represents the ideal marker to predict disease 
progression. Moreover the presence of coinfections increases CD4
+
 T cell hyperactivation, and worsen the 
situation. [100, 101] 
Excessive destruction might also be due to an exaggerated apoptosis, Pitrak and colleagues demonstrated 
that INR patients are characterized by high levels of apoptosis and they infer that this mechanism plays an 
important role in lymphocyte destruction because of the existence of a negative correlation between 
apoptosis and CD4
+
 cell count. [102] 
HAART reinvigorates cellular pool by blocking HIV replication and virus-induced hyperactivation, however in 
INR patients, immune activation is reduced compared to HAART-naïve patients but it never return to 
physiologic level. This persistent basal state of immune activation is identified as “residual immune 
activation” and several mechanisms might provoke it. Persistent low levels of virus replication and microbial 
translocation are two of them. Persistent virus replication may depend on the size of reservoir compartment 
established prior of HAART initiation suggesting that a more potent antiretroviral regimen and an early 
initiation of therapy might be more effective in reducing both virus replication and immune activation. [34] 
 
Moreover, as previously said, the acute phase of HIV infection is characterized by a strong activation of 
lymphocytes localized at the mucosal surfaces and T cell activation has been associated with disease 
progression in untreated HIV-infected individuals. Untreated HIV infected individuals are characterized by 
high level of lymphocytes proliferation and apoptosis due to ongoing T cell activation and enhanced HIV 
replication in infected cells caused by their increase susceptibility. 
In HAART-treated patients with persistent CD4
+
 T cell depletion, the level of immune activation of memory 
cells returned to physiologic level but remained elevated in the gastrointestinal tract. HIV replication in 
mucosal tissue might be the major reason behind the persistently low levels of mucosal CD4
+
 T cells in HIV-
infected individuals on HAART with undetectable virus in blood. Experimental evidences coming from studies 
conducted on SIV-infected macaques and further on HIV-infected individuals, suggested that mucosal CD4
+
 
T-cell reconstitution may be achieved if therapy is started enough early. Mucosal CD4
+
 T cells are able to 
repopulate the MALT as long as their depletion is stopped before the restoration capacity of the immune 
system is irreversibly compromised. Mehandru and colleagues conducted a study on HIV-infected patients 
which initiated early antiretroviral treatment and they identified reconstitutor and non reconstitutor patients 
according to the ability in reconstituting lymphocytes at mucosal level. They observed that in non 
reconstitutors there wasn‟t a complete restoration of gut lymphocyte‟s pool. The conclusion was that maybe 
several factors were implicated in this process: high level of CD8
+
 T cell activation, persistence of 
inflammatory responses, altered cellular recruitment and also increased cell death due to ongoing viral 
replication or immune activation in the effector sites. Finding the right combination of antiretroviral drugs 
might be useful to control viral replication and immune activation in order to reinvigorate mucosal 
lymphocytes. [103] 
It has been supposed that non-responsiveness to therapy observed in INR patients might be due to the 
abnormal T cell activation and that this can be induced by a persistent antigenic stimulation. Recently a 
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pathogenetic model of increased translocation of microbial products from the gastrointestinal lumen has 
been proposed as a mechanism continuously triggering immune system in HIV-infected patients. LPS is the 
major microbial product involved in the impairment in the gastrointestinal mucosal barrier. Considering that 
mucosal lymphocytes are the first to be destroyed by HIV action, mucosal barrier becomes leaky, allowing 
microbes to invade the organism. Microbial translocation may be one of the driver of immune activation and 
consequently of CD4
+
 T cell loss. [28, 30] 
Brenchely demonstrated that in HIV-infected individuals microbial translocation correlated with the rate of 
immune activation. Furthermore, continuous hyperactivation due to antigenic stimulation contributes to the 
persistent differentiation of naïve T cells into effector cells thereby accelerating the depletion of naïve T cell 
pool. Moreover after initiation of HAART, it was observed that LPS level decreased but they remained 
elevated compared uninfected individuals, this increase in LPS concentration was directly correlated with the 
poor CD4
+
 T cell reconstitution. [27, 36, 86, 91] 
HAART therapy is able to correct immune activation and cellular apoptosis characterizing HIV infection. 
Rajasuriar and colleagues showed that pre-HAART LPS level reflect the extent of gastrointestinal lymphoid 
tissue damage sustained in the absence of HAART. They demonstrated that lower level of LPS are positively 
correlated with a faster immune recovery and so the degree of residual microbial translocation after initiation 
of antiretroviral therapy is associated with the degree on immune restoration. [94] 
This allows to conclude that HAART might be able to induce a partial repair in mucosal barrier and to control 
LPS level, anyway lack of CD4
+
 T cell recovery observed in INR patients is due to a combination of several 
factors. 
 
Treg cells are specialized T cell subpopulation with the ability to down-modulate immune activation and 
function. Several studied concentrated on their role in controlling immune activation occurring in HIV 
infection and conflicting data have been reported. Some studies reported a significant reduction in Tregs 
count in INR compared to FR patients, allowing to suppose that low level of T-regulatory activity might be 
linked to failure in CD4
+
 T cell reconstitution, others studies support the opposite hypothesis. 
HAART displays its effect on Treg cells, experimental evidences shows that Treg frequency is reduced after 
6 month of effective HAART therapy and that is correlated with the increase in CD4
+
 T cell count and a 
decrease in immune activation, typical of full responder patients but not of immunological non responders to 
HAART. Considering that Treg activity plays an important role in controlling immune responses, reduction of 
immune activation, due to effective HAART, diminished the necessity of a sustained immune response and 
consequently of a immune suppressive action. [104] 
By contrast, in a study conducted by Kolte [105] on HIV-1 infected patients after 5 years of HAART, emerges 
an increase in Treg levels although in presence of viral load suppression, normalized CD4 counts, immune 
activation and cytokines patterns. It has been suppose that this augment in Tregs level might be correlated 
with the increase thymic output of naïve lymphocytes occurring in full responder individuals. 
Different studies have been conducted to elucidate the interplay between immune activation and immune 
suppression. The gastrointestinal tract of HIV infected patients naïve to HAART therapy is shown to be 
distinguished by a high concentration of mucosal Treg cells while in HAART-treated patients the frequency of 
this cellular populations is similar to that characterizing healthy subjects. In the periphery there‟s a normal or 
a small increase of Treg level. This allows to suppose that mucosal recruitment and the subsequent 
accumulation of Treg is driven by HIV replication in order to control the infection even this implies a reduction 
in the immune response at this level and so a high susceptibility to gastrointestinal opportunistic infections in 
untreated HIV-infected patients. The same findings were observed by an other group of researchers working 
on lymphoid tonsilar biopsies and in addition they also pointed out the higher expression level of typical 
markers of Treg activity. [106, 107] 
Moreover in a study conducted by Weiss, it has been suggested that in presence of HAART, the activity of 
Treg cells in controlling residual immune activation is promoted while in absence or after interruption of 
antiretroviral therapy viral replication re-induces immune activation, this might be due to a decrease in 
absolute number of Tregs. [108] 
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6. HYDROXYCHLOROQUINE TREATMENT 
The first study in which the possible application of Chloroquine (CQ) and Hydroxychloroquine (HCQ) in the 
treatment of HIV infection was tested dates back to 1990. CQ and HCQ are antimalarial drugs most widely 
use in the world. To date, CQ has been dismissed because of continuous emerging of CQ-resistant 
Plasmodium Falciparum strains while HCQ is commonly used also in autoimmune diseases like rheumatoid 
arthritis and Lupus Eritematosus Sistemicus (LES). HCQ has practical advantages, it‟s economic, well 
distributed and not stigmatizing so a possible application in third world could have a positive effect in 
controlling HIV spreading. 
6.1. Structure and biological effects 
HCQ is a weak base that affects acid vesicles leading to dysfunction. At extracellular level it‟s in a protonated 
form disable to cross the plasma membrane, just the non-protonated form can enter in the cell where it‟s 
protonated in a manner inversely proportional to the present pH. HCQ is so accumulated in acid organelles 
like endosomes, lysosomes, Golgi vesicles where the pH is low, it affects several enzymes and post-
translational modification of proteins by increasing the pH of these acid vesicles. HCQ can be extruded 
through these organules thanks to the action of specific transporter or exocytosis mechanism. 
On the immune system, HCQ displays an anti-inflammatory action. Its accumulation in lymphocytes and 
macrophages reduces the secretion of TNFα and the expression of TNFα receptor on monocytes. HCQ can 
cause muscle weakness and retinophaty if administrated in high doses or in prolonged therapy. [109, 110] 
6.2. Anti-HIV effects of HCQ 
CQ and HCQ exert similar anti-HIV effects. They act both on X4, R5 and X4/R5 HIV-1 isolates from subtypes 
A-E, against HIV-2 and at different stages of infection. CQ and HCQ can affect the early stage of HIV 
infection or the replicative cycle of the virus, they: 1) augment pH in acid vesicles, 2) alter gp120 production, 
3) act on Tat and integrase, 4) reduce intracellular iron, and 5) reduce pro-inflammatory status. 
HCQ augments pH in acid vesicles of non infected and infected cells in a dose-dependent manner. It has 
been demonstrated that HIV-1 passed through HCQ-treated cells is non-infectious.  
The main role of HCQ is directed on gp120 glycosylation, considering the effect on pH of acid organules, it 
alters the functionality of several enzymes necessary for post-translational modification of proteins like 
gp120. The production of gp120 is reduced in cells treated with HCQ and so newly production of virion is 
compromised or anyway new virus are not able to infected other cells because of the altered conformation of 
gp120. 
Inhibitory effect of HCQ is directed to 2G12 epitope of gp120, this epitope is a conserved portion important 
for HIV infectivity. [111, 112] 
HCQ/CQ displays an inhibitory effect also on LTR activation, it reduces Tat-mediated transactivation of HIV-1 
LTR. LTR function as regulator of HIV genome transcription and define the interaction with host enzymes, 
their activation is directed by Tat activity. Moreover Tat is able to induce pro-inflammatory cytokine secretion 
when it translocates in the cytosol from endosome: HCQ/CQ blocks the translocation of Tat and 
consequently cytokine secretion and the immune activated status typical of HIV infection. [113, 114] 
HIV uses host cellular enzymes for its replicative cycle but cofactors such as iron are also necessary. This 
tissue accumulation increases HIV transcription and decreases host immunological defense. HCQ/CQ 
reduces the accumulation of iron because it interferes with cytoplasmic release from ferritin and with 
transferring-transferrin receptor uptake. Ribonucleotide reductase is an enzyme involved in HIV replicative 
cycle it contains an iron ion in its catalytic site, in the absence of iron this enzyme is inhibited and as a 
consequence there‟s a decrease in the integration of pro-viral DNA in host genome. [115] 
6.3. HIV immune activation and HCQ 
HIV infection is characterized by a strong and persistent immune activation that provokes apoptosis in 
continuously activated cells and the establishment of a pro-inflammatory state. HCQ/CQ is known to 
suppress immune activation by several mechanism like inhibition of TLR signaling and inflammatory cytokine 
secretion. 
As previously said immune activation can be detected thanks to specific markers expressed on cell surface 
(CD38) or at intracellular level (KI67), it can be induced in presence of persistent antigenic stimulation and 
microbial translocation. 
Recently in literature it has been published a study based on a double-blind, randomized placebo-controlled 
trial on chronically HIV-infected subjects receiving CQ or placebo. In this clinical trial it was verified that the 
administration of CQ decrease in the expression of CD38 on CD8
+
 T memory cells and of Ki67 on both 
lymphocyte population. HCQ/CQ reduces TLR signaling pathway, and this in turn might be responsible for 
the reduction in immune activation. [116] 
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HCQ/CQ blocks the translocation of TLR from endoplasmic reticulum to early/late lysosomes because it 
alters the acid pH present in the endosome useful for the binding between TLR and viral nucleus acid 
products. In vitro studies confirmed that CQ inhibits pDC activation and maturation, the MyD88 pathway 
signaling molecules IRF-7 and IRAK4, IFNα production and IDO synthesis. Inhibition of pDC activation and 
maturation is due to the ability of CQ to block endosomal fusion and acidification leading to a suppression in 
HIV-1 TLR signaling with consequently inactivation of pDC due to the failure in upregulating IRAK 4 and IRF 
7. Moreover IFNα production is induced by the activation of genes regulated by TLR signaling pathway and 
in previously studies it has been demonstrated that immune activation of CD8
+
 lymphocytes is correlated 
with IFNα action. Thus, it can be infer that CQ is able to reduce immune activation thanks to the reduction in 
IFNα concentration. 
A consequence of HIV infection is the induction of the IDO enzyme in virus activated pDC which directly 
inhibits T-cell proliferation thanks to the induction and stimulation of Tregs, and the induction of PDL1/PD1 
pathway. HIV-1 up-regulates the expression of PDL-1 on pDC surface which in turn can exert immune 
suppressive activity in T target cells expressing PD1 receptor. CQ, inhibiting IDO and PDL1 expression on 
pDC, reverts immune suppression improving T cell survival. In conclusion CQ is able to control HIV-induced 
immune activation and immune suppression, consequently the use of CQ as an adjuvant in combination with 
HAART could be an effective and inexpensive approach to control immune activation and reduce the risk of 
comorbidities for HAART-HIV-infected individuals. [117, 118] 
6.4. Combined therapies: HCQ and antiretroviral drugs 
HCQ shows anti-HIV effects and absence of cross-resistance with other HIV-1 drugs, so several studies 
have been conducted to evaluate a possible and positive combined therapy.  
It has been demonstrated that in vitro HCQ could have different effects depending on the association with 
specific antiretroviral drugs. 
In vitro HCQ shows synergistic effect with protease inhibitors (PIs) because it inhibits efflux mediated by two 
important cell surface drug transporters P-glycoprotein and MRP-1. These transporters are responsible for 
the efflux of intracellular antiretroviral pools to extracellular compartments, HCQ blocks their activity leading 
to an increase of intracellular concentration of antiretrovirals. This discover is important for the treatment of 
drug-experienced HIV infected patients who have developed multiple resistances to antiretroviral drugs and 
thus have limited therapeutic options. [119] 
Several pilot studies concerning the treatment of HIV infected patients with hydroxychloroquine are 
documented in literature. The first study was directed by Sperber in 1995. It was a randomized, double-blind, 
placebo-controlled study in which HCQ or placebo was given to HIV infected patients asymptomatic, with 
CD4
+
 T cell counts between 200 and 500 cells/mm3, and not under antiretroviral therapy for at least 2 month 
because HCQ was given at higher dose (800mg/d) than the one normally used in the treatment of rheumatic 
disease (400mg/d). Anti-viral effect of HCQ was demonstrated by the significant decrease in plasmatic levels 
of viral RNA and by the marked reduction in plasmatic concentration of IL6 and viral RNA in HCQ group 
compared to placebo one despite a stable CD4
+
 T cell count. [120] 
In an other study, 144 weeks long, it was evaluated a combined therapy with HCQ, Hydroxyurea (HU) (an 
inhibitor of ribonucleotide reductase) and Didanosine (DDN). At the end of the study positive effects on 
immune system responses, were observed for example a reduction of CD8 percentage accompanied by a 
significant increase in CD4
+
 cell count, moreover this drug combination was well tolerated and safe when 
administered in asymptomatic HIV infected patients. [121] 
Paton and collegues concentrated on a possible association between HCQ, HCM and DDN. HCM (also 
called HU) is an inhibitor of ribonucleotide reductase while DDI is a NRTI. HIV infected patients were treated 
with this drug combination for 48 weeks. After 12 weeks it was observed an increase in the percentage of 
CD4
+
 T cell count and a reduction in viral load, these positive effects were sustained up to week 48. Even if 
the recovery of CD4
+
 cell count is less than that obtained during HAART therapy alone, HCQ shows slow 
development of resistance so it increases the durability of this regimen. Above all, this drug combination is 
well-tolerated with mild side-effects none of which resulted in discontinuation of treatment so it can be easily 
used in developing countries even because of its low cost. [122] 
In conclusion combined therapy based on the association of HCQ and antiretroviral drugs might be useful in 
the treatment of HIV infected patients which show multi-drug resistance or in developing countries where 
there are economic and drug-manufacturing problems  
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HIV infection is characterized by a profound and continuous depletion of CD4
+
 T lymphocytes and by an 
impairment of immune response. To date antiretroviral therapy is a combined therapy able to persistently 
reduce viral replication and induce CD4
+
 T cell recovery. Despite the efficacy of this therapy, demonstrated 
by several clinical studies, 15%-30% of patients have discordant responses to long-term HAART consisting 
in the lack of CD4
+
 T cell increase despite a full suppression of HIV replication; these patients are known as 
immunological non responders (INR). 
Several factors are thought to be involved in the failure of the immune recovery, the most important are: 
failure in de novo CD4
+
 T cell production, excessive in CD4
+
 T cell destruction, CD4
+
 T cell nadir pre-therapy 
and adherence to antiretroviral therapy. Failure in de novo production of CD4
+
 T cells might be provoked by 
damage of primary lymphoid organs and damage in cytokine circuit that should ensure cell survival (mainly 
IL7 and IL7R pathway). To date it‟s supposed that persistent depletion of CD4
+
 T cells is correlated with an 
excessive hyperactivation of immune system, so that CD4
+
 T cells are induced to apoptosis by the presence 
of HIV infection and continuous hyperactivation depletes naïve T cell pool leading to the failure of immune 
system to properly respond to the infection. 
The aim of this study was to better understand the mechanisms responsible for the excessive CD4
+
 T cell 
destruction observed in INR patients. According to what described in the literature, CD4
+
 T hyperactivation, 
ongoing viral replication, persistent antigenic stimulation and immune-regulatory mechanism, are all factors 
that might explain this process. 
Moreover, recent evidences show that HCQ, an anti-malarian drug, has been widely used for the treatment 
of various autoimmune diseases because of its ability in modifying pH in endosomal vesicles. HCQ has 
immune-modulating properties and it has been also demonstrated that HCQ has anti-HIV activity. 
Considering the role played by HCQ in the treatment of HIV infection, the second part of this study aims to 
determine whether HCQ might be useful in augmenting CD4
+
 T cell count in immunological non responder 
patients and in modifying the most common parameters usually altered in HIV infected patients 
characterized by a cell count less than 200 cells/µl. 
 
Thus, in the first part of the study we are going to compare HAART-treated patients presenting CD4
+
 cell 
counts more than 500 cells/µl and HAART-treated patients presenting CD4
+
 cell counts less than 500 
cells/µl, analyzing: 
 Treg cell percentage 
 apoptosis 
 immune activation 
 microbial translocation 
 
In the second part of the study, our attention will be focused on the population of HIV-infected patients 
immunological non responder to HAART with an absolute CD4 count less than 200cells/µl and treated with 
HCQ to evaluate: 
 markers of immune activation 
 presence of a pro-inflammatory environment 
 changes in microbial translocation in INR patients  
 modulation of TLR7 and TLR8 pathway of expression 
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1. HAART AND IMMUNE RECOVERY 
1.1. Study population 
All individuals of this study were enrolled by the Departments of Infectious diseases of the Luigi Sacco 
Hospital in Milan and of the San Gerardo Hospital in Monza and written informed consent was obtained 
before enrolment. 
For the first part of this project 67 HIV-infected patients with suppressed viremia (<50 copies/µl) were 
enrolled and all of them were treated with combined HAART according to currently guidelines (NRTI plus PI 
or NRTI plus NNRTI). In all patients, HIV plasma viremia has been under the threshold for at least 7 years 
and they were stratified into two groups on the basis of the CD4 cell counts (<500 cells/µl or >500 cells/µl).  
1.2. Sample collection and processing 
Whole blood was collected by venipuncture in Vacutainer tubes containing EDTA 
(ethylenediaminetetraacetic acid) (Becton Dickinson, Rutherford, NJ, USA). Samples were centrifugated 
1400rpm for 10 minutes, plasma obtained was collected and stored at -20°C for subsequent analyses. The 
remaining sample, composed by erythrocytes, PBMC, granulocytes and platelets, was diluited in PBS 
(phosphate buffered saline) (PBI International, Milano, Italy) and separated thanks to a density-gradient 
centrifugation on lymphocyte separation medium (Ficoll-Hypaque) (Cedarlane Laboratories Limited, Hornby, 
Ontario Canada) for 25 minutes at 2300rpm. PBMC are localized between the phase of fycoll-hypaque and 
the phase including granulocytes and erythrocytes, they are collected and washed twice in PBS for 10 
minutes at 1900 rpm. Cellular pellet was resuspended in PBS and washed twice in phosphate-buffered 
saline (PBS) (PBI International, Milano, Italy). Cellular count was conducted using an automatic cell counter. 
1.3. Cell count 
The number of viable leukocytes was determined by the use of an automatic cell counter ADAM-MC (Digital-
Bio, NanoEnTek Inc., Corea). ADAM-MC automatic cell counter measures total cell numbers and cell 
viabilities by cutting edge detection technologies. The instrument is able to count the cells thanks to the use 
of propidium iodide, a fluorescent dye that intercalates in the DNA of cell characterized by damage cell 
membranes. It‟s based on two different solution, AccuStain Solution T is composed by propidium iodide and 
lysis solution while AccuStain Solution N is composed by propidium iodide and PBS. AccuStain Solution T 
allows to count all cells present in the sample while AccuStain Solution N just non-viable cells. 
To evaluate cell concentration, a small quantity of sample (30µl) is combined with an equal volume of each 
solution. Samples prepared in this way are directly transferred in a disposable slide and this is read by the 
instrument. A green laser (532nm) is focalized on the slide and the cells colored are detected by a CCD 
camera (B/W CCD). On the screen it‟s shown total cell count, the count of non-viable cells and the vitality of 
each sample is calculated by ADAM-MC software. The number of cell/ml is obtain with the substraction of 
total number of non-viable cells from the number of total cells.  
1.4. Analyses on PBMC 
1.4.1. Stimulation of PBMC 
PBMC were incubated for 18 hours in the presence/absence of a pool of gag/env peptides (HIV), CMV 
protein (Microbics Biosystems inc., Toronto, Ontario, Canada). For cytokine analyses, 10µg/ml Brefeldin A 
(Sigma-Aldrich) was added to cell cultures during the last 6 hours to block vesicular transport of cytokines 
between the Golgi apparatus and endoplasmic reticulum. In some experiments PD1 or PDL1 neutralizing 
antibodies (eBiosciences Inc., San Diego, CA, USA) were added to the cultures to evaluate the PD1-PDL1 
pathway activity. 
1.4.2. Identification of Treg cells 
Unstimulated, basal and stimulated PBMC were washed in PBS and subsequently incubated with 5µl anti-
CD4 PC7, 5µl of anti-CD25 ECD, and 5µl of anti-PD1 PE mAbs for 15 min at RT. After the incubation, cells 
were washed with PBS and they were resuspended in fix/perm solution (eBioscience Inc.) for 30 minutes. 
Cells were then washed twice with PBS (PBI International) and with 10-fold diluted Perm buffer solution 
(eBioscience Inc.), 5µl of intracellular mAbs for PD1 and FoxP3 (respectively labeled with FITC and PC5 
fluorocromes) were added. After the 30-minutes incubation, cells were washed, resuspended in PBS and 
read in an hour. All the incubations were conducted at 4°C in the dark. 
Intracellular or surface co-staining of PD1 and intracellular FoxP3 was performed by flow cytometry on 
CD4
+
CD25
bright
 gated T cell. 
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1.4.3. Evaluation of TLR2 and TLR4 expression on Treg cells 
Both basal and stimulated PBMC were resuspended in PBS (PBI International) and stained for anti-CD4 
PC7, anti-CD25 ECD, anti-FoxP3 PC5, anti-TLR2 FITC, anti-TLR4 PE. See paragraph 1.5.2. for details 
about the methods. 
1.4.4. Intracellular cytokine expression 
Antigen-stimulated PBMC were stained for CD4 expression. After a 15-minute incubation at room 
temperature in the dark, cells were fixed in 100µl of 1% PFA (Sigma-Aldrich) and incubated for 15-min at 4°C 
in the dark. Cells were then washed, permeabilized with 100µl of 0.5% saponin (Sigma-Aldrich) and 
incubated with 5µl of anti-TGFβ PE and of anti-IL10 FITC mAbs for 45 minutes at 4°C. After this incubation 
cells were washed, fixed 1% PFA (Sigma-Aldrich) and analyzed by flow cytometry. 
1.4.5. Ki67 evaluation 
The protocol used to evaluate KI67 expression is the same described in the paragraph 1.5.4. Basal and 
stimulated PBMC were stained with 5µl of the following mAbs: anti-CD4 PC7, anti-KI67 FITC or mouse 
FITC-coupled IgG1 (as isotype control).  
1.4.6. Identification of viable, early apoptotic and late apoptotic cells 
Stimulated PBMCs were washed and resuspended in D-PBS (Euroclone, Siziano, Pavia, Italy). They were 
then stained with 5µl of CD4 FITC, 5µl of annexinV PE and 5µl of 7AAD mAbs. After 20-minutes incubation 
at room temperature in agitation, cells were washed in cold D-PBS and resuspended in D-PBS. The cells 
were read immediately by flow cytometry. Lymphocytes population were identified based on the FS and SS 
characteristic and an immunological gate was create considering SS characteristic and CD4 expression. In 
this gate, 7AAD and Annexin V positivity were considered at the same time.  
1.4.7. Detection of activated caspases 8 and 9 
The FLICA Apoptosis detection kit (Immunochemistry Technologies, Bloomington, Minnesota, USA) was 
used to analyze activated caspases. FLICA reagent were prepared according to manufacture‟s instructions 
and added to the resuspended cells followed by 1 hour incubation at 37°C under 5% CO2. After this 
incubation cells were washed twice with wash buffer, resuspended and stained with CD4 mAb for 30-min in 
ice. Cells were immediately analyzed by flow cytometry. 
1.5. Cytometric analyses 
Flow cytometry analyses were performed using FC500 flow cytometer (Beckman Coulter, Fullerton, CA, 
USA) equipped with a double 15-mW argon ion laser operating at 456 and 488nm interfaced with Intercorp 
Computer (Intercorp, Verona, Italy). For each analyses 20000 events were acquired and gated on CD4, CD8 
and CD14 expression and SSC properties. Green florescence from FITC (FL1) was collected through a 525-
nm band pass filter, red fluorescence from PE (FL2) collected by 575-nm band pass filter, orange 
fluorescence from ECD (FL3) was collected through a 620-nm band pass filter, deep-red fluorescence from 
PC5 (FL4) was collected through a 670-nm band pass filter, red-fluorescence from APC (FL4) was collected 
through a 650-nm band pass filter and far-red fluorescence from PC7 (FL5) collected by a 770-nm band 
pass filter. For forward and side scatter were used linear amplifiers, logarithmic amplifiers for FL1, FL2, FL3, 
FL4 and FL5. Flow data were analyzed by first gating on the lymphocyte or monocyte population as defined 
by forward and side light scatters. From this population a single color CD4 or CD14 histogram was made, 
and the T cells or monocytes were selected and put into a two-dimensional dot plot to achieve the results.  
1.6. Plasma LPS concentration 
LPS concentration was measured on plasma samples with LAL Chromogenic Endopoint Assay (Hycult 
Biotechnology, Uden, The Netherlands). All the samples, standards and reagents were prepared according 
to manufacture‟s instructions. Considering that plasma may contain endotoxin inhibiting compounds, it is 
required to heating the sample at 75°C for 5 minutes in order to neutralize these compounds. Moreover, 
plasma samples required a 3-fold dilution. 50µl of each diluted sample and standard was plated in duplicate 
in a 96-well plate and immediately 50µl of LAL reagent was added in each well. After 45-minutes incubation 
at room temperature, reaction was stopped with the addiction of 50µl of stop solution. Absorbance was 
measured at 405nm with a spectrophotometer and for the calculation of results, from the average of the 
duplicate readings for each standard and sample was subtracted the blank optical density. The standard 
curve was constructed by plotting the optical density on the y-axis against the concentration of the standards 
on the x-axis (logarithmic scale). LPS concentration was calculated relatively to the standard curve, 
multiplied by the dilution factor, expressed in EU/mL and subsequently transformed in pg/ml. 
 
                                                                                                                                          Material and methods 
35 
 
1.7. Statistical analyses 
Data were analyzed according to standard statistical tests; t test were performed to compare groups. 
Procedures were based on parametric analyses. The rank-transformed variables were analyzed if 
distributions were not normal. To account for different patient‟s characteristics between groups, an analysis 
of variance was run through a general linear model, including sex and age as independent variables. 
Possible relationship were evaluated using Pearson‟s correlation test. 
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2. HCQ THERAPY 
2.1. Study population 
The second part of this study regarded the evaluation of efficacy of hydroxychloroquine treatment in 
increasing percentage of CD4
+
 T cells in HIV patients non responder to HAART therapy. 
20 HAART-treated HIV-infected patients with an absolute CD4 count less than 200 cells/µl during the last 
year of therapy and with suppressed viremia (less than 37 HIV RNA copies/ml) were enrolled. All patients 
were treated with combined antiretroviral therapy according to the current guidelines: a NNRTI plus PI or 
NRTI plus NNRTI. Exclusion criteria included glucose-6-phosphate dehydrogenase deficit, pregnancy, breast 
feeding, acute infectious disease, or 5% CD4
+
 T cell count increase in the last year.  
All patients received 400 mg/die of HCQ daily for 6 months. Virologic and immunologic parameters were 
evaluated at baseline, at the end of the treatment and at 2 month after HCQ suspension. 
All patients were enrolled by Infectious Diseases Units at Luigi Sacco Hospital, Milan, Italy which approved 
this study; written informed consent was obtained before enrollment in accordance with the Declaration of 
Helsinki. 
2.2. Sample collection, processing and cell count 
See paragraphs 1.2 and 1.3 for details about the methods. 
2.3. Immunophenotypic analyses 
Lymphocytes subsets and monocytes were evaluated using 50µl of EDTA-treated peripheral blood incubated 
for 10 minutes at room temperature with 5µl of fluorochrome-labeled mABs: anti-CD4, -CD8 and –CD14 
PC7; anti-CD69 APC; anti-HLA-DRII, -CD38, -TLR4 and -TLR5 PE; and anti-CD8, -CD16, -CD45RO and -
TLR2 FITC, according to the different analyses. Erythrocyte lysis and fixation of stained cells were performed 
at the end of the incubation period using Immunoprep Epics Kit and Q-Prep Workstation (Coulter 
Electronics). 
2.4. Stimulation of PBMC 
PBMC were incubated for 18 hours in the presence/absence of a pool of gag/env peptides (HIV), single 
strand RNA (ssRNA) (InvivoGen, San Diego, CA, USA), LPS antigen (Sigma-Aldrich, St. Louis, MO, USA). 
For cytokine analyses, 10µg/ml Brefeldin A (Sigma-Aldrich) was added to cell cultures during the last 6 hours 
before cell analyses to block cytokines secretion. 
2.4.1. Evaluation of TLR4, TLR7 and TLR8-expression on stimulated monocytes 
PBMC were stimulated for 18 hours with LPS (Sigma-Aldrich), agonist of TLR4, and ssRNA (InvivoGen), 
agonist of TLR7 and TLR8. Evaluation of TLR4 were conducted on PBMC stimulated with LPS while TLR7 
an TLR8 on ssRNA stimulated PBMC. For TLR4 evaluation mAbs used were: 5µl of anti-CD14 PC5 and of 
anti-TLR4 PE. For the identification of TLR7 and TLR8 expression mAbs used were: 5µl of anti-CD14 PC5 of 
anti-TLR8 PE and of anti-TLR7 FITC. The protocol used for the evaluation of TLR expression is the same 
explained in the paragraph 1.5.4.  
2.4.2. Intracellular cytokines expression 
Antigen-stimulated PBMC were stained for CD4 or CD14 expression. After a 15-minute incubation at room 
temperature in the dark, cells were fixed with 100µl of 1% PFA (Sigma-Aldrich) and incubated for 15-min at 
4°C in the dark. Cells were then washed, permeabilized with 100µl of 0.5% saponin (Sigma-Aldrich) and 
incubated with 5µl of anti-TNFα PE, anti-TNFα FITC and anti-IL6 APC mAbs for 45 minutes at 4°C. After this 
incubation cells were washed and fixed with 500µl 1% PFA (Sigma-Aldrich). For details in the methods see 
paragraph 1.5.4. 
2.4.3. Identification of plasmacytoid dendritic cells and IFNα expression 
Analyses were conducted with both basal and stimulated condition with gag/env peptides. For the 
identification of plasmacytoid dendritic cells, PBMC were washed in PBS (PBI International) and incubated 
with 5µl of anti-CD123 PECy7, 20µl of lineage- PC5 (mix of 5µl of each following mAbs: anti -CD3, -CD14, -
CD16, -CD19, -CD56) and 5µl anti-HLA DRII PE for 15 min at RT. After this incubation cells were fixed with 
1% PFA (Sigma-Aldrich) and incubated 15 minutes at 4°C in the dark, washed with PBS (PBI International) 
and permeabilized with 0.5% saponin (Sigma-Aldrich). The addiction of anti-IFNα mAb was followed by 45 
minutes incubation at 4°C in the dark. At last, cells were washed with PBS (PBI International) and fixed with 
500µl of 1% PFA (Sigma-Aldrich). Plasmacytoid dendritic cells were identify by flow cytometry as cells 
                                                                                                                                          Material and methods 
37 
 
CD123
+
HLADR
+
LIN
-
, expression of IFNα was evaluated on plasmacytoid dendritic cells. For details about the 
methods see paragraph 1.5.4. 
2.4.4. KI67 evaluation 
Analyses were conducted with both basal and stimulated condition with gag/env peptides. mAbs used were 
anti-CD4 PC7 to identify lymphocytes population, anti-KI67 and mouse FITC-coupled IgG1 (isotype control) 
for the intracellular staining. For details about the methods see paragraph 1.5.4. 
Flow data were analyzed by first gating on the lymphocyte population as defined by forward and side scatter 
properties and on CD4
+
 T cells. Results were expressed as the percentage of CD4
+
KI67
+
 cells on CD4
+
 
population. 
2.4.5. Identification of Treg cells and of TLR-expressing Treg cells 
Analyses were conducted with both basal and stimulated condition with gag/env peptides and LPS antigen. 
PBMCs were incubated for 15 minutes at room temperature with 5µl of the following mAbs: anti-CD4 PC7, 
anti-CD25 ECD and anti-PD1 PE. The intracellular staining of PD1 and FoxP3 was performed using 5µl of 
anti-PD1 FITC and anti-FoxP3 PC5 mAbs. To detect TLR-expressing Treg, PBMCs were stained with anti-
CD4 PC7, -CD25 ECD, -TLR4 PE and -TLR2 FITC (5µl of each mAbs). Intracellular staining was performed 
according to manufacturer‟s instruction, for details see paragraph 1.5.2. 
2.5. Cytometric analysis 
See paragraphs 1.5 for details about the methods. 
2.6. Serological assay 
Proinflammatory cytokines (TNFα and IL6) and IFNα were evaluated in plasma samples using commercial 
ELISA kits (TNFα and IL6: R&D Systems, Minneapolis, MN, USA; IFNα: Hycult Biotechnology) in 96-well 
plate. 
2.6.1. Plasma TNFα concentration 
All the samples, standards and reagents were prepared according to manufacture‟s instruction. 50µl of assay 
diluent was added to each well and subsequently 200µl of each sample and standard were plated in 
duplicate. After the incubation of 2 hours at room temperature, the plate was washed 4 time with 25-fold 
diluted wash buffer and 200µl of conjugate was added to each well and the plate was incubated 2 hours at 
room temperature. Plate was then washed four times and 200µl of substrate solution were added. After the 
incubation of 20 minutes in the dark, the reaction was stopped with the addiction of stop solution (50µl in 
each well). The optical density of each well was determined within 30 minutes using a microplate reader set 
to 450nm. To avoid optical imperfections in the plate, wavelength correction was added and set to 540nm. 
For the calculation of results, form the average of the duplicate readings for each standard and sample was 
subtracted the average zero standard optical density. Plasma concentration of TNFα was calculated 
relatively to a standard curve construct by plotting the log of mean absorbance for each standard on the y-
axis against the log of the concentration on the x-axis (logarithmic scale). Values was expressed in pg/ml. 
2.6.2. Plasma IL6 concentration 
High sensitivity ELISA assay was used for the quantitative determination of IL6 concentration in plasma and 
all the samples, standards and reagents were prepared according to manufacture‟s instruction. 100µl of 
assay diluent and of each sample and standard was added to each singular well in duplicate. The plate was 
incubated for 2 hours in agitation at room temperature. After the incubation, the plate was washed six times 
with 10-fold diluted wash buffer and 200µl of conjugate was added to each well. Subsequently 2 hours of 
incubation at room temperature on the shaker, the plate was washed 6 times with wash buffer and 50µl of 
substrate solution was added to each well. This incubation lasted 1hour at room temperature and it was 
followed by the addiction of 50µl of amplifier solution. The reaction was stopped after 30 minutes with the 
addiction of 50µl of stop solution to each well. The optical density was evaluated within 30 minutes using a 
microplate reader set to 490nm and wavelength correction (640nm) was used to avoid optical imperfections 
in the plate. For the calculation of results, from the average of the duplicate readings for each standard and 
sample was subtracted the average zero standard optical density. IL6 plasma concentration was calculated 
relatively to standard curve obtained by plotting the optical density on the y-axis of the standards versus the 
concentration of the standards on the x-axis (logarithmic scale) and expressed in pg/ml.  
2.6.3. Plasma LPS concentration 
For details about the methods see paragraph 1.7. 
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2.7. Gene analysis 
2.7.1. RNA extraction from PBMC 
PBMC were analyzed in both basal and after 3 hours with antigen specific stimulations. Basal and stimulated 
PBMC were processed to extract total RNA. mRNA was extracted from 1x106 PBMC by the using of acid 
guanidium thiocyanate-phenol-chloroform method modified for RNAzol B (guanidine thiocyanate, 2-
mercaptoethanol). Samples were resuspended in 200μl of RNAzol B to which 10% of chloroform was added. 
Samples were incubated at 4°C for 15 minutes and subsequently centrifugated at 13000g for 15 minutes. 
After centrifugation, three phases can be distinguished: in the upper phase, clear and transparent, there‟s 
the RNA, in the intermediate, formed by a white ring, proteins can be found while the lower is composed by 
DNA and RNAzolB. To the aqueous phase, collected and transferred to a sterile tube, was added an equal 
volume of isopropanol, samples were so stored at -20°C overnight to allow complete precipitation of RNA. 
The day after, samples were heated at 4°C for 15 minutes and centrifugated at 13000g for 15 minutes. 
Supernatant was removed and RNA pellet was washed with 100μl of ethanol (70%). Subsequently the 
sample was centrifugated for 8 minutes at 12000g at 4°C, once the supernatant was removed, pellet was 
dried under laminal flow cabin. 10,3μl of hydration buffer (10mM TRIS, 1mM EDTA) (Promega, Madison, 
Wisconsin, USA) were added to resuspend the pellet and allow a complete hydration. 
2.7.2. DNAse treatment 
The RNA was subjected to treatment with DNase to eliminate contamination of genomic DNA. For each 
sample a reaction mix was prepared containing 1μg of RNA, 0.5μl of TURBO DNAse 2U/μl, 1.2μl of 10x 
TURBO DNAse buffer (10mM TRIS-HCl ph 7.5, 25mM MgCl2, 5mM CaCl2) to obtain a final volume of 12μl. 
The final volume was established considering that DNAse treatment must not exceed 40% of final volume of 
RT-PCR. Reaction mix was incubated at 37°C for 15 minutes, at the end of which 2μl of DNAse inactivation 
reagent (Ambion Inc., Austin, Texas, USA). Samples were agitated for 2 minutes at room temperature and 
subsequently centrifugated at 10000g for 2 minutes to pellet DNAse inactivation reagent. The supernatants, 
containing RNA, was transferred in new tubes. 
2.7.3. Retrotrascription of RNA into cDNA 
After DNAse treatment, RNA samples were retrotranscripted in cDNA. The protocol of retrotranscription 
provides a reaction containing 1μg of RNA, 0.5μl of 1mM random hexanucleotide primers and 0.5μl of oligo 
(dT) primer 1mM. The reaction mix was heated at 70°C for 5 minutes and immediately placed on ice. 
Subsequently 1μl of 0.5mM dNTP mix, 4μl of 5X M-MLV reaction buffer, 0.5μl of recombinant RNAse 
inhibitor 40U/μl, 1μl of 200 U Moloney murine leukemia virus reverse transcriptase (M-MLV) (Promega) were 
added. The reaction mix was incubated at 42°C for 1 hour and at the end RT enzyme was inactivated by 
heating at 95°C for 5 minutes. M-MLV enzyme has a 5‟-3‟ RNA-dependent DNA polymerase activity and a 
low RNAse H activity. Finally each sample of cDNA has been 4-fold diluited. 
2.7.4. Evaluation of TLR signalling pathway 
Evaluation of TLR pathway was performed with 96-well plate array specific for analyses of 84 genes involved 
in TLR pathway signaling (SABiosciences Corporation, Frederick, MD, USA). A mix was prepared by adding 
9μl of SYBR Green PCR mix (Finnzymes, Vantaa, Finland), 2μl of 4-fold diluited cDNA pool and 8μl of 
double-distilled water. Each well contain a couple of primer specific for a gene of interest (A1-G12 well), 5 
housekeeping gene (H1-H5), genomic DNA control (H6), reverse transcription controls (H7-H9) and positive 
PCR controls (H10-H12). 
Quantification of gene expression levels was performed with DNA Engine Opticon 2 (MJ Reasearch, Ro, 
Nevada, USA) and the thermic profile was as follows: one initial step of denaturation at 95°C for 2 minutes 
followed by 40 cycles including one step of denaturation at 92°C for 15 seconds, one step of annealing at 
55°C for 20 seconds and one step of extension at 68°C for 20 seconds. Fluorescence was measured after 
extension step at the end of each cycle. Melting curve was constructed from 55°C to 62°C and fluorescence 
was measured at each 0.5°C increment and it was analyzed for each sample to confirm the specificity of the 
amplified and the absence of primer-dimer. 
Analysis of the results required the elimination of background noise, all samples were normalized by 
subtracting the background fluorescence, calculated as the mean fluorescence detected from the third to the 
tenth cycle. The relative efficiency of the gene of interest is calculated taking into account the efficiency of 
amplification of the target and the difference between Ct of the target normalized to the expression of the 
housekeeping gene GAPDH. 
2.8. Statistical analyses 
Data were analyzed according to standard statistical tests, t test were performed to compare patients during 
treatment. Procedures were based on parametric analyses. The rank-transformed variables were analyzed if 
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distributions were not normal. Statistical analysis was performed using the SPSS statistical package (SPSS 
Inc.). 
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1. HAART AND T CELL RECOVERY 
1.1. Study population 
In this study 67 HIV-infected, HAART-treated individuals were enrolled. In all of them HAART was effective 
because it maintained the viral load at undetectable level (<50 copies/µl). 
According to several evidences present in literature [89, 90], patients were divided in two groups on the basis 
of the CD4 cell count reached after 7 years of HAART. 32 patients presented CD4 cell count >500 cells/µl 
while 35 patients had <500 cells/µl.  
HIV-infected individuals in whom HAART was not associated with CD4
+
 T cells recovery were characterized 
by a lower CD4 nadir (p=0.01). As per inclusion criteria, lower absolute numbers (p<0.001) and percentages 
(p=0.002) of CD4
+
 T cells/μl. The epidemiologic characterization of the two groups of individuals is presented 
in table 1. 
 
Parameter 
CD4 cell count 
>500 cells/ml 
CD4 cell count 
<500 cells/ml 
P 
N
o
 32 35  
Sex 25M 7F 25M 10F  
Age 48.13±1.12 52.11±1.39 0.03 
Years of HAART 10.34±0.46 11.51±0.52 NS 
CD4 nadir (cells/ml) 195.84±24.35 119.37±15.70 0.01 
CD4 cell count (cells/ml) 705.52±25.87 245.83±24.31 <0.001 
% CD4 20.96±1.49 12.93±1.34 0.002 
Table 1. Demographic and clinical characteristics of the HIV-infected antiretroviral therapy-treated patients 
enrolled in the study. Mean values, SE and P are shown. 
 
1.2. Evaluation of immune suppression 
1.2.1. Identification of naïve and activated Treg cells 
Treg cells control immune responses against self and non self antigens, they play a pivotal role in 
maintaining the right balance between tolerance and immunity.  
In physiologic conditions, Treg cells represent 2-5% of CD4
+
 T lymphocyte population, while in HIV infection 
it has been demonstrated an increase in the percentage of Treg cells and an induction of their suppressor 
activity. It has been formulated the hypothesis that their action might provoke the impairment of CD4
+
 T cell 
recovery observed in HIV infected patients non responsive to antiretroviral therapy. Their immune 
suppressive activity might be due to the inhibition of T cell proliferation and survival because of reduction in 
survival cytokines availability, induction of apoptosis through PD1/PDL1 pathway and increase secretion of 
immune suppressive cytokines by lymphocytes. 
Recent data indicating that Treg cells can be further subdivided into two populations based on the intra 
(naïve)- or extra (activated)-cellular expression of the PD1 molecule, this stimulated us to examine such 
populations in our patients. We started to evaluate changing in Treg subpopulation percentages between 
patients with CD4
+
 cell counts less than 500cells/μl and patients with more than 500 CD4
+
 T cells/μl. 
Analyses were conducted in both basal and stimulated conditions on PBMC of patients enrolled (see 
paragraph 1.5.2 in material and methods, for further details). 
Treg cells were identified in flow cytometry according to the methods present in literature. Total 
(CD4
+
CD25
bright
Foxp3
+
), naïve (CD4
+
CD25
bright
Foxp3
+ 
intracellular PD1
+
), and activated 
(CD4
+
CD25
bright
Foxp3
+
 extracellular PD1
+
) regulatory T cells were analyzed. All the population examined 
were increased in patients with CD4
+
 cell counts less than 500cells/μl compared with individuals with more 
than 500 CD4
+
 T cells/μl. These differences reached statistical significance in the case of total (p=0.004) and 
naïve (p=0.040) Treg cells (fig.15). 
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Figure 15. Percentage of Treg subpopulations in patients with CD4 cell counts >500 cells/µl and with <500 
cells/µl. Mean values, SE and P are shown ( p<0.05,  p<0.01). 
 
Total Treg cells was subsequently analyzed after stimulation of PBMC with HIV or CMV. HIV-stimulated, but 
not CMV-stimulated total Treg cells were significantly increased in patients with CD4
+
 cell counts less than 
500cells/μl compared to patients with more than 500 CD4
+
 T cells/μl (basal: p=0.045, and HIV-specific: 
p=0.039) as shown in figure 16. 
 
Figure 16. Percentage of total Treg in basal, HIV-, CMV-specific conditions in patients with CD4 cell counts 
>500 cells/µl and with <500 cells/µl. Mean values, SE and P are shown ( p<0.05). 
 
1.2.2. Immune suppressive cytokines 
One of the most validated hypothesis to explain HIV-associated immune activation stems from the 
observation that acute HIV infection is associated with a rapid and probably irreversible destruction of the 
extensive CD4
+
 T cell population that resides in gut-associated lymphoid tissues. The lamina propria 
macrophages can induce Treg cells differentiation and limit the generation of pro-inflammatory immune 
responses. Spontaneous IL-10 production by lamina propria macrophages controls their reactivity to various 
TLR ligands and promotes the generation of tolerogenic IL10-producing T cells and, when combined to 
TGFβ, Foxp3 Treg cells. Given the deleterious effects of sustained inflammatory responses, the immune 
system goes to great length to prevent such responses. The main mechanism involves Treg cells, a subset 
of CD4
+
 T lymphocytes that suppress local T cell activation via direct and indirect mechanisms. Treg cells 
mediate their effect via two complementary mechanisms: IL10-mediated and TGFβ-mediated functional 
impairment of immune cells, and induction of apoptosis of such cells.  
IL10 and TGFβ are the main cytokines produced and used by Treg cells to exert their immune suppressive 
activities. We decided to analyze the expression of TGFβ and IL10 in CD4
+
 T cells following stimulation for 
18 hours with HIV peptides and CMV protein (see paragraph 1.5.4 in material and methods, for further 
details). The results obtained showed that HIV-specific IL10
+
CD4
+
 and TGFβ
+
CD4
+
 T cells were augmented 
in patients with CD4
+
 T cell counts less than 500cells/μl compared to patients with CD4
+
 cell counts more 
than 500 CD4
+
 T cells but only IL10
+
CD4
+
 parameter was statistically significant (p=0.047) (fig. 17 panel A); 
in contrast no differences were observed with CMV stimulation (fig. 17 panel B). 
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            A 
 
            B 
Figure 17, panel A and panel B. Percentage of HIV-specific (A) and CMV-specific (B) immune suppressive 
cytokines in patients with CD4 cell counts >500 cells/µl and with <500 cells/µl. Mean values, SE and P are 
shown ( p<0.05). 
 
Our results showed that HIV-stimulated production of both IL10 and TGFβ was increased in patients with 
CD4
+
 cells counts less than 500 cells/μl in comparison to patients with CD4
+
 cell counts more than 500 
cells/μl. 
1.3. Evaluation of apoptosis 
1.3.1. Viable, early apoptotic and late apoptotic T cells 
HIV infection is characterized by a profound T cell depletion that can be caused by both direct and indirect 
action of the virus. HIV proteins might play a role in inducing apoptosis in CD4
+
 T cells, this cellular process 
may be initiated in two different ways: the extracellular way is activated consequently to intracellular signal 
translation by death receptors expressed on the surface of target cell, while the intracellular one is due to 
impairment in mitochondria permeability. Apoptosis process plays an important role in CD4
+
 T cell depletion 
observed during HIV infection. We decided to investigate the role of apoptosis in the lack of CD4
+
 T cell 
recovery characterizing immunological non responder patients. The distinguish between viable and necrotic 
cells was effectuated using 7AAD/Annexin V method (for detail see paragraph 1.5.6 in material and 
methods). Annexin V binds to phosphatidylserine, a phospholipid usually expressed in the intracellular side 
of the plasma membrane but it is the first relocated at the extracellular side during the initial phase of 
apoptosis. Annexin V lets to identify cells entering in the early phase of apoptosis. 7AAD is a vitality dye that 
enters in the cell which presents a strong impairment of the cellular membrane. Annexin V and 7AAD allow 
to identify cells in apoptosis and in necrosis. PBMC were evaluated in basal condition and after stimulation 
with HIV peptide and CMV protein. Viable cells were identified as CD4
+
/AnnV
-
/7AAD
-
, cells in early apoptosis 
as CD4
+
/AnnV
+
/7AAD
-
 and late apopotic cells as CD4
+
/AnnV
+
/7AAD
+
. 
Comparing individuals with CD4
+
 T cell count less than 500 cells/µl to patients characterized by T cell counts 
more than 500 cells/µl, both in basal conditions, upon HIV and CMV stimulation (fig.18 panel A, panel B, and 
                                                                                                                                        Results and discussion 
44 
 
panel C), viable CD4
+
 T cells were diminished (viable cells: basal: p=0.002; HIV-specific: p=0.003; CMV-
specific: p=0.05), whereas early apoptotic and late apoptotic CD4
+
 T cells were augmented in individuals 
with CD4
+
 T cell counts less than 500cells/µl (early apoptotic: basal: p=0.005; late apoptotic cells: basal: 
p=0.005; HIV-specific: p=0.05; CMV-specific: p=0.05).  
 
            A 
 
            B 
 
            C 
Figure 18, panel A, panel B and panel C. Percentage of viable (AnnexinV
-
7AAD
-
), early apoptotic 
(AnnexinV
+
7AAD
-
) and late apoptotic (AnnexinV
+
7AAD
+
) CD4
+
 T cells in patients with >500 cells/µl and with 
<500 cells/µl, in basal condition (A) and HIV- (B) and CMV-specific stimulation (C). Mean values, SE and P 
are shown ( p<0.05,  p<0.01). 
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Apoptotic process is driven by specific cellular enzymes, called caspases. Caspases are enzymes involved 
in the apoptotic mechanism, in particular caspase 8 being specific for the extracellular way while caspase 9 
being linked to the intracellular pathway. 
We decided to identify the activation of both of these caspases (for details see paragraph 1.5.7 in material 
and methods section). 
In our experiment we evaluated the presence of caspase 8 and 9 activated in CD4
+
 T cells, the analyses 
were conducted in basal condition and after HIV and CMV stimulation. Results showed that expression of 
caspase 8 and 9 was augmented in cells of patients with CD4
+
 T cell counts less than 500cells/μl, these 
differences reached statistical significance for HIV-specific and CMV-specific caspase 9
+
 CD4
+
 cells (fig. 19 
panel A, HIV-specific: p=0.044; CMV-specific: p=0.026). No statistical significance was reached when the 
expression of caspase 8 was analyzed (fig. 19 panel B). 
 
            A 
 
            B 
Figure 19, panel A and panel B. Percentage of caspase 9
+
CD4
+
 (A) and of caspase 8
+
CD4
+ 
(B) in 
unstimulated-, HIV- and CMV-condition in patients with CD4 cell count >500 cells/µl and with <500 cells/µl. 
Mean values, SE and P are shown ( p<0.05). 
 
1.3.2. Blocking of PD1/PDL1 pathway and its effect on cell vitality 
Because activated Treg cells express PD1, and the PD1/PDL1 pathway is fundamental importance in 
inducing apoptosis of CD4
+
 T cells, we analyzed this pathway adding to the cultures antibodies able to block 
this interaction. PD1 blocking resulted in an increase of viable and a decrease of early and late apoptotic 
cells in individuals with CD4
+
 T cell counts less than 500 cells/μl (fig. 20 panel B), whereas no effects were 
observed in patients with more than 500 CD4
+
 T cells/μl (fig. 20 panel A). 
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             A 
 
            B 
Figure 20, panel A and panel B. Percentage of viable (AnnexinV
-
7AAD
-
), early apoptotic (Annexin
+
7AAD
-
) 
and late apoptotic (AnnexinV
+
7AAD
+
) in HIV stimulated condition in absence/presence of anti-PD1 or anti-
PDL1 antibodies in patients with CD4 cell count >500 cells/µl (A) and with <500 cells/µl (B). Mean values are 
shown. 
 
Considering all these data just presented herein it can be inferred that all populations of Treg cells were 
indeed augmented in patients in whom HAART does not increases CD4
+
 cell counts, suggesting a full-blown 
effort of the immune system in the attempt to reduce immune activation. Treg cells mediate their effect via 
two complementary mechanisms: IL-10-mediated and TGFβ-mediated functional impairment of immune 
cells, and induction of apoptosis of such cells. Our results show that both mechanisms are active in patients 
in whom HAART does not increases CD4
+
 cell counts. Thus, in these patients HIV-stimulated production of 
IL10 and TGFβ was increased, and expression of caspases 8 and 9 (apoptotic cells), as well as early and 
late apoptotic CD4
+
 T cells, were augmented. 
Preliminary results showing that in individuals with CD4
+
 T cells less than 500cells/μl the blockage of the 
PD1-PDL1 pathway, a mechanism of pivotal importance in inducing apoptosis, induces an increase in viable 
and a decrease of early and late apoptotic cells indicate that this pathway likely plays a role in lack of CD4 
recovery in HAART-treated individuals. 
1.4. Immune activation in HIV infection 
HIV infection is strongly characterized a persistent immune depletion of CD4
+
 T cells that mainly occurs in 
gastrointestinal tract during early phase of the disease. It has been supposed that CD4
+
 T cells depletion and 
progression to AIDS might be dependent by chronic generalized immune activation. 
Generalized immune activation might be due to direct viral action and, considering that loss of CD4
+
 T cells 
occurs mainly in mucosal sites, also for impairment of mucosal barrier. Mucosal barrier represents a defense 
mechanism by which the organism can be preserved from microbial invasion and consequently a damage of 
the barrier allows microbial translocation. Microbial products invade submucosal tissues and induce the 
activation of the immune system. 
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1.4.1. Percentage of activated CD4+ T lymphocytes 
One of the first event, characterizing early phase of HIV infection, is the hyperactivation of CD4
+
 T 
lymphocytes in response to persistent antigenic stimulation. T lymphocytes activation was evaluated by KI67 
expression in both basal and stimulated conditions (see paragraph 1.5.5 in material and methods, for further 
details). The percentage of CD4
+
/KI67
+
 T cells was significantly augmented in individuals with CD4
+
 cell 
counts less than 500cells/μl compared with individuals with more than 500cells/μl. As shown in fig. 21, this 
difference was detected both in unstimulated cells and upon stimulation with HIV (unstimulated: p=0.032; 
HIV-specific: p=0.027) 
Figure 21. Percentage of KI67
+
CD4
+
 T cells in patients with CD4 cell count >500 cells/µl and with <500 
cells/µl in basal and HIV-specific stimulated condition. Mean values, SE and P are shown ( p<0.05). 
 
1.4.2. Identification of TLR-expressing Treg cells 
Loss mucosal integrity results in impaired local cellular immunity and translocation of microbial products, 
including LPS, which in turn contributes to persistent inflammation through TLR activation. Because LPS 
ligates TLR4, a molecule expressed on a variety of immune cells, the LPS-TLR4 axis has repeatedly been 
postulated as being responsible for HIV-associated immune activation. Recent evidences in literature report 
the expression of TLR2 and TLR4 on Treg cells and underline how TLR expression might display different 
effect on Treg activity, Treg cells activation mediated by TLR induce an increase their survival and their 
immune suppressive actions. 
We analyzed the expression of these two TLRs on Treg cells in both basal and after 18 hours of antigen-
specific stimulations (see paragraph 1.5.3 in material and methods, for further details). As shown in figure 22 
panel A, basal TLR2- and TLR4-expressing Treg cells were augmented in patients with CD4
+
 cell counts less 
than 500 cells/μl compared with patients with more than 500 CD4
+
 T cells/μl (TLR2: p=0.05). After 18 hours 
of stimulation, as shown in figure 22 panel B, results showed that unstimulated TLR2-expressing and TLR4-
expressing and HIV-stimulated Treg cells were significantly increased in patients with CD4
+
 cell counts less 
than 500 cells/μl compared with patients with more than 500 CD4
+
 T cells/μl (unstimulated: TLR2: p=0.005 
and TLR4: p=0.001; HIV-specific: TLR2: p=0.037 and TLR4: p=0.048).  
            A 
Figure 22, panel A. Percentage of TLR2- and TLR4- expressing Treg cells in basal condition in patients with 
CD4 count >500 cells/µl and with CD4 count <500 cells/µl. Mean values, SE and P are shown ( p<0.05). 
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            B 
Figure 22, panel B. Percentage of TLR2- and TLR4- expressing Treg cells in unstimulated and upon HIV-, 
CMV-specific stimulation in patients with CD4 count >500 cells/µl and with CD4 count <500 cells/µl. Mean 
values, SE and P are shown ( p<0.05,  p<0.01). 
 
We observed significantly increased percentages of HIV-specific TLR2 and TLR4-expressing Treg cells in 
patients in whom HAART does not increases CD4
+
 T lymphocytes. 
1.4.3. Plasma LPS concentration 
Brenchley was the first that proposed the hypothesis that HIV immune activation might mainly due to a 
disruption in the gastrointestinal barrier. Early stage of HIV infection is characterized by an impairment of 
mucosal barrier that allows translocation of microbial products, like LPS. Microbial products contribute to 
maintain an inflammatory and hyperactivation status leading to a profound depletion of gut CD4
+
 T 
lymphocytes. 
Plasma LPS concentration is an ideal index to detect microbial translocation and its augmented 
concentration has been directly correlated with an alteration of gut permeability.  
According to this hypothesis we decided to evaluate plasma LPS concentration in our population enrolled 
(see paragraph 1.5.7 in material and methods, for further details). 
Our data showed that plasma LPS concentrations were significantly higher in individuals with CD4
+
 cell 
counts less than 500cells/µl compared with individuals with more than 500 cells/µl (fig. 23, p<0.001).  
 
Figure 23. Plasma LPS concentration in patients with CD4 cell count >500 cells/µl and with <500 cells/µl. 
Mean values, SE and P are shown ( p<0.001). 
 
Notably, serum concentrations of LPS were significantly increased as well in the same patients in whom 
HAART does not increases CD4
+
 T lymphocytes. Altered gut permeability resulting in increased LPS serum 
concentrations would trigger TLR4-mediated immune activation of multiple cell types, including Treg cells. 
The presence of significant negative correlations between CD4
+
 T lymphocytes, immune activation, microbial 
translocation, and CD4 cell counts indicate that these parameters likely play a pathogenetic role in these 
patients. 
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1.5. Correlations 
Impairment of immune responses observed during HIV infection is supposed to be due to several 
mechanism. In this first part of the study we have evaluated different parameters linked to immune activation 
and immune suppression. It‟s thought that they are both strictly correlated. Correlation analyses were 
conducted between CD4
+
 T cells, lymphocyte activation, LPS concentration, Treg cells and apoptosis. 
Significant negative correlations were observed between CD4
+
 T cell counts and HIV-specific CD4
+
/KI67
+
 
cells (fig. 24 panel A, Pearson correlation: P=0.01), plasma LPS concentration (fig. 24 panel B), percentage 
of total Treg cells (fig. 24 panel C, Pearson correlation: P=0.01), percentage of naïve Treg cells (fig. 24 panel 
D, Pearson correlation: P=0.01), percentage of activated Treg cells (fig. 24 panel E, Pearson correlation: 
P=0.05) and percentage of HIV-specific late apoptotic CD4
+
 T cells (fig. 24 panel F, Pearson correlation: 
P=0.01). 
 
            A 
            B 
            C 
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            D 
 
            E 
 
            F 
Figure 24, panel A, panel B, panel C, panel D, panel E and panel F. Correlation between percentage of HIV-
specific KI67
+
CD4
+
 cells (A), plasma LPS concentration (B), percentage of total Treg cells (C), percentage of 
naïve Treg cells (D), percentage of activated Treg cells (E) and percentage of HIV-specific late apoptotic 
CD4
+
 cells (F) and CD4 cell count in HIV-infected HAART-treated patients. Pearson correlation values are 
shown. 
 
 
Analyses of correlation clearly showed the strict negative relationship between immune activation, microbial 
translocation, immune suppression, apoptosis and nadir of CD4
+
 T cells previously supposed: a low CD4
+
 T 
cell counts pre-therapy is a negative prognostic factor of a better outcome of the disease. Results herein 
suggest a multifactorial model explaining failed CD4 recovery in successfully HAART-treated patients. 
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Thus, altered gut permeability resulting in increased LPS serum concentrations would trigger TLR4-mediated 
immune activation of multiple cell types, including Treg cells. Activated Treg lymphocytes could prevent full 
CD4
+
 T cell reconstitution via both direct (apoptosis) and indirect (immunosuppressive cytokines) 
mechanisms. The observation that, with the exception of caspase 9-expression, all the immune parameters 
examined are altered upon HIV but not CMV stimulation, deserves further analyses and underlines the 
extreme expansion of HIV-specific lymphocytes in this infection. From a clinical standpoint, the observation 
that lower nadir likely result in a more difficult increase of CD4
+
 T cells heightens the suggestion that the CD4 
threshold actually used to start HAART could be reassessed, and reinforces the need for effective immune 
modulators in the therapy of HIV infection. 
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2. IMMUNE MODULATORY EFFECTS OF HCQ 
2.1. Study population 
HCQ is an antimalarial drug which displays also immune modulating and antiviral effects. We decided to test 
its activity in patient non responder to antiretroviral therapy. 
The clinical and demographic characterization of the patients enrolled in the study is presented in table 2. 
HCQ was well tolerated in all patients with the exception of one individual who reported a maculopapular 
exanthema after 10 days of treatment. The individual was excluded from the final analyses. HIV viremia was 
undetectable throughout the study period. 
 
Parameter HCQ patients (n=20) 
Age (year) 49.78±2.92 
Sex (male/female) 14/6 
HIV infection 5.33±1.38 
Duration of HAART (year) 4.43±1.22 
  
Viral load, copies HIV RNA/ml  
Baseline <37 
6 months of HCQ treatment <37 
2 months after HCQ interruption <37 
  
Coinfections  
HBV 1/20 
HCV 4/20 
  
HAART treatment, n  
PI 10 
NNRTI 7 
Other 3 
Table 2. Clinical and epidemiologic characteristics of HCQ-treated patients 
 
The percentage of CD4
+
 T cells was significantly augmented after six months of HCQ treatment (p<0.001 fig. 
25 panel A) without changes in total lymphocytes counts as shown in figure 25 panel B and this increase in 
percentage was retained 2 months after suspension (p=0.001). A similar trend was observed in CD4
+
 T cell 
count even if changes did not reach statistical significance (fig. 25 panel C). 
 
           A 
Figure 25, panel A. Percentage of CD4
+
 T cells in HIV-infected INR patients enrolled in the study. Mean 
values, SE and P are shown (  p<0.01,  p<0.001). 
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            B 
 
            C 
Figure 25, panel B and panel C. Percentage of CD4
+
 T cell counts (B) and total lymphocytes count (C) in 
HIV-infected INR patients enrolled in the study. Mean values and SE are shown. 
 
2.2. Evaluation of immune activation 
2.2.1. Identification of activated lymphocytes and monocytes 
Immune activation results in the detection in peripheral blood of increased quantities of subsets of immune 
cells expressing particular proteins. To evaluate a possible immunomodulatory effect of HCQ on this immune 
activation, we analyzed such subsets in all the individuals enrolled in the study. The best markers of immune 
activation are HLA-DRII, CD38 and CD69. HLA-DRII is constitutively expressed on APC, it‟s not expressed 
by most T cells but a subset of activated T cells become HLA-DRII
+
 during immune response and it‟s a 
hallmark of HIV disease progression. CD38 is constitutively expressed by naïve T cells, down-regulated in 
memory cells and upregulated in activated cells. CD69 is a glycoprotein expressed following activation in all 
bone marrow-derived cells except erythrocytes. CD69 crosslinking induces TGF-β production in both 
subpopulation of T cells and in macrophages. Finally activation of CD4
+
 T lymphocytes is detected with the 
intracellular marker KI67 [123, 124]. 
CD4
+
 T cell activation was evaluated in unstimulated cells and HIV-specific stimulated cells. As shown in 
figure 26 panel A and panel B, the percentage of KI67-expressing CD4
+
 T cells (activated T cells) was 
significantly reduced after 6 months of HCQ in both unstimulated (panel A, p=0.005) and in stimulated 
condition (panel B, HIV-specific: p=0.003). This effect was retained 2 months after HCQ interruption 
(unstimulated, p=0.024; HIV-specific: p=0.044). 
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            A 
            B 
Figure 26, panel A and panel B. Percentage of KI67
+
CD4
+
 T cells in unstimulated (A) and HIV-specific 
stimulation (B) in HIV-infected INR patients enrolled in the study. Mean values, SE and P values are shown 
( p<0.05,  p<0.01). 
 
The percentage of HLA-DRII-, CD69-, and CD38/CD45RO-expressing CD8
+
 T cells decreased as well, albeit 
not significantly, after 6 months of HCQ treatment. A different pattern was seen when these populations were 
analyzed 2 months after HCQ interruption. Thus, HLA-DRII
+
CD8
+
 cells were significantly reduced both in 
comparison with baseline and with month 6 (p=0.013 and p=0.05, respectively, figure 27 panel A), whereas 
CD69
+
CD8
+
 (figure 27 panel B) and CD38
+
CD45RO
+
CD8
+
 (figure 27 panel C) T cells were significantly 
augmented compared with month 6 (p=0.043 and p=0.039 respectively). 
            A 
Figure 27, panel A. Percentage of HLA-DRII
+
CD8
+
 T cells in HIV-infected INR patients enrolled in the study. 
Mean values, SE and P are shown ( p<0.05). 
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            B 
 
            C 
Figure 27, panel B and panel C. Percentage of CD69
+
CD8
+
 T cells (B) and percentage of 
CD38
+
CD45RO
+
CD8
+
 T cells (C) in HIV-infected INR patients enrolled in the study. Mean values, SE and P 
are shown ( p<0.05). 
 
The existence of a positive correlation between the activated status of monocytes and progression of HIV 
infection [125], is well documented.  
CD69-expressing CD14
+
 cells (figure 28) were also significantly reduced after 6 months of HCQ treatment 
(p=0.041). Percentages of these cells returned to baseline values after 2 months of HCQ interruption. 
 
            D 
Figure 28. Percentage of CD69
+
CD14
+
cells in HIV-infected INR patients enrolled in the study. Mean values, 
SE and P are shown ( p<0.05). 
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2.2.2. TLR expression on monocytes 
It has been documented that HCQ down-modulates the expression of intracellular TLRs in vitro as well as in 
murine models. The effect of this compound in HIV infection was analyzed by evaluating TLR2, TLR4, TLR5, 
TLR7 and TLR8 expression on CD14
+
 cells both in whole blood and on stimulation with specific agonist. 
Results obtained in whole blood showed that HCQ induced a significant reduction in TLR2-, TLR4-, and 
TLR5-expressing CD14
+
 cells as shown in fig. 29 panel A and panel B (TLR2, p=0.032; TLR4, p=0.004; 
TLR5, p=0.008) 
 
            A 
Figure 29, panel A. MFI of TLR2 on CD14
+
 cells in whole blood in HIV-infected INR patients enrolled in the 
study. Mean values, SE and P are shown ( p<0.05). 
 
            B 
Figure 29, panel B. Percentage of TLR4- and TLR5-expressing monocytes in whole blood in HIV-infected 
INR patients enrolled in the study. Mean values, SE and P are shown ( p<0.01). 
 
 
Results obtained when cell cultures were stimulated with TLR agonists showed a significant reduction in 
LPS-stimulated cells alone (figure 29 panel C, TLR4, p=0.006) that vanished 2 months after interruption of 
HCQ treatment (p=0.050). In contrast, no changes in ssRNA-stimulated TLR7 and TLR8-expressing CD14
+
 
cells were detected (fig. 29 panel C). 
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            C 
Figure 29, panel C. Percentage of antigen stimulated TLR4-, TLR7-, TLR8- expressing monocytes (C) in 
HIV-infected INR patients in HIV-infected INR patients enrolled in the study. Mean values, SE  and P are 
shown ( p<0.05,  p<0.01). 
 
The data so far obtained allow to confirm the ability of HCQ in modulating the expression of TLRs and most 
of all of TLR4, directly involved in responses to microbial translocation and further analyses are required to 
investigate if HCQ might influence TLR intracellular signaling pathway. 
 
Notably, HCQ-associated reduction of immune activation was mostly retained after therapy interruption and 
was accompanied by a real increase in CD4
+
 T cell percentage, as total lymphocyte counts did not change 
during the study period. This reduction of immune activation was also associated with a similar trend, albeit 
not reaching statistical significance, in CD4
+
 T cell counts. These data suggest that HCQ is effective in 
reducing CD4
+
 T cells activation, resulting in an increase of CD4
+
 T cell percentage. 
We have shown the presence of LPS/TLR-dependent immune activation in HIV-infected individuals lacking 
CD4 normalization during HAART, and recently a reduction in immune activation and a decrease in CD38
+
 
CD8
+
 T cells and of KI67 memory CD4
+
 T cells was reported in HAART-treated and naïve HIV-infected 
patients treated with HCQ [116]. Data herein confirm and expand those results and indicate a possible 
therapeutic benefit of HCQ in HAART-treated individuals in whom a satisfactory recovery of CD4
+
 T cells is 
not achieved. HCQ was effective in reducing the percentage of proliferating CD4
+
 T lymphocytes and of 
activated (CD69
+
) monocytes, whereas its effect on CD8
+
 T cells was marginal, indicating a possible lack of 
effect of HCQ on this lymphocytes population. 
2.3. Evaluation of immune suppression 
2.3.1. Identification of Treg cells 
As previously said, Treg cells are a subpopulation of CD4
+
 T cells that exert immune regulatory activity. 
controlling different cellular processes. 
According to the immune modulating properties of HCQ we studied if Treg cells percentage was influenced 
by HCQ therapy. Treg cells were evaluated both in basal and with HIV-specific stimulation. Both naïve and 
activated Treg cells were significantly increased after HCQ; this effect persisted 2 months after HCQ 
interruption. In unstimulated condition (figure 30 panel A), HCQ induced a strong increase in activated Treg 
cells percentage after 6 month therapy (activated: p=0.002) and this effect was retained also after 
suspension of the treatment (naïve: p<0.001; activated: p<0.001) when compared to baseline. Moreover 
comparing the percentage of Treg cells 2 months after treatment interruption with 6 months of HCQ, a 
significant increase in the percentage of both naïve and activated subpopulations emerged (naïve: p<0.001; 
activated: p=0.004). 
 
                                                                                                                                        Results and discussion 
58 
 
      A 
Figure 30, panel A. Percentage of subpopulations of Treg cells in unstimulated condition in HIV infected INR 
patients enrolled in the study. Mean values, SE and P are shown ( p<0.01,  p<0.001). 
 
Upon HIV-specific stimulation (fig. 30, panel B), we observed the same trend showed in unstimulated 
conditions. Comparing 6 months of treatment with baseline we observed a significant increase in the 
percentage of activated Treg cells (p=0.001); a significant augment of both naïve and activated Treg cells 
was found when comparing 2 months of treatment suspension with baseline (naïve: p<0.001; activated: 
p<0.001); and furthermore comparing 2 months after HCQ suspension with 6 months of treatment we found 
a significant increase in both naïve (p=0.004) and activated (p=0.011) Treg subpopulations. 
Percentage of total Treg cells remain unchanged throughout the study period in both unstimulated and HIV-
specific stimulated condition. 
 
       B 
Figure 30, panel B. Percentage of subpopulations of Treg cells in HIV-specific stimulated condition in HIV 
infected INR patients enrolled in the study. Mean values, SE and P are shown ( p<0.05,  p<0.01,  
 p<0.001). 
 
Data regarding analysis of Treg subpopulations showed that HCQ induces an increase in the percentage of 
both naïve and activated Treg cells, supporting its role as an immune modulating agent. 
2.3.2. Identification of TLR-expressing Treg cells 
Several studies underlined that TLR activation on Treg cells increases their survival and leads to the 
induction of their suppressor activity. 
Analyses were conducted in both unstimulated (fig. 31, panel A) and stimulated conditions with HIV peptides 
(fig. 31, panel B) and LPS (fig. 31, panel C) (see paragraph 2.4.5. in material and methods, for details). 
Our data showed that percentages of TLR2-, TLR4-expressing Treg cells in both unstimulated and 
stimulated conditions were significantly augmented after HCQ, and this increased was maintained 2 months 
after HCQ suspension in all culture conditions. In detail, in both unstimulated and HIV specific stimulation 
(figure 31 panel A and B), a statistically significant increase was observed when comparing 2 months after 
HCQ suspension with baseline (unstimulated: TLR2, p=0.009 and TLR4: p=0.009; HIV-specific: TLR2, 
p=0.038 and TLR4: p=0.033) and 6 months of HCQ therapy with baseline (unstimulated: TLR2, p<0.001 and 
TLR4, p<0.001; HIV-specific: TLR2, p=0.005 and TLR4, p=0.019). Moreover, as shown in figure 31 panel C, 
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the percentage of LPS stimulated TLR4-expressing Treg cells increased throughout the entire period of the 
study and reached a statistically significant difference when comparing 2 months after HCQ treatment 
interruption with baseline (p=0.002). 
 
            A 
 
            B 
Figure 31, panel A, panel B. Percentage of TLR2 and TLR4 expressing Treg cells in both basal (A) and HIV-
stimulated condition (B) in HIV-infected INR patients enrolled in the study. Mean values, SE and P are 
shown ( p<0.05,  p<0.01,  p<0.001). 
 
            C 
Figure 31, panel C. Percentage of LPS stimulated TLR4-expressing Treg cells in HIV-infected INR patients 
enrolled in the study. Mean values, SE and P are shown ( p<0.01). 
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Thus, the observed increase in Treg cells induced by HCQ was at least partially supported by TLR2- and 
TLR4-expressing cells. 
Of note, the use of this compound resulted in increased percentages of circulating Treg cells. The role of 
these cells in HIV infection is still not totally clarified but it is likely that the destruction or inactivation of Treg 
cells by HIV would result in a lack of control over immune activation. Treg-mediated suppression of antigen-
specific responses in vitro was shown to be more effective with cells isolated from relatively healthy HIV 
infected individuals compared with later stage AIDS patients, suggesting that Treg cells (total or HIV-specific) 
are depleted and/or dysfunctional later in HIV disease [126]. HCQ treatment induced an increase in naïve 
and activated Treg cells both in unstimulated and in HIV-specific populations. These subpopulations of Treg 
cells are endowed with strong immunosuppressive activity and likely play a role in the HCQ ability to reduce 
immune activation. Of note, the increases in Treg cells seen as a results of HCQ were at least partially 
supported by TLR2- and TLR4-expressing cells; these subpopulations of Treg cells were recently shown to 
mediate a strong immunosuppressive activity. 
2.4. Evaluation of antiviral response 
2.4.1. Percentage of pDCs and expression of IFNα 
pDCs are low-frequency cell found in peripheral blood and lymphoid tissues that are best known for their 
ability to produce large quantities of IFNα in response to viruses. We decided to analyze the percentages of 
pDC and pDC-expressing IFNα during all the study and unstimulated conditions and presence of HIV-
specific stimulation (see paragraph 2.4.3. in material and methods, for further details). 
The percentage of pDCs was significantly augmented after 6 months of HCQ treatment; this effect persisted 
2 months after HCQ interruption (p<0.001 in both cases, figure 32 panel A). 
 
            A 
Figure 32 panel A. Percentage of plasmacytoid dendritic cells in unstimulated condition in HIV-infected INR 
patients enrolled in the study. mean values, SE and P are shown ( p<0.001). 
 
Furthermore, considering that pDCs are the main producer of IFNα, we wanted to analyzed if there were 
changes in the expression of this interferon by pDCs. Of note, as shown in figure 32 panel B, IFNα-secreting 
pDCs were diminished during HCQ treatment and 2 months after HCQ suspension (6 months of HCQ vs 2 
months after HCQ treatment interruption, p=0.036, baseline vs 6 months of HCQ p=0.05, and baseline vs 2 
months after HCQ suspension p=0.021). 
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          B 
Figure 32 panel B. Percentage of IFNα expressing pDCs in unstimulated condition in HIV-infected INR 
patients enrolled in the study. Mean values, SE and P are shown ( p<0.05). 
 
The increase in pDCs percentage is consistent with their antiviral activity and moreover supports HCQ ability 
in restoring immune responses. The reduction in IFNα expression by pDC is a positively aspect because it 
has been demonstrated that elevated level of this cytokine in advanced HIV disease is associated with 
microbial translocation and immune activation, factors worsening the progression of the disease. 
An impairment of pDC function was described in HIV infection and the pre-HAART era pDCs were shown to 
inversely correlate with CD4
+
 T counts and viral loads. These observations, together with the facts that 
HAART increases pDC counts and the higher levels of pDC are seen in long-term non progressor, led to the 
suggestion that pDCs play a protective role against the progression of HIV infection [127, 128, 129, 130, 
131]. Although IFNα reduces viral burden in the acute phase of infection, elevated level of this cytokine in 
advance HIV disease is associated with increased microbial translocation and could contribute to immune 
activation. Of note, despite increasing the number of pDCs, HCQ reduced IFNα production by these cells. 
Finally, whereas pDCs activated through TLR7 and TLR9 work as antiviral cells via IFNα, it was recently 
suggested that non-IFNα producing pDCs can act as tolerogenic cells promoting Treg cells activation via the 
indoleamine 2,3-dioxygenase and PD1 pathways [118]. Data herein suggest that this phenomenon could 
take place in vivo in HCQ-treated individuals. 
2.4.2. Proinflammatory cytokines 
Inflammatory state was evaluated both with flow cytometry and immune enzymatic assays.  
IL6 and TNFα production by CD14
+
 was analyzed in LPS- and ssRNA-stimulated conditions and IL6 and 
TNFα production by CD4
+
 T cells was investigated env/gag-stimulated condition; the plasma concentration of 
these cytokines was evaluated as well. Results showed IL6 and TNFα-secreting CD14
+
 (figure 33 panel A 
and panel B) and CD4
+
 cells (figure 33 panel C) to be diminished after HCQ treatment, reaching statistical 
significance only for ssRNA-stimulated CD14
+
 cells (2 months after HCQ vs 6 months of therapy, IL6: 
p=0.0074, 2 months after treatment suspension vs baseline IL6: p=0.006; 6 months of therapy vs baseline, 
TNFα: p=0.038).  
            A 
Figure 33, panel A. Percentage of proinflammatory cytokines-expressing CD14
+
 monocytes following LPS 
stimulation. Mean values and SE are shown. 
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            B 
Figure 33, panel B. Percentage of proinflammatory cytokines-expressing CD14
+
 monocytes following ssRNA 
specific stimulation in HIV-infected INR patients enrolled in the study. Mean values, SE and P are shown  
( p<0.05,  p<0.01). 
 
            C 
Figure 33, panel C. Percentage of proinflammatory cytokines-expressing CD4
+
 T cells in HIV-specific 
stimulated condition in HIV-infected INR patients enrolled in the study. Mean values and SE. 
 
These data from antigen stimulated conditions, showed an increase in the percentage of pro-inflammatory 
cytokines expressed by monocytes at baseline but once more HCQ administration was able to reduce the 
pro-inflammatory status. Moreover the suspension of HCQ treatment lead to a rebound in pro-inflammatory 
cytokines expressions suggesting once more the need for a prolonged HCQ treatment. 
 
Immunoenzymatic assay (figure 34 panel A and panel B) showed that plasma IL6 concentration was 
significantly reduced after HCQ treatment (baseline vs 2 months of therapy, p=0.048), these results are 
consistent with those previously obtained with flow cytometry analyses. In contrast, no changes in plasmatic 
TNFα concentrations were detected. 
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          A 
 
            B 
Figure 34, panel A and panel B. Plasma IL6 (A) and TNFα (B) concentration in HIV-infected INR patients 
enrolled in the study. Mean values and P are shown ( p<0.05). 
 
 
These data are in concert with the ones reported about immune activation and strengthen the possibility to 
exploit the immune modulating properties of HCQ in the treatment of HIV infection. 
The down modulation of TLR expression and the decrease production of IL6 put in evidence even more the 
significant effect on immune activation displayed by HCQ. 
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2.5. Evaluation of microbial translocation 
The plasma LPS concentration is an index of microbial translocation; an augmented LPS concentration is 
associated with alterations of the gut permeability. As shown in figure 35, HCQ treatment induced a 
reduction in LPS plasma concentration that was maintained after interruption of therapy (baseline vs 2 
months after interruption, p=0.05; 6 months HCQ vs 2 months after interruption, p=0.001). 
 
Figure 35. Plasma LPS concentration in HIV-infected INR patients enrolled in this study. Mean values, SE 
and P are shown ( p<0.05,  p<0.01). 
 
The reduction of LPS concentration suggests an improvement in gut mucosa permeability. It will be 
interesting to determine whether this is a direct consequence of HCQ or rather a consequence of the 
reduced peripheral immune activation seen in these patients. These considerations notwithstanding, 
because LPS directly triggers TLR4-expressing immune cells, the HCQ-associated reduction of plasmatic 
LPS probably plays a major role in the effect on immune activation by HCQ described herein. 
All the data presented herein regarding immune activation and antiviral responses, indicate that HCQ has a 
significant effect on immune activation, as shown by the reduction of circulating activated immune cells, the 
down-modulation of TLR-mediated signal transduction and the decreased production of IL6. This effect is 
probably associated with the increased concentration of Treg lymphocytes and the reduced quantities of 
serum LPS observed in HCQ-treated individuals and is accompanied by significantly augmented 
percentages of circulating pDCs. 
2.6. Evaluation of TLR signaling pathway 
Beside having an effect on TLR expression, HCQ reduces TLR-mediated signal transduction in vitro and in 
the murine model. To evaluate whether a similar effect could be seen in vivo in HIV-infected patients. TLR-
mediated signaling pathways were evaluated using an RT-PCR array screening for the expression of 84 
genes involved in such pathway. Engagement of TLR7/8 with specific agonists at baseline resulted in the 
activation of TLR-signaling pathways as demonstrated by increased expression of mediators involved in the 
transduction pathway (MAP2K3, MAP2K4, MAP3K1, MAP3K7, MAP3K7IP1, MAP4K4, MAPK8, MAPK8IP3, 
MYD88, NFKB1, NFKB2, NFKBIA, NFKBIL1, NFRKB, NR2C2, PELI1, PPARA, PRKRA, REL ,RELA, RIPK2, 
SARM1, SIGIRR, ECSIT, TBK1, TICAM2 and TIRAP) and of effector molecules (CSF2, CSF3, IL1, IL6, IL10, 
IL12 and PTGS2). After 6 months of HCQ therapy, however TLR7/8 responsiveness was markedly down-
modulated, and it was not restored even after treatment suspension. Of note, TLR7 and TLR8 mRNA 
specific expression progressively decreased from baseline to suspension of HCQ treatment, suggesting a 
possible explanation for the decreased responsiveness observed after ssRNA stimulation (figure 36, panel 
A). 
Data collected after TLR4 stimulation resembled the immunologic profile observed in TLR7/8-stimulated 
PBMCs. Thus, at baseline PBMCs were highly responsive to LPS, and HCQ therapy resulted in a marked 
inhibition of TLR4 pathway that persisted after treatment suspension. Similarly to what observed for TLR7/8, 
the gradual decrease in cytokine/chemokine expression after LPS stimulation was accompanied by reduced 
expression of TLR4 mRNA (figure 36, panel B). 
 
Considering the previous data regarding immune activation and antiviral responses, HCQ reduced IFNα 
production by pDCs is dependent on TLR9 engagment [118]. We did not directly examined the TLR9 
pathway but rather concentrated on TLR4 and TLR7/8. Nevertheless, because we saw decreased mRNA 
synthesis for these 3 TLRs, as well as down-regulation of TLR4 and TLR7/8 signaling pathways, it is 
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possible to speculate that reduced expression of TLR9 on pDCs and/or diminished efficacy of the TLR9-
mediated signaling could justify the reduced IFNα production seen in pDCs of HCQ-treated individuals. In-
depth analyses will be needed to clarify the exact mechanisms. 
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     A 
Figure 36, panel A. TLR7/8 signaling pathway after ssRNA stimulation in HIV-infected INR patients enrolled 
in the study. NFold values are shown. 
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        B 
Figure 36, panel B. TLR4 signaling pathway after LPS stimulation in HIV-infected INR patients enrolled in the 
study. NFold values are shown. 
                                                                                                                                                         Conclusions 
68 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusions 
 
 
 
 
                                                                                                                                                         Conclusions 
69 
 
Antiretroviral therapy changed the classical course of HIV infection. HAART therapy is highly effective in 
increasing survival and life quality of HIV-infected patients through the reduction of HIV replication to 
undetectable level and the increase of CD4
+
 T cell count. Nevertheless 15-30% of HIV-infected HAART-
treated patients are immunological non responder (INR); in fact, despite optimal suppression of viral 
replication, restoration of CD4
+
 T cell counts is not always achieved. 
Several factors seem to be involved in the lack of CD4
+
 T cell recovery: residual viral replication, altered 
thymic function, older age, immune activation, apoptosis and viral coinfections were all proposed to play a 
significant role in this phenomenon. Moreover it has been demonstrated that CD4
+
 T cell nadir influences not 
only the possibility to normalize cell counts in response to therapy but also affects the time to reach this goal. 
The time between HAART initiation and achievement of CD4
+
 T cell count more than 500cells/µl is 
significantly longer in individuals with lower baseline lymphocyte counts. Recent evidences, coming from 
clinical studies, assess that CD4
+
 T cell count greater than 500 cells/µl and long-term combination of 
antiretroviral therapy might be positive factors for a better outcome of the disease. In particular, the presence 
of 500 cells/µl has been associated with the same rates of mortality as among the general population after 6 
years of HAART.  
Recent evidences indicate that immune activation plays a key role in the pathogenesis of HIV infection. The 
main cause of immune activation is the destruction of CD4
+
 T cells in the gastrointestinal mucosa 
characterizing the earliest phase of the disease. Loss of mucosal barrier integrity results in impaired local 
cellular immunity and translocation of microbial products, including LPS, which contribute to persistent 
inflammation and immune activation through TLR activation. Given the deleterious effects of sustained 
inflammatory responses, the immune system tries to restore homeostasis with immune suppressive activity 
displayed by Treg cells. Treg cells are divided in two subpopulations, naïve and activated, and they act 
mainly through the secretion of immune suppressive cytokines and the induction of apoptosis. It has been 
demonstrated that Treg cells can, however, display opposite effects: a positive effect in preventing chronic 
immune activation or worsen the course of infection by blocking the development of antiviral immune 
responses. Moreover it has been elucidated that Treg cells express TLRs, above all TLR2 and TLR4, and 
their TLR-mediated activation increase the immune suppressive activity.  
Aim of the first part of this project was to analyze possible relationships between CD4
+
 T cell nadir and the 
lack of CD4
+
 T cell recovery observed in HIV-infected INR patients treated with HAART therapy and to 
identify immune mechanisms involved in these interactions.  
In literature conflicting results regarding the role of Tregs in the immunopathogenesis of HIV disease have 
been reported. Our results suggest that both subpopulation of Treg cells were augmented in patients with 
CD4 cell count less than 500cells/µl and they were fully competent in mediating immune suppression. In 
particular, activated Treg cells could prevent full CD4
+
 T cells reconstitution via both direct (immune 
suppressive cytokines) and direct (apoptosis) mechanisms. Our data put in evidence that, following HIV 
specific stimulation, PBMCs of patients with CD4
+
 cell count less than 500cells/µl were characterized by an 
increase in the expressions of immune suppressive cytokines, caspase 8/9 activation and apoptotic cells 
than PBMCs of patients with CD4
+
 cell count more than 500cells/µl. Furthermore we observed that blockage 
of PD1/PDL1 pathway with a neutralizing antibody against PD1 induces an increase in viable cells and a 
decrease in early and late apoptotic cells in patients with CD4
+
 cell count less than 500cells/µl but patients 
with CD4
+
 T lymphocytes counts more than 500cells/µl. The addition of a neutralizing antibody against PDL1 
didn‟t influence the percentage of both viable and apoptotic cells. 
As previously explained, acute HIV infection is characterized by depletion of cellular population localized in 
the gut-associated lymphoide tissue. This massive destruction of CD4
+
 T cells enhances the pathogenesis of 
HIV infection and our experiments were designated to verify the immune activation status and the presence 
of microbial translocation. Data herein presented showed that patients with CD4
+
 cell count less than 
500cells/µl were characterized by an increase of activated CD4
+
 T cells and of TLR2 and TLR4 expression 
on Treg cells. The augmented expression of TLR expression on multiple cell types is well correlated with the 
observed increased concentration of plasmatic LPS, index for microbial translocation. Thus, altered gut 
permeability resulting in the increase of plasmatic LPS concentration would trigger TLR4-mediated immune 
activation of several cell types like CD4
+
 T cells, monocytes and Treg cells. 
Correlation analysis was conducted and indicated that defective CD4
+
 T cell count recovery in HAART-
treated individuals with suppressed viremia was associated with lower CD4
+
 T cell nadir, increased microbial 
translocation, immune activation, immune suppression and higher susceptibility to apoptosis. The 
observation that all immune parameters analyzed are altered upon HIV-specific but not CMV-specific 
stimulation deserves further analyses and underlines the strong expansion of HIV-specific lymphocytes in 
this infection. Data presented herein are in agreement with earlier studies reporting a correlation between 
CD4
+
 T cell nadir and increases in CD4
+
 T cells during HAART, and identify novel mechanisms possibly 
responsible for lack of CD4
+
 T cell recovery. 
Aim of the second part of this study was to verify the immune modulating and antiviral activity displayed by 
HCQ. HCQ is endowed with immune modulating effects including the reduction of inflammatory cytokine 
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production and a down modulation of natural killer cell activity. In vitro experiments have shown that HCQ is 
also able to modulate the intracellular TLR pathway as it reduces TLR9 and TLR4 expression and 
subsequent activation of NF-κB and AP-1. In addition, HCQ is characterized by antiviral activity in preventing 
the entry of virus into target cells and, regarding HIV, in blocking HIV-1 replication and Tat-mediated 
transactivation of HIV-1 LTR, leading to a reduction in virion production. Based on the assumption that HCQ 
down regulates TLR signaling and the production of inflammatory cytokines, we decided to verify whether 
this compound might modulate immune activation. Results herein presented, indicate that HCQ reduces the 
activation status of both lymphocyte and monocyte population and down modulates TLR expression on 
monocyte‟s population. HCQ was effective in reducing the percentage of proliferating CD4
+
 T lymphocytes 
and of activated monocytes, whereas its effect on CD8
+
 T cells was reduced. 
The “immune activation hypothesis”, proposed by Brenchley and Douek, asserts that during HIV infection, a 
state of chronic immune activation is determinant for CD4
+
 T cell depletion and progression to AIDS and that 
an increased microbial translocation drives systemic immune activation through the persistence presence of 
microbial products such as LPS. According to this hypothesis, we dosed plasma LPS concentration and data 
obtained showed that HCQ was effective in reducing its quantities, this effect might suggest a HCQ-driven 
improvement in gut mucosa permeability. 
The immune system tries to counterbalance immune activation with the immune suppression activity 
displayed by Treg cells and, as previously observed, these processes are strictly correlated. Analysis 
conducted to evaluate Treg cells percentages showed that, in both unstimulated and HIV-stimulated 
conditions, HCQ induced an increase of Treg cells subpopulation all throughout the entire study. Moreover it 
has been observed a strong increase in TLR expression on Treg cells, these subpopulation are endowed 
with a strong immune suppressive activity and probably play a pivotal role in the reduction of immune 
activation. 
An impairment of pDC function was described in HIV infection and pDCs were shown to inversely correlate 
with CD4
+
 T counts and viral loads so it has been supposed that pDCs may play a fundamental role in the 
protection against the progression of HIV infection. pDCs are the main producer of IFNα whose level has 
been correlated with the prognosis of the infection: presence of elevated level of this cytokine in acute 
infection reduces viral burden while in the advanced phase of the disease it is associated with increased 
microbial translocation and immune activation. Results herein presented demonstrate that HCQ is effective 
in augmenting the number of pDCs and in reducing the production of IFNα. Furthermore analysis conducted 
to evaluate plasmatic concentration of pro inflammatory cytokines, put in evidence the ability of HCQ in 
reducing IL6 production throughout the entire study. This effect might be associated with the increased 
percentage of Treg cells, with the reduced immune activation and concentration of plasma LPS previously 
observed. 
On the basis of the effect played by HCQ on TLR signaling pathway and consequently on gene expression, 
we decided to verify the functionality of the main TLR involved in HIV infection. Data herein presented, 
showed a decrease in mRNA expression specific for TLR4 and TLR7/8, as well as the down regulation of 
their signaling pathway under specific stimulation.  
 
In conclusion, data presented herein suggest a multi factorial model explaining failed CD4
+
 T cell recovery in 
successfully HAART-treated patients. Moreover HCQ exerts a beneficial effect on TLR/LPS-mediated 
immune activation, which is responsible for the lack of CD4
+
 T-cell recovery in INR patients. HCQ could be 
considered to be a useful immune modulating drug in particular groups of HIV-infected patients. The 
observation that lower nadir results in a more difficult increase of CD4
+
 T cells supports the hypothesis that 
the CD4
+
 T cell threshold actually used to start HAART should be reassessed and supports even more the 
need to introduce an immune modulator agent in the therapy of HIV infection. 
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PRINCIPLES OF FLOW CYTOMETRY 
The flow cytometry allows automatic analysis of cell suspensions, by measuring the physical and/or 
biochemical in a laminar flow that is hit by a beam of monochromatic light. By cytometry you can capture and 
store multiple parameters for each measured cell, such as volume, granularity and fluorescence, using 
different windows electronic analysis on specific populations, discriminated according to different parameters 
brands.  
The principle underlying the cytometry is the possibility to analyze each individual event of the test sample, 
thanks to a fluidic system that generates a single line of cells. While proceeding, the individual cells through 
a measuring point where interacting with the beam of excitation. The fluorescent emission signal generated 
(due to the phenomena of diffraction, refraction and reflection), is collected by a system of lenses, dichroic 
mirrors and optical filters and sent to the sensors (photomultiplier) that measures the amplitude of signal. The 
signals from each sensor are digitized, combined with each other and sent to a computer that provides the 
presentation of data and their statistical definition.  
 
Figure 1. Schematic representation of a cytometer: laser, dicroic filters, band pass filter 
and photomultiplier are in evidence. 
 
The cytometer consists of four main components (fig. 1), detailed explaining in the following paragraphs: 
 fluidics system, that allows to obtain a monodisperse flux of cells; 
 optics and detectors, that allow the excitation of the fluorochrome and the detection of fluorescent 
signal and of the physical and/or biochemical characteristic of cells; 
 signal processing, that allows the conversion of light in analogical signals, that can be received by a 
computer; 
 data analysis, that allows to display data acquired in different graphic representations. 
 
Fluidic System 
When a sample in solution is injected into a flow cytometer, the particles are randomly distributed in three-
dimensional space. The sample must therefore be ordered into a stream of single particles that can be 
interrogated by the machine‟s detection system. This process is managed by the fluidics system.  
Essentially, the fluidics system (fig. 2) consists of a central channel/core through which the sample is 
injected, enclosed by an outer sheath that contains faster flowing fluid. As the sheath fluid moves, it creates 
a massive drag effect on the narrowing central chamber. This flow is characterized by two coaxial flows: the 
internal flow (flow core) contains the cells, while the outside retains the ideal flow along the axis. By 
controlling the difference between the internal and the external flow, adjust the speed of flow cell (flow rate), 
usually measured as the number of events per second. This alters the velocity of the central fluid whose flow 
front becomes parabolic with greatest velocity at its centre and zero velocity at the wall. The effect creates a 
single line of particles and is called hydrodynamic focusing. Under optimal conditions (laminar flow) the fluid 
in the central chamber will not mix with the sheath fluid. Without hydrodynamic focusing the nozzle of the 
instrument (typically 70 μM) would become blocked, and it would not be possible to analyze one cell at a 
time. 
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Figure 2. Hydrodynamic focusing produces a single stream of particles. 
 
Optics and detection of fluorescence 
After hydrodynamic focusing, each particle passes through one or more beams of light. Light scattering or 
fluorescence emission (if the particle is labelled with a fluorochrome) provides information about the particle‟s 
properties. The laser and the arc lamp are the most commonly used light sources in modern flow citometry  
Laser produce a single wavelength of the light at one or more discreet frequencies. Arc lamps tend to be less 
expensive than lasers and exploit the color emissions of an ignited gas within a sealed tube. 
The interaction of the light with the cell gives rise to the phenomena of light scattering and fluorescence. 
Light scattering allows to discriminate physical characteristic of the cell based on two factors: forward scatter 
(FS) and side scatter (SS). Light that is scattered in the forward direction, typically up to 20° offset from the 
laser beam‟s axis, is collected by a lens known as the forward scatter channel (FSC) and it defines cell 
dimension while when the light is scattered at a 90° angle to the excitation line it is collected by a side scatter 
channel (SSC) and it provides information about the cellular roughness, ratio nucleus/cytoplasm and cell 
surface irregularity. Both FSC and SSC are unique for every particle, and a combination of the two may be 
used to differentiate different cell populations in an heterogeneous sample.  
Once the radiation was deflected by the cell, depending on the parameter taken into account, it collides 
against the detector, usually consisting of photodiodes, or material that, when stimulated by a radiation to 
generate electricity. The signals from the sensors, proportional to the size of continuously measured 
parameter, are transformed into electrical signals by photomultiplier which are then interpreted by 
appropriate software, into numerical values. The combination of the two types of signals (SS and FS) is 
obtained by a two-dimensional diagram known as "cytogram", in which it is possible to detect different cell 
populations based solely on physical characteristics. 
Fluorescence is the phenomenon whereby a molecule hit by a light radiation of defined wavelength (λ), λ 
emits another at higher and lower energy, and enables quantification of a macromolecule of interest within 
the cell. Many biological molecules can be identified with fluorescent ligands or with specific monoclonal 
antibodies (mAb) labeled with fluorochromes (FITC, PE, ECD, PC5, APC, PC7). Initially, the dye absorbs 
laser energy, then releases the energy consumption for both vibration and heat dissipation, and the emission 
of photons of a wavelength longer than in all directions of space, which are then collected by a 
photomultiplier and processed into an electrical signal (fig.3).  
Figure 3. Schematic overview of cytometer setup. FL channel and optical filters are shown. 
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The photomultiplier is preceded by an optical system characterized by filters to select the characteristic 
wavelength of the fluorochrome in question. The intensity of fluorescence emitted is directly proportional to 
the binding sites for the fluorochrome present on the cell. Each dye has a characteristic band of λ for 
excitation and emission and when using more fluorochromes in the same protocol, it‟s important to minimize 
the possible signal interference by setting the right compensation (for detail see data analysis section).  
Flow cytometers use separate fluorescence (FL-) channels to detect light emitted. The number of detectors 
will vary according to the machine and its manufacturer. Detectors are either silicon photodiodes or 
photomultiplier tubes (PMTs). Silicon photodiodes are usually used to measure forward scatter when the 
signal is strong. PMTs are more sensitive instruments and are ideal for scatter and fluorescence readings. 
The specificity of detection is controlled by optical filters, which block certain wavelengths while transmitting 
(passing) others. There are three major filter types (fig. 4). „Long pass‟ filters allow through light above a cut-
off wavelength, „short pass‟ permit light below a cut-off wavelength and „band pass‟ transmit light within a 
specified narrow range of wavelengths (termed a band width). All these filters block light by absorption. 
When a filter is placed at a 45 degrees angle to the oncoming light it becomes a dichroic filter/mirror. As the 
name suggests, this type of filter performs two functions, first, to pass specified wavelengths in the forward 
direction and, second, to deflect blocked light at a 90 degrees angle. To detect multiple signals 
simultaneously, the precise choice and order of optical filters will be an important consideration. 
 
Figure 4. Different types of optical filters. 
 
Signal processing 
When light hits a photodetector a small current (a few microamperes) is generated. Its associated voltage 
has an amplitude proportional to the total number of light photons received by the detector. This voltage is 
then amplified by a series of linear or logarithmic amplifiers, and by analog to digital convertors (ADCs), into 
electrical signals large enough (5–10 volts) to be plotted graphically. 
Log amplification is normally used for fluorescence studies because it expands weak signals and 
compresses strong signals, resulting in a distribution that is easy to display on a histogram. Linear scaling is 
preferable where there is not such a broad range of signals e.g. in DNA analysis. 
The measurement from each detector is referred to as a „parameter‟ e.g. forward scatter, side scatter or 
fluorescence. The data acquired in each parameter are known as the „events‟ and refer to the number of 
cells displaying the physical feature or marker of interest. 
 
Data analysis 
The data analysis software permits to analyse the data acquired also in presence of different colour 
(multicolour) of fluorescence and to represent the data themselves in different graphic formats. One 
consideration to be aware of when performing multicolor fluorescence studies is the possibility of spectral 
overlap. As previously said, when two or more dye are used in the same protocol, fluorescence 
compensation is applied during data analysis. 
Fluorescence compensation calculates how much interference (as a %) a fluorochrome will have in a 
channel that was not assigned specifically to measure it. So, this mean that when the two fluorochromes are 
used for a dual colour experiment, the true reading for fluorochrome A is (total fluorescence measured in 
FL1) minus (5% of fluorochrome B‟s total fluorescence). Similarly, for B, the true signal is (total fluorescence 
measured in FL2) minus (17% of fluorochrome A‟s total fluorescence).  
                                                                                                                                                           Appendix 
75 
 
Figure 5. Fluorescence compensation, spectral overlap is shown. 
 
Gating is the procedure by which cells of interest can be selective visualize while eliminating results from 
unwanted particles (dead cells and debris). Cells have traditionally been gated according to physical 
characteristics. For instance, subcellular debris and clumps can be distinguished from single cells by size, 
estimated by forward scatter. Also, dead cells have lower forward scatter and higher side scatter than living 
cells. The different physical properties of granulocytes, monocytes and lymphocytes allow them to be 
discriminated. 
To represent data deriving from fluorochrome labelling, two different ways are used: the single-parameters 
histograms and two-parameters histograms. 
The first type display a single measurement parameter (relative fluorescence or light scatter intensity) on the 
x-axis and the number of events (cell count) on the y-axis: the histogram is a very basic representation but is 
useful for evaluating the total number of cells in a sample that possess the physical proprieties selected for 
or which express the marker of interest. Cells with the desired characteristics are known as the positive 
dataset. Ideally, flow cytometry will produce a single distinct peak that can be interpreted as the positive 
dataset. However, in many situations, flow analysis is performed on a mixed population of cells resulting in 
several peaks on the histogram. In order to identify the positive dataset, flow citometry acquisition should be 
repeated in the presence of an appropriate negative control. 
 
Figure 6. Schematic representation of a single parameter histogram 
 
The two-parameter histograms are graphs that display two measurement parameters, one on the x-axis and 
one on the y-axis. The parameters could be SSC, FSC or fluorescence. This graph permits to evaluate the 
correlation between two data set acquired. 
 
Figure 7. Schematic representation of a two parameter dot plot. 
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PRINCIPLES OF REAL-TIME PCR 
Real-time PCR allows the accumulation of amplified product to be detected and measured as the reaction 
progresses, that is, in “real time”. 
Real-time detection of PCR products is made possible by including in the reaction a fluorescent molecule 
that reports an increase in the amount of DNA with a proportional increase in fluorescent signal. The 
fluorescent chemistries employed for this purpose include DNA-binding dyes and fluorescently labeled 
sequence specific primers or probes. Specialized thermal cyclers equipped with fluorescence detection 
modules are used to monitor the fluorescence as amplification occurs. The measured fluorescence reflects 
the amount of amplified product in each cycle. 
Real-time PCR data can be evaluated without gel electrophoresis, resulting in reduced experiment time and 
increased throughput. Finally, because reactions are run and data are evaluated in a closed-tube system, 
opportunities for contamination are reduced and the need for post amplification manipulation is eliminated. 
Realtime PCR is based on the monitoring and detection of fluorescence emitted during the reaction, by a 
fluorescent dye used as an indicator of production of new amplified. This is possible because the 
fluorescence signal emitted by the fluorophores increases in direct proportion to the amount of product that is 
being formed that is, the higher the initial number of copies of target, before you will see a significant 
increase in fluorescence. 
The fluorescence emitted in response to a specific part of the radiation from a light source of the instrument 
is measured in real time by a detector (photomultiplier or CCD camera) and all operations related to the 
measurement is carried out under the control of a software controlled by a computer. 
 
Detection systems 
Detection system for real-time PCR is based on generating a fluorescent signal that can be obtained using 
three different strategies: non-specific detection system, detection system based on probes and on 
primer/oligo. 
Non-specific detection system is based on the use of intercalating dyes that emit fluorescence when they 
bind to the double helix of dsDNA. The most common dye used is the SYBR Green I, it exhibits little 
fluorescence when it is free in solution, but its fluorescence increases up to 1,000-fold when it binds to minor 
groove of dsDNA. Therefore, the overall fluorescent signal from a reaction is proportional to the amount of 
dsDNA present, and will increase as the target is amplified. SYBR Green I fluorescence depends on the 
amount of dsDNA present, but this system is not specific because it binds indiscriminately to all dsDNA and 
therefore also to nonspecific products or primer dimers that can be formed during the PCR reaction. The 
specificity of these dyes can still be monitored by analyzing the melting curve with which you can highlight 
the presence of undesirable products. The advantages of using dsDNA-binding dyes include simple assay 
design (only two primers are needed; probe design is not necessary), ability to test multiple genes quickly 
without designing multiple probes (e.g., for validation of gene expression data from many genes in a 
microarray experiment), lower initial cost (probes cost more), and the ability to perform a melt-curve analysis 
to check the specificity of the amplification reaction. 
 
Figure 8. SYBR green during PCR amplification, the fluorescence of this dye increases when bound to the 
minor groove of double stranded DNA. [132] 
 
Detection system based on probes: it allows a high sensible and specific detection for a single target 
sequence. This system requires a double tag of the probes. The most common probes are: TaqMan and 
molecular beacons.  
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TaqMan probe contains a fluorescent reporter at the 5' end and a quencher at the 3' end. When intact, the 
fluorescence of the reporter is quenched due to its proximity to the quencher. During the combined 
annealing/extension step of the amplification reaction, the probe hybridizes to the target and the dsDNA-
specific 5'→3' exonuclease activity of Taq cleaves off the reporter. As a result, the reporter is separated from 
the quencher, and the resulting fluorescence signal is proportional to the amount of amplified product in the 
sample. One commonly used fluorescent reporter quencher pair is fluorescein (FAM, which emits green 
fluorescence) and Black Hole Quencher 1. The main advantages of using TaqMan probes include high 
specificity, a high signal-to-noise ratio, and the ability to perform multiplex reactions. The disadvantages are 
that the initial cost of the probe may expensive.  
Molecular beacon probe employs a sequence-specific, fluorescently labeled oligonucleotide probe, which is 
a dye-labeled oligonucleotide (25–40 nucleotides) that forms a hairpin structure with a stem and a loop. A 
fluorescent reporter is attached to the 5' end of the molecular beacon and a quencher is attached to the 3' 
end. The loop is designed to hybridize specifically to a 15–30 nucleotide section of  the target sequence. On 
either side of the loop are 5–6 nucleotides that are complementary to each other, and form a stem structure 
that serves to bring the reporter and quencher together. In the hairpin structure, no fluorescence is detected 
from the reporter due to its physical proximity to the quencher. During the annealing step of the amplification 
reaction, the molecular beacon binds to its target sequence, separating the reporter and quencher such that 
the reporter is no longer quenched.  
 
Detection system based on primer/oligo: it allows a high sensible and specific detection of DNA and RNA, 
in this case the fluorophor is directly bind to the primer.  
The two probes are designed to bind to adjacent sequences in the target. The first probe carries a donor dye 
at its 3' end, while the second carries an acceptor dye at its 5' end. The donor and the acceptor dyes are 
selected such that the emission spectrum of the donor dye overlaps significantly with the excitation spectrum 
of the acceptor dye, while the emission spectrum of the donor dye is spectrally separated from the emission 
spectrum of the acceptor dye. Excitation is performed at a wavelength specific to the donor dye, and the 
reaction is monitored at the emission wavelength of the acceptor dye. During the annealing step of PCR, the 
probes hybridize to their target sequences in a head-to-tail arrangement. This brings the fluorescent 
molecules into proximity, allowing fluorescence resonance energy transfer from donor to acceptor. The 
increasing amount of acceptor fluorescence is proportional to the amount of amplicon present. The most 
common are Amplifluor primers characterized by both a fluorophor and a quencher. In the hairpin 
conformation, the reporter fluorescence is quenched due to its proximity to the quencher. 
Several components are requested to set up a Real-Time PCR assay. DNA polymerase and design of the 
primers are two important factors.  
The performance of a PCR depends largely on the specificity of the enzyme, so the choice of polymerase is  
a critical parameter. Taq polymerase present a residual activity even at low temperatures, an activity that 
could lead to the synthesis of nonspecific products, to overcome this problem nowadays Hot start 
polymerases are commonly used, the peculiarity of these enzymes is that it‟s activated only with an 
incubation of 2 minutes at 95°C. At last optimal primer design is critical for efficient amplification of desired 
sequences. 
 
 
Real-Time PCR thermal cycler 
Real-time PCR thermal cyclers combine PCR product generation and recognition into one integrated format 
that allows for the subsequent analysis of the captured data. To accomplish these two tasks, real-time PCR 
machines incorporate traditional PCR thermal cycler technology with integrated fluorimeters and detectors 
that provide the ability to both excite a fluorochrome and detect the emitted light.  
One fundamental difference between platforms is the ability to detect more than one fluorochrome with the 
addition of multiple excitation and detection channels. Because real-time PCR reactions are quantified at 
each cycle by measuring fluorescence, most realtime thermal cyclers need to be calibrated for the particular 
tube or microtiter plate and microtiter plate seal used, and for the PCR reaction volume.  
As shown in figure, the light from the halogen lamp passes through an optical filter that cuts to 485nm. this 
wavelength is possible to excite both fluorophores SYBR green, which related to various probes. The light is 
then reflected on a switch and is conveyed through a mirror on a Fresnel lens and then on the samples. The 
light emitted from the sample is collected by a CCD camera that captures and stores the signal. During each 
cycle of PCR, multiple images of the samples are captured, which at the end of the reaction are analyzed by 
a software able to construct an amplification curve.  
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Figure 9 Schematic representation of a Real-Time PCR thermal cycle 
 
Analyses of the data 
Several parameters must to be set in an accurate way to perform analysis of the data, these parameters are: 
baseline, threshold line, threshold cycle and melting curve. 
Baseline, is the initial cycle of PCR in which we observe a small change in the fluorescence signal. Baseline 
must be carefully specified to allow an accurate determination of the CT, moreover also must be large 
enough to eliminate the background of the initial cycles of amplification, but must not overlap with the area 
where the signal begins to increase compared to background noise.  
Threshold cycle (CT) is specific for each sample tested and it identifies the cycle at which the fluorescence 
signal gets over the threshold.  
Threshold line is parallel to baseline and it cut the exponential curve at the CT point. 
Melting curve identifies the fluorescence variation observed when there are the reaction temperature 
augments and so when the dsDNA melts in ssDNA. The analysis of melting curve is an easy way to control 
the quality of the PCR reaction, it allows to detect primer-dimer formation, contamination and specificity of 
the reaction. It can be performed only when SYBR green is used. 
 
The amplification plot shows two phases, an exponential phase followed by a non exponential plateau 
phase. During the exponential phase, the amount of PCR product approximately doubles in each cycle. As 
the reaction proceeds, however, reaction components are consumed, and ultimately one or more of the 
components becomes limiting. At this point, the reaction slows and enters the plateau phase (cycle 28-40 in 
fig.10). Initially, fluorescence remains at background levels, and increases in fluorescence are not detectable 
(fig. 10, cycle 1-18) even though product accumulates exponentially. Eventually, enough amplified product 
accumulates to yield a detectable fluorescent signal, the cycle number at which this occurs is the CT. 
 
Figure 10 Example of amplification plot. 
 
Since the CT value is measured in the exponential phase when reagents are not limited, real-time PCR can 
be used to reliably and accurately calculate the initial amount of template present in the reaction. The CT of a 
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reaction is determined mainly by the amount of template present at the start of the amplification reaction. If a 
large amount of template is present at the start of the reaction, relatively few amplification cycles will be 
required to accumulate enough product to give a fluorescent signal above background. Thus, the reaction 
will have a low, or early, CT. In contrast, if a small amount of template is present at the start of the reaction, 
more amplification cycles will be required for the fluorescent signal to rise above background. Thus, the 
reaction will have a high, or late, CT. This relationship forms the basis for the quantitative aspect of real-time 
PCR. 
 
Quantification of the amplicon 
Real-time PCR is a method for the quantification of the amount of nucleic acid in a sample, it can be 
performed in absolute and relative ways. For both absolute and relative quantification methods, quantities 
obtained from a PCR experiment must be normalized in such a way that the data become biologically 
meaningful. This is done through the use of normalizers. Although the normalizer for either quantification 
method can be the number of cells used for template preparation, μg of nucleic acid used as PCR template, 
or the expression level of a reference gene, the first two are more commonly used for absolute quantification, 
whereas the third is typically used for relative quantification. A reference gene is one whose expression level 
is constant across all test samples and whose expression is not affected by the experimental treatment 
under study. The use of a reference gene is advantageous in cases where the precise quantification of input 
RNA amount is not possible, such as in cases where only a small amount of starting template is available. 
Absolute quantification is achieved by comparing the CT values of the test samples to a standard curve. 
The result of the analysis is quantity of nucleic acid (copy number, μg) per given amount of sample (per cell, 
per μg of total RNA). In this case normalizers are used to adjust or standardize the obtained target quantity 
to the unit amount of sample. 
In relative quantification, the analysis result is a ratio: the relative amount (fold difference) of a target 
nucleic acid for equivalent amounts of test and control sample normalized to a reference gene. 
The advantage of using a relative quantification approach is that there is no need for generating a standard 
calibration curve. If amplification efficiencies of the target and control sequences are identical, then one 
simply compares relative expression values for the target gene in different samples expressed as a ratio. 
The ratio is then normalized using the housekeeping gene‟s expression in the same samples. There are 
several mathematical models available for calculating relative expression. Pfaffl developed a mathematical 
formula that takes into account the contribution of PCR amplification efficiencies and is widely used for the 
relative quantification of gene expression in real-time RT-PCR. 
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